{"matching_results": 22932, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1666, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1464}, {"key": "negative", "matching_results": 188}, {"key": "neutral", "matching_results": 14}]}]}, {"key": "icrowdnewswire.com", "matching_results": 1343, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1149}, {"key": "negative", "matching_results": 185}, {"key": "neutral", "matching_results": 9}]}]}, {"key": "freelancer.com.co", "matching_results": 869, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 780}, {"key": "negative", "matching_results": 76}, {"key": "neutral", "matching_results": 13}]}]}, {"key": "dailypolitical.com", "matching_results": 730, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 654}, {"key": "negative", "matching_results": 75}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "tickerreport.com", "matching_results": 717, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 660}, {"key": "negative", "matching_results": 56}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "watchlistnews.com", "matching_results": 714, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 658}, {"key": "negative", "matching_results": 56}]}]}, {"key": "wkrb13.com", "matching_results": 694, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 628}, {"key": "negative", "matching_results": 66}]}]}, {"key": "zolmax.com", "matching_results": 674, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 614}, {"key": "negative", "matching_results": 60}]}]}, {"key": "thelincolnianonline.com", "matching_results": 538, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 496}, {"key": "negative", "matching_results": 42}]}]}, {"key": "openpr.com", "matching_results": 432, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 382}, {"key": "negative", "matching_results": 40}, {"key": "neutral", "matching_results": 10}]}]}]}], "results": [{"id": "tAg61SRt-acqHteHg1N3ztoPmeP03Ojv3XBkIiFGguvvscEuehMD7oTs3Jn4TI8N", "result_metadata": {"score": 37.139862}, "author": "Pr Newswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.670187, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.492359, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Norges Bank", "sentiment": {"score": -0.230595, "label": "negative"}, "relevance": 0.966282}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.8818}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240447}]}, "crawl_date": "2018-11-05T07:46:50Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45185550-norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.957808, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.923955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "YesShire PLC", "relevance": 0.788874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.7562, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.680231, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.680231, "type": "Quantity"}], "sentiment": {"document": {"score": -0.63547, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2.", "object": {"text": "a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2", "keywords": [{"text": "possible cash offer"}, {"text": "YesShire PLC"}, {"text": "N/A"}], "entities": [{"type": "Company", "text": "YesShire PLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945508, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.824762, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.672196, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.546544, "label": "/real estate/buying and selling homes"}, {"score": 0.482893, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.470469, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.963268}, {"text": "POSITION DISCLOSURE/DEALING DISCLOSURE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.835375}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.729269}, {"text": "disclosure Dealing Disclosure02/11/2018", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.6707}, {"text": "RELEVANT SECURITIES REPRESENTING", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642298}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552319}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514888}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501531}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470999}, {"text": "possible cash offer", "sentiment": {"score": 0.403939, "label": "positive"}, "relevance": 0.464383}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392215}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321408}, {"text": "Norges Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313157}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310819}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291474}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281263}, {"text": "vehicle companies", "sentiment": {"score": -0.502585, "label": "negative"}, "relevance": 0.277052}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260288}, {"text": "YesShire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2488}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237089}]}, "extracted_metadata": {"sha1": "29ad472a082ad72b9c1ddccb72a25ddc6a20eb05", "filename": "1541404010468.zip-258acab317a2ab496fd54eceed85cc96.xml", "file_type": "json"}, "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd"}, {"id": "u0BFiWojEVB_ax7EoIbhNhBJJuEQobgfWhZ2gBE2h5AJkdqRCVRdpA5KuaRKuLth", "result_metadata": {"score": 35.904144}, "author": "euroinvestor.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.768513, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.920731}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544011}]}, "crawl_date": "2018-11-05T07:54:51Z", "url": "https://www.euroinvestor.com/news/2018/11/05/form-83-takeda-pharmaceutical-co-ltd/13923020", "host": "euroinvestor.com", "text": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd PR Newswire London, November 5 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \u201cCode\u201d) 1.", "country": "DK", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T07:03:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.844255, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.266625, "label": "negative"}, "text": "Norges Bank", "relevance": 0.794566, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.562855, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.555189, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.537057, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.535405, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.531807, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.516783, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.48939, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.48939, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.48939, "type": "Quantity"}], "sentiment": {"document": {"score": -0.0858814, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.970276, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.534103, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.514581, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.510849, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.483767, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.431176, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.415212, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.404337, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.380918, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Unit type", "relevance": 0.372177, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.371367, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Option contract", "relevance": 0.368038, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Security", "relevance": 0.362844, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Security", "relevance": 0.353454, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.352479, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Derivative", "relevance": 0.348005, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.338862, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.718547, "label": "/real estate/buying and selling homes"}, {"score": 0.51003, "label": "/finance/financial news"}, {"score": 0.273409, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "populationOf", "sentence": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd PR Newswire London, November 5 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.226785, "arguments": [{"text": "8.3", "location": [90, 93], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "FORM", "location": [85, 89], "entities": [{"type": "Organization", "text": "Norges Bank - Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd PR Newswire London, November 5 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.594818, "arguments": [{"text": "PUBLIC", "location": [94, 100], "entities": [{"type": "Person", "text": "PUBLIC"}]}, {"text": "FORM", "location": [85, 89], "entities": [{"type": "Organization", "text": "Norges Bank - Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Sale 59,700 JPY 4,592.0000 Ordinary Sale 6,000 JPY 4,592.0000 Ordinary Sale 38,300 JPY 4,602.9121 Ordinary Sale 3,800 JPY 4,602.9121 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii)", "score": 0.763044, "arguments": [{"text": "i", "location": [3313, 3314], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Writing", "location": [3316, 3323], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3913, 3918], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3923, 3927], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4287, 4293], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4304, 4311], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 05/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5180, 5186], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5194, 5198], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5341, 5365], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5333, 5338], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5500, 5505], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5519, 5546], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.398424, "label": "positive"}, "relevance": 0.928131}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.793832}, {"text": "short positions", "sentiment": {"score": -0.446215, "label": "negative"}, "relevance": 0.529579}, {"text": "disclosure", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.464705}, {"text": "Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421365}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.411714}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405906}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.392086}, {"text": "Norges Bank", "sentiment": {"score": -0.266625, "label": "negative"}, "relevance": 0.376248}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.364296}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.359189}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35644}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354539}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354319}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352842}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.347535}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.346171}, {"text": "derivative transactions", "sentiment": {"score": -0.426963, "label": "negative"}, "relevance": 0.344071}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342024}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.429787, "label": "negative"}, "relevance": 0.340361}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338232}, {"text": "long/short position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335102}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333564}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333192}, {"text": "person", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.332602}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324971}, {"text": "reference securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32497}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.298479}, {"text": "option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.29563}, {"text": "PR Newswire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.293415}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.293367}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.29177}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.29174}, {"text": "vehicle companies", "sentiment": {"score": -0.671605, "label": "negative"}, "relevance": 0.291627}, {"text": "interests", "sentiment": {"score": -0.467783, "label": "negative"}, "relevance": 0.288458}, {"text": "JPY", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.287731}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285914}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285139}, {"text": "agreements", "sentiment": {"score": 0.0297727, "label": "positive"}, "relevance": 0.284765}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.28122}, {"text": "Cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280443}, {"text": "Option money", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279767}, {"text": "employee options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279557}, {"text": "e.g. CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278821}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278635}, {"text": "Stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278296}, {"text": "Telephone number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278158}, {"text": "e.g. American", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277924}, {"text": "Details", "sentiment": {"score": 0.256651, "label": "positive"}, "relevance": 0.277809}, {"text": "option relates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.277806}]}, "extracted_metadata": {"sha1": "79305df381ce8f235f1ba3f44cfcf2db4e44cb53", "filename": "1541404491461.zip-e18e032e845c78ce6829436ead62ae4d.xml", "file_type": "json"}, "external_links": ["https://www.thetakeoverpanel.org.uk/", "https://www.xmlnews.org/ns/"], "title": "Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "Euroinvestor.com A/S"}, {"id": "Zf3dxtaG_j7A4yVQR4iNvAyLreG1VHC8j8ytUKqkYs-TtDr7e8h61XwMeI0bLpdu", "result_metadata": {"score": 35.45617}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Varian Pharmed", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sun Pharmaceutical Industries Ltd.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Leuprolide", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "TAP Pharmaceuticals", "relevance": 0.97547, "dbpedia_resource": "http://dbpedia.org/resource/TAP_Pharmaceuticals"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.67551, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Ramelteon", "relevance": 0.56561, "dbpedia_resource": "http://dbpedia.org/resource/Ramelteon"}], "categories": [{"score": 0.670702, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "partOfMany", "sentence": "Leuprolide Acetate Market Detail Analysis | Focusing on Eminent Players as Varian Pharmed, avenit AG, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., etc", "score": 0.547984, "arguments": [{"text": "Detail Analysis", "location": [26, 41], "entities": [{"type": "Person", "text": "Detail Analysis"}]}, {"text": "Players", "location": [64, 71], "entities": [{"type": "Person", "text": "Players"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.90835}, {"text": "Leuprolide Acetate Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.89801}, {"text": "Sun Pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.720266}, {"text": "Varian Pharmed", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.689437}, {"text": "Eminent Players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.670719}, {"text": "avenit AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.617124}, {"text": "Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328729}, {"text": "Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326782}, {"text": "Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326173}]}, "crawl_date": "2018-11-05T10:01:35Z", "url": "https://www.openpr.com/news/1351619/Leuprolide-Acetate-Market-Detail-Analysis-Focusing-on-Eminent-Players-as-Varian-Pharmed-avenit-AG-Takeda-Pharmaceutical-Company-Limited-Sun-Pharmaceutical-Industries-Ltd-etc.html", "host": "openpr.com", "text": "(India), Livzon Pharmaceutical Group Co., Ltd.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T09:47:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0.104317, "label": "positive"}, "text": "Leuprolide Acetate Market", "relevance": 0.924945, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Leuprolide Acetate Market", "relevance": 0.482769, "type": "Company"}, {"count": 11, "sentiment": {"score": -0.121642, "label": "negative"}, "text": "leuprolide", "relevance": 0.472658, "type": "Drug"}, {"count": 4, "sentiment": {"score": -0.601625, "label": "negative"}, "text": "prostate cancer", "relevance": 0.328107, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Prostate cancer", "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Market Research", "relevance": 0.287977, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.550239, "label": "negative"}, "text": "Leuprolide Acetate", "relevance": 0.208586, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.585055, "label": "negative"}, "text": "United States", "relevance": 0.176094, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 4, "sentiment": {"score": 0.14169, "label": "positive"}, "text": "China", "relevance": 0.174861, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "World Cancer Research", "relevance": 0.173393, "type": "PrintMedia"}, {"count": 3, "sentiment": {"score": -0.610224, "label": "negative"}, "text": "Europe", "relevance": 0.164155, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": -0.734581, "label": "negative"}, "text": "Switzerland", "relevance": 0.162673, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 2, "sentiment": {"score": -0.550239, "label": "negative"}, "text": "Middle East", "relevance": 0.160135, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie", "relevance": 0.152023, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.150739, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": -0.534793, "label": "negative"}, "text": "India", "relevance": 0.145926, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hadapsar", "relevance": 0.14525, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Hadapsar, Pune", "dbpedia_resource": "http://dbpedia.org/resource/Hadapsar,_Pune"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.138651, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.136854, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma", "relevance": 0.134719, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": 0.219165, "label": "positive"}, "text": "Asia", "relevance": 0.134042, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRFR", "relevance": 0.133024, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Beijing Biote Pharmaceutical Co.", "relevance": 0.13215, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.131119, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.131094, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Livzon Pharmaceutical Group Co.", "relevance": 0.129812, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "mechanism of action", "relevance": 0.129695, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sun Pharmaceutical Industries Ltd.", "relevance": 0.129431, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.734581, "label": "negative"}, "text": "Myovant Sciences", "relevance": 0.129366, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.128073, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.126765, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.124508, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Varian Pharmed", "relevance": 0.123588, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.123202, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "avenit AG", "relevance": 0.121822, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.550239, "label": "negative"}, "text": "Africa", "relevance": 0.121412, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Consulting Services", "relevance": 0.121262, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott", "relevance": 0.118722, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.324541, "label": "negative"}, "text": "Iran", "relevance": 0.118577, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.116522, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.116158, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.112298, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.110407, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.105176, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.236177, "label": "negative"}, "text": "TOLMAR Pharmaceuticals", "relevance": 0.105069, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Five Years", "relevance": 0.105069, "type": "Quantity"}], "sentiment": {"document": {"score": -0.120409, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Market Research Future Market Research Future This MRFR Market Perspective", "keywords": [{"text": "MRFR Market Perspective"}, {"text": "Research Future Market"}, {"text": "Market Research"}]}, "sentence": "Press release from: Market Research Future Market Research Future This MRFR Market Perspective Examines the Historical Trends and Current Scenario of the \u201cGlobal Leuprolide Acetate Market\u201d to Deliver a Highly Pertinent Growth Forecast.", "object": {"text": "the Historical Trends and Current Scenario of the \u201cGlobal Leuprolide Acetate Market\u201d to Deliver a Highly Pertinent Growth Forecast", "keywords": [{"text": "Pertinent Growth Forecast"}, {"text": "Current Scenario"}, {"text": "Acetate Market"}, {"text": "Historical Trends"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "Examines", "tense": "present"}, "text": "Examines", "normalized": "Examines"}}, {"subject": {"text": "the \u201cGlobal Leuprolide Acetate Market", "keywords": [{"text": "Acetate Market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": "Press release from: Market Research Future Market Research Future This MRFR Market Perspective Examines the Historical Trends and Current Scenario of the \u201cGlobal Leuprolide Acetate Market\u201d to Deliver a Highly Pertinent Growth Forecast.", "object": {"text": "a Highly Pertinent Growth Forecast", "keywords": [{"text": "Pertinent Growth Forecast"}, {"text": "Highly"}]}, "action": {"verb": {"text": "Deliver", "tense": "future"}, "text": "to Deliver", "normalized": "to Deliver"}}, {"subject": {"text": "Key Trends, Drivers And Restraints That Are Likely To Influence The Market Over The Next Five Years", "keywords": [{"text": "Key Trends"}, {"text": "Restraints"}, {"text": "Drivers"}, {"text": "Market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}, {"type": "Quantity", "text": "Five Years"}]}, "sentence": " The Report Includes Key Trends, Drivers And Restraints That Are Likely To Influence The Market Over The Next Five Years.", "object": {"text": "The Report", "keywords": [{"text": "Report"}]}, "action": {"verb": {"text": "Includes", "tense": "present"}, "text": "Includes", "normalized": "Includes"}}, {"subject": {"text": "Key Trends, Drivers And Restraints", "keywords": [{"text": "Key Trends"}, {"text": "Restraints"}, {"text": "Drivers"}]}, "sentence": " The Report Includes Key Trends, Drivers And Restraints That Are Likely To Influence The Market Over The Next Five Years.", "action": {"verb": {"text": "Are", "tense": "present"}, "text": "Are", "normalized": "Are"}}, {"subject": {"text": "Drivers And Restraints", "keywords": [{"text": "Restraints"}, {"text": "Drivers"}]}, "sentence": " The Report Includes Key Trends, Drivers And Restraints That Are Likely To Influence The Market Over The Next Five Years.", "object": {"text": "The Market", "keywords": [{"text": "Market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "Influence", "tense": "future"}, "text": "To Influence", "normalized": "To Influence"}}, {"subject": {"text": "Global Leuprolide Acetate Market - Overview Leuprolide acetate", "keywords": [{"text": "Global Leuprolide Acetate"}, {"text": "Overview Leuprolide acetate"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}, {"type": "Drug", "text": "leuprolide"}]}, "sentence": " Global Leuprolide Acetate Market - Overview Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone names as Lupron.", "object": {"text": "a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone names as Lupron", "keywords": [{"text": "synthetic nonapeptide analog"}, {"text": "hormone names"}, {"text": "Lupron"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the treatment of endometriosis, breast cancer and prostate cancer", "keywords": [{"text": "prostate cancer"}, {"text": "breast cancer"}, {"text": "endometriosis"}], "entities": [{"type": "HealthCondition", "text": "prostate cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Prostate cancer", "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}}]}, "sentence": " There are various uses of Lupron include the treatment of endometriosis, breast cancer and prostate cancer.", "object": {"text": "various uses of Lupron", "keywords": [{"text": "Lupron"}, {"text": "various uses"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "It"}, "sentence": " It is one of the on important medicines and is the WHO Model List of, essential medical required in a fundamental well-being system.", "object": {"text": "one of the on important medicines and is the WHO Model List of, essential medical required in a fundamental well-being system", "keywords": [{"text": "fundamental well-being"}, {"text": "important medicines"}, {"text": "Model List"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "essential medical"}, "sentence": " It is one of the on important medicines and is the WHO Model List of, essential medical required in a fundamental well-being system.", "action": {"verb": {"text": "require", "tense": "past"}, "text": "required", "normalized": "require"}}, {"subject": {"text": "The global Leuprolide Acetate market", "keywords": [{"text": "global Leuprolide Acetate"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " The global Leuprolide Acetate market is expected to grow at a steady growth during the forecast period 2017-2023.", "object": {"text": "at a steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "The major factor", "keywords": [{"text": "major factor"}]}, "sentence": " The major factor increasing the growth of the market include increasing prevalence of Prostate cancer among individuals especially with aged individuals.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "increasing prevalence of Prostate cancer among individuals especially with aged individuals", "keywords": [{"text": "Prostate cancer"}, {"text": "prevalence"}, {"text": "individuals"}], "entities": [{"type": "HealthCondition", "text": "prostate cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Prostate cancer", "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}}]}, "sentence": " The major factor increasing the growth of the market include increasing prevalence of Prostate cancer among individuals especially with aged individuals.", "object": {"text": "increasing the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "endometriosis treatment", "keywords": [{"text": "endometriosis treatment"}]}, "sentence": " Increasing use of leuprolide for the purpose of endometriosis treatment has fuelled the growth of the market.", "object": {"text": "fuelled the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Increasing use of leuprolide for the purpose of endometriosis treatment", "keywords": [{"text": "endometriosis treatment"}, {"text": "leuprolide"}, {"text": "purpose"}], "entities": [{"type": "Drug", "text": "leuprolide"}]}, "sentence": " Increasing use of leuprolide for the purpose of endometriosis treatment has fuelled the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "fuel", "tense": "past"}, "text": "has fuelled", "normalized": "have fuel"}}, {"subject": {"text": "endometriosis", "keywords": [{"text": "endometriosis"}]}, "sentence": " Between the ages of 15 and 44 women, endometriosis is affected to one or more in ten women in the United States, leading to pelvic discomfort and infertility, production loss and poor quality of life.", "object": {"text": "to one or more"}, "action": {"verb": {"text": "affect", "tense": "past"}, "text": "is affected", "normalized": "be affect"}}, {"subject": {"text": "The demand for leuprolide in veterinary treatment", "keywords": [{"text": "demand"}, {"text": "veterinary treatment"}, {"text": "leuprolide"}], "entities": [{"type": "Drug", "text": "leuprolide"}]}, "sentence": " The demand for leuprolide in veterinary treatment is another factor which adds to the growth of leuprolide acetate market.", "object": {"text": "another factor which adds to the growth of leuprolide acetate market", "keywords": [{"text": "leuprolide acetate market"}, {"text": "factor"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " The market is forecasted to demonstrate a steady growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017\u20132023.", "object": {"text": "forecasted"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " The market is forecasted to demonstrate a steady growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017\u20132023.", "object": {"text": "a steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "demonstrate", "tense": "future"}, "text": "is forecasted to demonstrate", "normalized": "be forecast to demonstrate"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " The market is forecasted to demonstrate a steady growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017\u20132023.", "object": {"text": "its previous growth records", "keywords": [{"text": "previous growth records"}]}, "action": {"verb": {"text": "surpass", "tense": "present"}, "text": "surpassing", "normalized": "surpass"}}, {"subject": {"text": "by the presence of several well-established and small players", "keywords": [{"text": "small players"}, {"text": "presence"}]}, "sentence": " Global Leuprolide Acetate Market - Competitive Analysis Characterized by the presence of several well-established and small players, the global market of leuprolide acetate appears to be highly competitive and fragmented.", "object": {"text": "Competitive Analysis", "keywords": [{"text": "Competitive Analysis"}]}, "action": {"verb": {"text": "Characterized", "tense": "past"}, "text": "Characterized", "normalized": "Characterized"}}, {"subject": {"text": "the global market of leuprolide acetate", "keywords": [{"text": "leuprolide acetate"}, {"text": "global market"}], "entities": [{"type": "Drug", "text": "leuprolide"}]}, "sentence": " Global Leuprolide Acetate Market - Competitive Analysis Characterized by the presence of several well-established and small players, the global market of leuprolide acetate appears to be highly competitive and fragmented.", "object": {"text": "highly competitive and fragmented"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "appears to be", "normalized": "appear to be"}}, {"subject": {"text": "major companies", "keywords": [{"text": "major companies"}]}, "sentence": " With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share.", "object": {"text": "their home in the regions and generating maximum market share", "keywords": [{"text": "maximum market share"}, {"text": "regions"}, {"text": "home"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "major companies", "keywords": [{"text": "major companies"}]}, "sentence": " With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share.", "object": {"text": "maximum market share", "keywords": [{"text": "maximum market share"}]}, "action": {"verb": {"text": "generate", "tense": "present"}, "text": "generating", "normalized": "generate"}}, {"subject": {"text": "These companies", "keywords": [{"text": "companies"}]}, "sentence": " These companies have expanded their operating unit in various other emerging regions as well.", "object": {"text": "expanded their operating unit in various other emerging regions", "keywords": [{"text": "operating unit"}, {"text": "regions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "These companies", "keywords": [{"text": "companies"}]}, "sentence": " These companies have expanded their operating unit in various other emerging regions as well.", "object": {"text": "their operating unit", "keywords": [{"text": "operating unit"}]}, "action": {"verb": {"text": "expand", "tense": "past"}, "text": "have expanded", "normalized": "have expand"}}, {"subject": {"text": "the other small and medium scale players", "keywords": [{"text": "medium scale players"}]}, "sentence": " Moreover the other small and medium scale players are generating revenue from local market.", "object": {"text": "revenue from local market", "keywords": [{"text": "revenue"}, {"text": "local market"}]}, "action": {"verb": {"text": "generate", "tense": "present"}, "text": "are generating", "normalized": "be generate"}}, {"subject": {"text": "various other companies", "keywords": [{"text": "various other companies"}]}, "sentence": " Although there are various other companies involved in the development of the product.", "object": {"text": "in the development of the product", "keywords": [{"text": "development"}, {"text": "product"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "Myovant Sciences a Switzerland based company", "keywords": [{"text": "Switzerland based company"}, {"text": "Myovant Sciences"}], "entities": [{"type": "Company", "text": "Myovant Sciences"}, {"type": "Location", "text": "Switzerland", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}]}, "sentence": " Myovant Sciences a Switzerland based company involved in the development of new drug that may be able to cure both women\u2019s health disorders and prostate cancer.", "object": {"text": "in the development of new drug that may be able to cure both women\u2019s health disorders and prostate cancer", "keywords": [{"text": "prostate cancer"}, {"text": "new drug"}, {"text": "women\u2019s health"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "prostate cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Prostate cancer", "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "Myovant with its new product relugolix", "keywords": [{"text": "new product relugolix"}]}, "sentence": " Myovant with its new product relugolix has a diverse mechanism of action that that of AbbVie's Lupron Depot, letting it work faster, while the therapy is presently in last-stage of its development, with data predicted in 2019.", "object": {"text": "a diverse mechanism of action that that of AbbVie's Lupron Depot", "keywords": [{"text": "Lupron Depot"}, {"text": "diverse mechanism"}, {"text": "action"}, {"text": "AbbVie"}], "entities": [{"type": "HealthCondition", "text": "mechanism of action"}, {"type": "Company", "text": "AbbVie Inc."}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the therapy", "keywords": [{"text": "therapy"}]}, "sentence": " Myovant with its new product relugolix has a diverse mechanism of action that that of AbbVie's Lupron Depot, letting it work faster, while the therapy is presently in last-stage of its development, with data predicted in 2019.", "object": {"text": "presently in last-stage of its development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Myovant with its new product relugolix has a diverse mechanism of action that that of AbbVie's Lupron Depot, letting it work faster, while the therapy is presently in last-stage of its development, with data predicted in 2019.", "action": {"verb": {"text": "predict", "tense": "past"}, "text": "predicted", "normalized": "predict"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " On the basis of application, the market is segmented into prostate cancer, precocious, uterine fibroid, and others.", "object": {"text": "segmented into prostate cancer", "keywords": [{"text": "prostate cancer"}], "entities": [{"type": "HealthCondition", "text": "prostate cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Prostate cancer", "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " On the basis of application, the market is segmented into prostate cancer, precocious, uterine fibroid, and others.", "object": {"text": "into prostate cancer", "keywords": [{"text": "prostate cancer"}], "entities": [{"type": "HealthCondition", "text": "prostate cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor"], "name": "Prostate cancer", "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " On the basis of the mode of administration, the market is categorized into intramuscular and subcutaneous.", "object": {"text": "into intramuscular and subcutaneous"}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " On the basis of end-user, the market is segmented into hospitals, clinics, medical institutes, and others.", "object": {"text": "segmented into hospitals, clinics, medical institutes, and others", "keywords": [{"text": "medical institutes"}, {"text": "hospitals"}, {"text": "clinics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " On the basis of end-user, the market is segmented into hospitals, clinics, medical institutes, and others.", "object": {"text": "into hospitals, clinics, medical institutes, and others", "keywords": [{"text": "medical institutes"}, {"text": "hospitals"}, {"text": "clinics"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "Regional Analysis The global market", "keywords": [{"text": "Regional Analysis"}, {"text": "global market"}], "entities": []}, "sentence": " Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "object": {"text": "into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa", "keywords": [{"text": "various regions"}, {"text": "North America"}, {"text": "Asia Pacific"}, {"text": "Middle East"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "North America, Europe, Asia Pacific, and the Middle East & Africa", "keywords": [{"text": "North America"}, {"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "object": {"text": "the various regions", "keywords": [{"text": "various regions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America accounted for the largest market share.", "object": {"text": "for the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "The major factor", "keywords": [{"text": "major factor"}]}, "sentence": " The major factor influencing the growth of the market include increasing aging population that is key factor which will drive the demand for leuprolide acetate market in this region.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "influence", "tense": "present"}, "text": "influencing", "normalized": "influence"}}, {"subject": {"text": "increasing aging population that is key factor which will drive the demand for leuprolide acetate market in this region", "keywords": [{"text": "leuprolide acetate market"}, {"text": "key factor"}, {"text": "demand"}, {"text": "population"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "sentence": " The major factor influencing the growth of the market include increasing aging population that is key factor which will drive the demand for leuprolide acetate market in this region.", "object": {"text": "influencing the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "increasing aging population", "keywords": [{"text": "population"}]}, "sentence": " The major factor influencing the growth of the market include increasing aging population that is key factor which will drive the demand for leuprolide acetate market in this region.", "object": {"text": "key factor which will drive the demand for leuprolide acetate market in this region", "keywords": [{"text": "leuprolide acetate market"}, {"text": "key factor"}, {"text": "demand"}, {"text": "region"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "key factor", "keywords": [{"text": "key factor"}]}, "sentence": " The major factor influencing the growth of the market include increasing aging population that is key factor which will drive the demand for leuprolide acetate market in this region.", "object": {"text": "the demand", "keywords": [{"text": "demand"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "will drive", "normalized": "will drive"}}, {"subject": {"text": "huge investment in Research and development and advancement of new techniques", "keywords": [{"text": "huge investment"}, {"text": "new techniques"}, {"text": "advancement"}, {"text": "Research"}]}, "sentence": " Furthermore, huge investment in Research and development and advancement of new techniques has caused in better care for the patients and understanding for the medical professionals.", "action": {"verb": {"text": "cause", "tense": "past"}, "text": "has caused", "normalized": "have cause"}}, {"subject": {"text": "Increase medical professionals", "keywords": [{"text": "medical professionals"}]}, "sentence": " Increase medical professionals has resulted in demand for better standards and quality end products which will further influence the demand in the leuprolide acetate market in the North American region.", "object": {"text": "resulted in demand for better standards", "keywords": [{"text": "better standards"}, {"text": "demand"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "products", "keywords": [{"text": "products"}]}, "sentence": " Increase medical professionals has resulted in demand for better standards and quality end products which will further influence the demand in the leuprolide acetate market in the North American region.", "object": {"text": "the demand", "keywords": [{"text": "demand"}]}, "action": {"verb": {"text": "influence", "tense": "future"}, "text": "influence", "normalized": "influence"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe accounted for the second largest market share for global leuprolide acetate market.", "object": {"text": "for the second largest market share for global leuprolide acetate market", "keywords": [{"text": "global leuprolide acetate"}, {"text": "largest market share"}], "entities": [{"type": "Company", "text": "Global Leuprolide Acetate Market"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "by World Cancer Research fund", "keywords": [{"text": "World Cancer Research"}, {"text": "fund"}], "entities": [{"type": "PrintMedia", "text": "World Cancer Research"}]}, "sentence": " According study published by World Cancer Research fund, Europe accounted for the largest number of individuals suffering from prone to prostate and breast cancer influencing the European market for leuprolide acetate.", "object": {"text": "study", "keywords": [{"text": "study"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " According study published by World Cancer Research fund, Europe accounted for the largest number of individuals suffering from prone to prostate and breast cancer influencing the European market for leuprolide acetate.", "object": {"text": "for the largest number of individuals suffering from prone to prostate and breast cancer influencing the European market for leuprolide acetate", "keywords": [{"text": "leuprolide acetate"}, {"text": "largest number"}, {"text": "European market"}, {"text": "individuals"}], "entities": [{"type": "Drug", "text": "leuprolide"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "individuals", "keywords": [{"text": "individuals"}]}, "sentence": " According study published by World Cancer Research fund, Europe accounted for the largest number of individuals suffering from prone to prostate and breast cancer influencing the European market for leuprolide acetate.", "object": {"text": "cancer", "keywords": [{"text": "cancer"}]}, "action": {"verb": {"text": "breast", "tense": "present"}, "text": "to prostate and breast", "normalized": "to prostate and breast"}}], "concepts": [{"text": "Prostate cancer", "relevance": 0.944365, "dbpedia_resource": "http://dbpedia.org/resource/Prostate_cancer"}, {"text": "TAP Pharmaceuticals", "relevance": 0.867573, "dbpedia_resource": "http://dbpedia.org/resource/TAP_Pharmaceuticals"}, {"text": "Leuprolide", "relevance": 0.778187, "dbpedia_resource": "http://dbpedia.org/resource/Leuprolide"}, {"text": "Cancer", "relevance": 0.664552, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Precocious puberty", "relevance": 0.633874, "dbpedia_resource": "http://dbpedia.org/resource/Precocious_puberty"}, {"text": "Metastasis", "relevance": 0.47703, "dbpedia_resource": "http://dbpedia.org/resource/Metastasis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.426882, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Marketing", "relevance": 0.419212, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Oncology", "relevance": 0.389646, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "BRCA2", "relevance": 0.386511, "dbpedia_resource": "http://dbpedia.org/resource/BRCA2"}, {"text": "GnRH agonists", "relevance": 0.384716, "dbpedia_resource": "http://dbpedia.org/resource/GnRH_agonists"}, {"text": "North America", "relevance": 0.362501, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Research and development", "relevance": 0.35766, "dbpedia_resource": "http://dbpedia.org/resource/Research_and_development"}, {"text": "Cancer research", "relevance": 0.338332, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_research"}, {"text": "Breast cancer", "relevance": 0.33762, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Brachytherapy", "relevance": 0.331614, "dbpedia_resource": "http://dbpedia.org/resource/Brachytherapy"}, {"text": "Estrogen", "relevance": 0.325822, "dbpedia_resource": "http://dbpedia.org/resource/Estrogen"}, {"text": "BRCA1", "relevance": 0.309453, "dbpedia_resource": "http://dbpedia.org/resource/BRCA1"}, {"text": "The Key", "relevance": 0.305928, "dbpedia_resource": "http://dbpedia.org/resource/The_Key_(novel)"}, {"text": "Ramelteon", "relevance": 0.304991, "dbpedia_resource": "http://dbpedia.org/resource/Ramelteon"}, {"text": "Radiation therapy", "relevance": 0.296496, "dbpedia_resource": "http://dbpedia.org/resource/Radiation_therapy"}, {"text": "Market research", "relevance": 0.294475, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Research", "relevance": 0.291779, "dbpedia_resource": "http://dbpedia.org/resource/Research"}, {"text": "Economic growth", "relevance": 0.29049, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "Economics", "relevance": 0.288961, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Competitor analysis", "relevance": 0.287589, "dbpedia_resource": "http://dbpedia.org/resource/Competitor_analysis"}, {"text": "Switzerland", "relevance": 0.284826, "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}, {"text": "Pharmacology", "relevance": 0.283987, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Innovation", "relevance": 0.281206, "dbpedia_resource": "http://dbpedia.org/resource/Innovation"}, {"text": "Prostate", "relevance": 0.278237, "dbpedia_resource": "http://dbpedia.org/resource/Prostate"}, {"text": "National Breast Cancer Coalition", "relevance": 0.277973, "dbpedia_resource": "http://dbpedia.org/resource/National_Breast_Cancer_Coalition"}, {"text": "Pharmaceutical industry", "relevance": 0.277604, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}], "categories": [{"score": 0.642375, "label": "/health and fitness"}, {"score": 0.496252, "label": "/health and fitness/disease/infertility"}, {"score": 0.361077, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "authorOf", "sentence": "Press release from: Market Research Future Market Research Future This MRFR Market Perspective Examines the Historical Trends and Current Scenario of the \"Global Leuprolide Acetate Market\" to Deliver a Highly Pertinent Growth Forecast.", "score": 0.721888, "arguments": [{"text": "Deliver", "location": [192, 199], "entities": [{"type": "Person", "text": "Deliver"}]}, {"text": "Global Leuprolide Acetate Market", "location": [155, 187], "entities": [{"type": "TitleWork", "text": "Global Leuprolide Acetate Market"}]}]}, {"type": "ownerOf", "sentence": "With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share.", "score": 0.387808, "arguments": [{"text": "companies", "location": [2608, 2617], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "home", "location": [2631, 2635], "entities": [{"type": "Facility", "text": "home"}]}]}, {"type": "locatedAt", "sentence": "With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share.", "score": 0.838144, "arguments": [{"text": "home", "location": [2631, 2635], "entities": [{"type": "Facility", "text": "home"}]}, {"text": "regions", "location": [2643, 2650], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "basedIn", "sentence": "Myovant Sciences a Switzerland based company involved in the development of new drug that may be able to cure both women's health disorders and prostate cancer.", "score": 0.906259, "arguments": [{"text": "company", "location": [3137, 3144], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Switzerland", "location": [3119, 3130], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Myovant Sciences a Switzerland based company involved in the development of new drug that may be able to cure both women's health disorders and prostate cancer.", "score": 0.638606, "arguments": [{"text": "women", "location": [3215, 3220], "entities": [{"type": "Person", "text": "women"}]}, {"text": "prostate cancer", "location": [3244, 3259], "entities": [{"type": "HealthCondition", "text": "Prostate cancer"}]}]}, {"type": "productOf", "sentence": "Myovant with its new product relugolix has a diverse mechanism of action that that of AbbVie's Lupron Depot, letting it work faster, while the therapy is presently in last-stage of its development, with data predicted in 2019.", "score": 0.989576, "arguments": [{"text": "Lupron Depot", "location": [3356, 3368], "entities": [{"type": "Product", "text": "Lupron Depot"}]}, {"text": "AbbVie", "location": [3347, 3353], "entities": [{"type": "Organization", "text": "AbbVie Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "score": 0.843185, "arguments": [{"text": "regions", "location": [4049, 4056], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "North America", "location": [4067, 4080], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "score": 0.87571, "arguments": [{"text": "regions", "location": [4049, 4056], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [4082, 4088], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "score": 0.813694, "arguments": [{"text": "regions", "location": [4049, 4056], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia", "location": [4090, 4094], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "score": 0.662812, "arguments": [{"text": "regions", "location": [4049, 4056], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Pacific", "location": [4095, 4102], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "score": 0.712789, "arguments": [{"text": "regions", "location": [4049, 4056], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Middle East", "location": [4112, 4123], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "productOf", "sentence": "Global Leuprolide Acetate Market - Overview Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone names as Lupron.", "score": 0.49382, "arguments": [{"text": "Lupron", "location": [517, 523], "entities": [{"type": "Substance", "text": "Lupron"}]}, {"text": "Global Leuprolide Acetate Market", "location": [357, 389], "entities": [{"type": "Organization", "text": "Global Leuprolide Acetate Market - Regional Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "score": 0.829897, "arguments": [{"text": "regions", "location": [4049, 4056], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [4126, 4132], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Leuprolide Acetate Market - Regional Analysis The global market is segmented into the various regions including North America, Europe, Asia Pacific, and the Middle East & Africa.", "score": 0.583585, "arguments": [{"text": "Asia", "location": [4090, 4094], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [4095, 4102], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "hasAttribute", "sentence": "Moreover, rising number of cancer patients in the region, and steady growth in the number of medical professionals in significantly contributes to the growth of the European leuprolide market.", "score": 0.907302, "arguments": [{"text": "patients", "location": [5101, 5109], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [5094, 5100], "entities": [{"type": "HealthCondition", "text": "Prostate cancer"}]}]}, {"type": "residesIn", "sentence": "Moreover, rising number of cancer patients in the region, and steady growth in the number of medical professionals in significantly contributes to the growth of the European leuprolide market.", "score": 0.877701, "arguments": [{"text": "patients", "location": [5101, 5109], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "region", "location": [5117, 5123], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}, {"type": "residesIn", "sentence": "Asia pacific expect to be fastest growing market due to raising of funds for research and development activities, and growing government initiatives for the awareness and preventive cancer.", "score": 0.328773, "arguments": [{"text": "pacific", "location": [5457, 5464], "entities": [{"type": "Person", "text": "pacific"}]}, {"text": "Asia", "location": [5452, 5456], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Browse Complete 122 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at www.marketresearchfuture.com/reports/leuprolide-acetate-m... About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.", "score": 0.477768, "arguments": [{"text": "Figures", "location": [6603, 6610], "entities": [{"type": "Person", "text": "Figures"}]}, {"text": "Market Research Future", "location": [6681, 6703], "entities": [{"type": "Organization", "text": "Market Research Future Market Research Future This MRFR Market Perspective Examines"}]}]}, {"type": "employedBy", "sentence": "Browse Complete 122 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at www.marketresearchfuture.com/reports/leuprolide-acetate-m... About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.", "score": 0.695424, "arguments": [{"text": "customers", "location": [6753, 6762], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "our", "location": [6749, 6752], "entities": [{"type": "Organization", "text": "Market Research Future Market Research Future This MRFR Market Perspective Examines"}]}]}, {"type": "agentOf", "sentence": "Browse Complete 122 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at www.marketresearchfuture.com/reports/leuprolide-acetate-m... About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.", "score": 0.930645, "arguments": [{"text": "our", "location": [6819, 6822], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "Report", "location": [6839, 6845], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "locatedAt", "sentence": "Contact Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar,", "score": 0.735392, "arguments": [{"text": "Amanora Chambers Magarpatta Road", "location": [7016, 7048], "entities": [{"type": "Organization", "text": "Amanora Chambers Magarpatta Road"}]}, {"text": "Hadapsar", "location": [7050, 7058], "entities": [{"type": "GeopoliticalEntity", "text": "Hadapsar"}]}]}, {"type": "hasAttribute", "sentence": "The major factor increasing the growth of the market include increasing prevalence of Prostate cancer among individuals especially with aged individuals.", "score": 0.706748, "arguments": [{"text": "individuals", "location": [988, 999], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "Prostate cancer", "location": [966, 981], "entities": [{"type": "HealthCondition", "text": "Prostate cancer"}]}]}, {"type": "hasAttribute", "sentence": "The major factor increasing the growth of the market include increasing prevalence of Prostate cancer among individuals especially with aged individuals.", "score": 0.559643, "arguments": [{"text": "individuals", "location": [1021, 1032], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "Prostate cancer", "location": [966, 981], "entities": [{"type": "HealthCondition", "text": "Prostate cancer"}]}]}, {"type": "residesIn", "sentence": "Between the ages of 15 and 44 women, endometriosis is affected to one or more in ten women in the United States, leading to pelvic discomfort and infertility, production loss and poor quality of life.", "score": 0.497017, "arguments": [{"text": "women", "location": [1318, 1323], "entities": [{"type": "Person", "text": "women"}]}, {"text": "United States", "location": [1331, 1344], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Request Sample copy at www.marketresearchfuture.com/sample_request/785 Key players: The key players in the global leuprolide acetate market are TOLMAR Pharmaceuticals, Inc. (U.S.) Varian Pharmed (Iran), avenit AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), Livzon Pharmaceutical Group Co., Ltd. (China), Beijing Biote Pharmaceutical Co., Ltd (China), Soho-YImIng (China), AbbVie Inc. (U.S.), Sanofi (France), Astellas Pharma (Japan), Abbott (U.S), Merck KGaA (Germany), Pfizer Inc. (U.S.), and others.", "score": 0.890576, "arguments": [{"text": "Pharmaceutical Industries Ltd.", "location": [2020, 2050], "entities": [{"type": "Organization", "text": "Pharmaceutical Industries Ltd."}]}, {"text": "Sun", "location": [2016, 2019], "entities": [{"type": "GeopoliticalEntity", "text": "Sun"}]}]}, {"type": "basedIn", "sentence": "Request Sample copy at www.marketresearchfuture.com/sample_request/785 Key players: The key players in the global leuprolide acetate market are TOLMAR Pharmaceuticals, Inc. (U.S.) Varian Pharmed (Iran), avenit AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), Livzon Pharmaceutical Group Co., Ltd. (China), Beijing Biote Pharmaceutical Co., Ltd (China), Soho-YImIng (China), AbbVie Inc. (U.S.), Sanofi (France), Astellas Pharma (Japan), Abbott (U.S), Merck KGaA (Germany), Pfizer Inc. (U.S.), and others.", "score": 0.947208, "arguments": [{"text": "Biote Pharmaceutical Co.", "location": [2115, 2139], "entities": [{"type": "Organization", "text": "Biote Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Beijing", "location": [2107, 2114], "entities": [{"type": "GeopoliticalEntity", "text": "Beijing"}]}]}, {"type": "partOf", "sentence": "With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share.", "score": 0.169021, "arguments": [{"text": "European", "location": [2581, 2589], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "region", "location": [2590, 2596], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}, {"type": "basedIn", "sentence": "With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share.", "score": 0.771547, "arguments": [{"text": "companies", "location": [2608, 2617], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "region", "location": [2590, 2596], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}, {"type": "locatedAt", "sentence": "With well-established market in the North America and European region with major companies having their home in the regions and generating maximum market share.", "score": 0.715829, "arguments": [{"text": "home", "location": [2631, 2635], "entities": [{"type": "Facility", "text": "home"}]}, {"text": "region", "location": [2590, 2596], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}], "keywords": [{"text": "leuprolide acetate market", "sentiment": {"score": 0.0231892, "label": "positive"}, "relevance": 0.985188}, {"text": "global leuprolide acetate", "sentiment": {"score": 0.44481, "label": "positive"}, "relevance": 0.687883}, {"text": "Market Research Future", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370792}, {"text": "market share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281182}, {"text": "Overview Leuprolide acetate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280084}, {"text": "largest market share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.275554}, {"text": "prostate cancer", "sentiment": {"score": -0.601625, "label": "negative"}, "relevance": 0.270958}, {"text": "Research Future Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265963}, {"text": "key market driver", "sentiment": {"score": -0.611748, "label": "negative"}, "relevance": 0.243944}, {"text": "MRFR Market Perspective", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242589}, {"text": "European leuprolide market", "sentiment": {"score": 0.445613, "label": "positive"}, "relevance": 0.242444}, {"text": "major market share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233148}, {"text": "steady growth", "sentiment": {"score": 0.445212, "label": "positive"}, "relevance": 0.228518}, {"text": "maximum market share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.22836}, {"text": "global market", "sentiment": {"score": -0.269732, "label": "negative"}, "relevance": 0.224348}, {"text": "key market trends", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.221363}, {"text": "fastest growing market", "sentiment": {"score": -0.534793, "label": "negative"}, "relevance": 0.2171}, {"text": "European market", "sentiment": {"score": -0.610224, "label": "negative"}, "relevance": 0.21157}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.205039}, {"text": "medical professionals", "sentiment": {"score": 0.572005, "label": "positive"}, "relevance": 0.20072}]}, "extracted_metadata": {"sha1": "726b1378c0197b6ac03035bcd6f69ab46f13ca2d", "filename": "1541412095118.zip-6cd747e982ef412d1e17a1a4baf73f1c.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/sample_request/785", "https://www.marketresearchfuture.com/reports/leuprolide-acetate-market-785"], "title": "Leuprolide Acetate Market Detail Analysis | Focusing on Eminent Players as Varian Pharmed, avenit AG, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., etc", "forum_title": "openPR.com - New Public Relations: Business, Economy, Finances, Banking & Insurance"}, {"id": "Ynd_cEBd_CjbZ3LEmW-TFINb5m9FP2--C3EmSykTJXxEZxSbZ-n-RhdxRSMedMaZ", "result_metadata": {"score": 35.206783}, "author": "wn.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.768513, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.920731}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544011}]}, "crawl_date": "2018-11-05T13:43:40Z", "url": "https://article.wn.com/view/2018/11/05/Form_83_TAKEDA_PHARMACEUTICAL_CO_LTD/", "host": "article.wn.com", "text": "LONDON--(BUSINESS WIRE )-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the ' Code ') 1. KEY INFORMATION (a) Full name of discloser: Barclays PLC . (b)", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC", "relevance": 0.954189, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.375, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.375, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}], "concepts": [{"text": "Barclays", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "Disclosure", "relevance": 0.88602, "dbpedia_resource": "http://dbpedia.org/resource/Disclosure"}, {"text": "Information disclosure statement", "relevance": 0.861444, "dbpedia_resource": "http://dbpedia.org/resource/Information_disclosure_statement"}], "categories": [{"score": 0.59864, "label": "/finance/financial news"}, {"score": 0.465106, "label": "/business and industrial"}, {"score": 0.435364, "label": "/finance/investing/funds/mutual funds"}], "relations": [], "keywords": [{"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.934873}, {"text": "Barclays PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.757549}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.697537}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.674086}, {"text": "BUSINESS WIRE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.673276}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597356}, {"text": "DISCLOSURE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452368}, {"text": "Rule", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.398704}, {"text": "PERSON", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.396846}, {"text": "LONDON", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355374}, {"text": "INTERESTS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.348113}]}, "extracted_metadata": {"sha1": "4286bf9ee93c705c43f8530dc1cfbc3a575740e6", "filename": "1541425420014.zip-1842ce4ab4fd19220b0f0f0551abd40d.xml", "file_type": "json"}, "title": "Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "WN.com - Business News"}, {"id": "-WBKmLXQMvu_izLPucOUxloAHto5IF7lMSO0lni_WAcfOFFi4PsL7vBiQoYBZS_A", "result_metadata": {"score": 34.843147}, "author": "seekingalpha.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Max Weber", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Max_Weber"}], "categories": [{"score": 0.739813, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "employedBy", "sentence": "Takeda Pharmaceutical Co. Ltd. (TKPHF) CEO Christophe Weber on Q2 2019 Transcript", "score": 0.412309, "arguments": [{"text": "CEO", "location": [39, 42], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "TKPHF", "location": [32, 37], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Takeda Pharmaceutical Co. Ltd. (TKPHF) CEO Christophe Weber on Q2 2019 Transcript", "score": 0.703957, "arguments": [{"text": "Q2", "location": [63, 65], "entities": [{"type": "Person", "text": "Q2"}]}, {"text": "Transcript", "location": [71, 81], "entities": [{"type": "Organization", "text": "Transcript", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "CEO Christophe Weber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.986049}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.834705}, {"text": "Q2", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342517}]}, "crawl_date": "2018-11-05T01:15:58Z", "url": "https://seekingalpha.com/article/4218094-takeda-pharmaceutical-co-ltd-tkphf-ceo-christophe-weber-q2-2019-results-earnings-call", "host": "seekingalpha.com", "text": "Takeda Pharmaceutical Co.", "main_image_url": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-04T20:03:00Z", "enriched_text": {"entities": [{"count": 15, "sentiment": {"score": -0.454113, "label": "negative"}, "text": "Shire", "relevance": 0.866679, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 13, "sentiment": {"score": 0.541763, "label": "positive"}, "text": "Takeda", "relevance": 0.775093, "type": "Company"}, {"count": 14, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.636684, "type": "Person"}, {"count": 10, "sentiment": {"score": 0.554015, "label": "positive"}, "text": "Shire", "relevance": 0.632408, "type": "Organization"}, {"count": 9, "sentiment": {"score": -0.627202, "label": "negative"}, "text": "Japan", "relevance": 0.595651, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 9, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.564811, "type": "Person"}, {"count": 11, "sentiment": {"score": -0.125992, "label": "negative"}, "text": "U.S.", "relevance": 0.554968, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Growth Drivers", "relevance": 0.543135, "type": "Organization"}, {"count": 9, "sentiment": {"score": 0, "label": "neutral"}, "text": "VELCADE", "relevance": 0.530982, "type": "Company"}, {"count": 6, "sentiment": {"score": -0.293634, "label": "negative"}, "text": "Shire", "relevance": 0.529483, "type": "Person"}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global OPEX Initiative", "relevance": 0.524105, "type": "Organization"}, {"count": 5, "sentiment": {"score": 0.0427097, "label": "positive"}, "text": "Shire", "relevance": 0.519174, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.653645, "label": "positive"}, "text": "ENTYVIO", "relevance": 0.493101, "type": "Company"}, {"count": 5, "sentiment": {"score": -0.55703, "label": "negative"}, "text": "Techpool", "relevance": 0.483718, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 7, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva JV", "relevance": 0.453313, "type": "Organization"}, {"count": 5, "sentiment": {"score": 0.445948, "label": "positive"}, "text": "Costa Saroukos", "relevance": 0.43208, "type": "Person"}, {"count": 4, "sentiment": {"score": 0.551852, "label": "positive"}, "text": "Steve Barker", "relevance": 0.425171, "type": "Person", "disambiguation": {"subtype": ["Actor", "FilmDirector"], "name": "Steve Barker", "dbpedia_resource": "http://dbpedia.org/resource/Steve_Barker"}}, {"count": 5, "sentiment": {"score": -0.599267, "label": "negative"}, "text": "Wako", "relevance": 0.416696, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Multilab", "relevance": 0.397773, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.385026, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.712506, "label": "positive"}, "text": "R&D", "relevance": 0.384366, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": -0.460045, "label": "negative"}, "text": "EPS", "relevance": 0.380488, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "United States Secret Service", "dbpedia_resource": "http://dbpedia.org/resource/United_States_Secret_Service"}}, {"count": 6, "sentiment": {"score": 0.256273, "label": "positive"}, "text": "GI", "relevance": 0.375353, "type": "HealthCondition"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Atsushi Seki", "relevance": 0.375056, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "UBS", "relevance": 0.373615, "type": "Company", "disambiguation": {"subtype": [], "name": "UBS", "dbpedia_resource": "http://dbpedia.org/resource/UBS"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Securities", "relevance": 0.369963, "type": "Company", "disambiguation": {"subtype": [], "name": "Daiwa Securities Group", "dbpedia_resource": "http://dbpedia.org/resource/Daiwa_Securities_Group"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.365884, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ritsuo Watanabe", "relevance": 0.36505, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Audit and Supervisory Committee", "relevance": 0.352861, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CFO", "relevance": 0.352774, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazuaki Hashiguchi", "relevance": 0.351312, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "analyst", "relevance": 0.346698, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.394581, "label": "negative"}, "text": "Merrill Lynch Securities", "relevance": 0.34609, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.6328, "label": "positive"}, "text": "Andrew Plump", "relevance": 0.344238, "type": "Person"}, {"count": 2, "sentiment": {"score": 0.528764, "label": "positive"}, "text": "Techpool", "relevance": 0.340597, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.349993, "label": "negative"}, "text": "Russia", "relevance": 0.336677, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oncology and Neuroscience", "relevance": 0.335827, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "noncore", "relevance": 0.3358, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.646237, "label": "positive"}, "text": "China", "relevance": 0.335291, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 6, "sentiment": {"score": 0.693414, "label": "positive"}, "text": "executive", "relevance": 0.33349, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.329847, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Company Representative", "relevance": 0.329484, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.357806, "label": "positive"}, "text": "Credit Suisse", "relevance": 0.328169, "type": "Company", "disambiguation": {"subtype": [], "name": "Credit Suisse", "dbpedia_resource": "http://dbpedia.org/resource/Credit_Suisse"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "partner", "relevance": 0.327767, "type": "JobTitle"}], "sentiment": {"document": {"score": 0.356804, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "you"}, "sentence": " Good afternoon, and thank you very much for joining us today.", "object": {"text": "us", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joining", "normalized": "join"}}, {"subject": {"text": "I"}, "sentence": " I know that you have a very busy day with many company presenting their results.", "object": {"text": "that you have a very busy day with many company presenting their results", "keywords": [{"text": "company"}, {"text": "results"}]}, "action": {"verb": {"text": "know", "tense": "present"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " So what we would like to do today is, first, share our first semester results with you, and then we will also provide an update about the Shire acquisition.", "object": {"text": "to do"}, "action": {"verb": {"text": "like", "tense": "future"}, "text": "like", "normalized": "like"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " So what we would like to do today is, first, share our first semester results with you, and then we will also provide an update about the Shire acquisition.", "action": {"verb": {"text": "do", "tense": "future"}, "text": "would like to do", "normalized": "would like to do"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " So what we would like to do today is, first, share our first semester results with you, and then we will also provide an update about the Shire acquisition.", "object": {"text": "an update about the Shire acquisition", "keywords": [{"text": "Shire acquisition"}, {"text": "update"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "will also provide", "normalized": "will also provide"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " So we have a tight schedule.", "object": {"text": "a tight schedule", "keywords": [{"text": "tight schedule"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We'll try to be swift but clear so that we have enough time for questions.", "object": {"text": "to be swift but clear"}, "action": {"verb": {"text": "try", "tense": "future"}, "text": "try", "normalized": "try"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We'll try to be swift but clear so that we have enough time for questions.", "object": {"text": "swift", "keywords": [{"text": "swift"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " We'll try to be swift but clear so that we have enough time for questions.", "object": {"text": "enough time for questions", "keywords": [{"text": "time"}, {"text": "questions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " We are overall having a strong -- what we believe are strong results both on the revenue side, with the growth of 4.2% if you look at our underlying growth; and profit growth or core earning growth of 31.8%; core EPS growth of 32.7%.", "object": {"text": "overall having a strong -- what we believe are strong results both on the revenue side", "keywords": [{"text": "strong results"}, {"text": "revenue"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We are overall having a strong -- what we believe are strong results both on the revenue side, with the growth of 4.2% if you look at our underlying growth; and profit growth or core earning growth of 31.8%; core EPS growth of 32.7%.", "object": {"text": "a strong"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "are overall having", "normalized": "be overall have"}}, {"subject": {"text": "you"}, "sentence": " We are overall having a strong -- what we believe are strong results both on the revenue side, with the growth of 4.2% if you look at our underlying growth; and profit growth or core earning growth of 31.8%; core EPS growth of 32.7%.", "object": {"text": "at our underlying growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "we"}, "sentence": " And with a margin improvement in H1 of 510 basis points, which is a combination of revenue growth, good margin growth as well because product growing have higher margin than the average of the company as well as very strong OpEx management as well, the two combined, we are able to have this margin growth.", "object": {"text": "this margin growth", "keywords": [{"text": "margin growth"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "to have", "normalized": "to have"}}, {"subject": {"text": "the operating profit", "keywords": [{"text": "profit"}]}, "sentence": " And the operating profit, as you know, is declining because we had a significant divestiture last year.", "object": {"text": "declining"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " And the operating profit, as you know, is declining because we had a significant divestiture last year.", "object": {"text": "a significant divestiture", "keywords": [{"text": "significant divestiture"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " But overall, we are able to raise our guidance and the outlook for the year because we're having this significant business momentum.", "object": {"text": "our guidance", "keywords": [{"text": "guidance"}]}, "action": {"verb": {"text": "raise", "tense": "future"}, "text": "to raise", "normalized": "to raise"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " But overall, we are able to raise our guidance and the outlook for the year because we're having this significant business momentum.", "object": {"text": "having this significant business momentum", "keywords": [{"text": "significant business momentum"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " But overall, we are able to raise our guidance and the outlook for the year because we're having this significant business momentum.", "object": {"text": "this significant business momentum", "keywords": [{"text": "significant business momentum"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "having", "normalized": "have"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We are also having a VELCADE upside.", "object": {"text": "a VELCADE upside", "keywords": [{"text": "VELCADE"}], "entities": [{"type": "Company", "text": "VELCADE"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "are also having", "normalized": "be also have"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We have not seen a second generic entry yet, so we are assuming now a second generic entry but later in 2019.", "object": {"text": "not seen a second generic entry yet", "keywords": [{"text": "generic entry"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We have not seen a second generic entry yet, so we are assuming now a second generic entry but later in 2019.", "object": {"text": "a second generic entry yet", "keywords": [{"text": "generic entry"}]}, "action": {"verb": {"text": "see", "tense": "past", "negated": true}, "text": "seen", "normalized": "see"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We have not seen a second generic entry yet, so we are assuming now a second generic entry but later in 2019.", "object": {"text": "a second generic entry but later in 2019", "keywords": [{"text": "generic entry"}]}, "action": {"verb": {"text": "assume", "tense": "present"}, "text": "are assuming", "normalized": "be assume"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " And so overall, very good business momentum, we are very pleased with that, good OpEx management, and this is why we are able to raise the full year outlook.", "object": {"text": "the full year outlook", "keywords": [{"text": "outlook"}]}, "action": {"verb": {"text": "raise", "tense": "future"}, "text": "to raise", "normalized": "to raise"}}, {"subject": {"text": "you"}, "sentence": " So if you look at more details, every region is growing.", "object": {"text": "at more details", "keywords": [{"text": "details"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We have some key products like ENTYVIO with very strong momentum.", "object": {"text": "some key products like ENTYVIO", "keywords": [{"text": "key products"}, {"text": "ENTYVIO"}], "entities": [{"type": "Company", "text": "ENTYVIO"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We have made a few divestiture of noncore assets in the first trimester, Multilab in Brazil and Techpool in China.", "object": {"text": "made a few divestiture of noncore assets in the first trimester, Multilab in Brazil and Techpool in China", "keywords": [{"text": "noncore assets"}, {"text": "Multilab"}, {"text": "Techpool"}, {"text": "divestiture"}], "entities": [{"type": "Location", "text": "Multilab", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Techpool", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We have made a few divestiture of noncore assets in the first trimester, Multilab in Brazil and Techpool in China.", "object": {"text": "a few divestiture of noncore assets", "keywords": [{"text": "noncore assets"}, {"text": "divestiture"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "have made", "normalized": "have make"}}, {"subject": {"text": "I"}, "sentence": " On the pipeline side, I will not dwell too much on the pipeline because we have done an R&D Day very recently.", "object": {"text": "too much"}, "action": {"verb": {"text": "dwell", "tense": "future", "negated": true}, "text": "dwell", "normalized": "dwell"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " On the pipeline side, I will not dwell too much on the pipeline because we have done an R&D Day very recently.", "object": {"text": "done an R&D Day", "keywords": [{"text": "R&D"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " On the pipeline side, I will not dwell too much on the pipeline because we have done an R&D Day very recently.", "object": {"text": "an R&D Day", "keywords": [{"text": "R&D"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "have done", "normalized": "have do"}}, {"subject": {"text": "I"}, "sentence": " Again, I think I will refer to our R&D Day that we did very recently.", "object": {"text": "I will refer to our R&D Day that we did very recently", "keywords": [{"text": "R&D"}], "entities": [{"type": "JobTitle", "text": "analyst"}]}, "action": {"verb": {"text": "think", "tense": "present"}, "text": "think", "normalized": "think"}}, {"subject": {"text": "our Global OPEX Initiative", "keywords": [{"text": "Global OPEX Initiative"}], "entities": [{"type": "Organization", "text": "Global OPEX Initiative"}]}, "sentence": " On the profitability, our Global OPEX Initiative is on full motion, and it's really delivering very strong OpEx management.", "object": {"text": "on full motion", "keywords": [{"text": "motion"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " On the profitability, our Global OPEX Initiative is on full motion, and it's really delivering very strong OpEx management.", "object": {"text": "really delivering very strong OpEx management", "keywords": [{"text": "strong OpEx management"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "it"}, "sentence": " On the profitability, our Global OPEX Initiative is on full motion, and it's really delivering very strong OpEx management.", "object": {"text": "very strong OpEx management", "keywords": [{"text": "OpEx management"}]}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "delivering", "normalized": "deliver"}}, {"subject": {"text": "by 2.4%", "entities": [{"type": "Quantity", "text": "2.4"}]}, "sentence": " And in fact, in the first semester, our overall OpEx declined by 2.4%, so you can really see the leverage on the P&L.", "object": {"text": "our overall OpEx", "keywords": [{"text": "overall OpEx"}]}, "action": {"verb": {"text": "decline", "tense": "past"}, "text": "declined", "normalized": "decline"}}, {"subject": {"text": "you"}, "sentence": " And in fact, in the first semester, our overall OpEx declined by 2.4%, so you can really see the leverage on the P&L.", "object": {"text": "the leverage", "keywords": [{"text": "leverage"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "can really see", "normalized": "can really see"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " And this is also why we are raising the outlook of the year.", "object": {"text": "the outlook of the year", "keywords": [{"text": "outlook"}], "entities": []}, "action": {"verb": {"text": "raise", "tense": "present"}, "text": "are raising", "normalized": "be raise"}}, {"subject": {"text": "It"}, "sentence": " It's all four regions, so Japan, U.S., EUCAN, Emerging Markets, are growing.", "object": {"text": "all four regions", "keywords": [{"text": "regions"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "the like-for-like growth in emerging market", "keywords": [{"text": "like-for-like growth"}, {"text": "market"}]}, "sentence": " The Emerging Market, the like-for-like growth in emerging market is actually closer to 10%.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "We", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " We had to terminate some significant contracts with relatively low margin.", "object": {"text": "some significant contracts", "keywords": [{"text": "significant contracts"}]}, "action": {"verb": {"text": "terminate", "tense": "past"}, "text": "had to terminate", "normalized": "have to terminate"}}, {"subject": {"text": "This"}, "sentence": " This is a bit explanation behind the 2.4%, but we are not concerned by that.", "object": {"text": "a bit explanation behind the 2.4%", "keywords": [{"text": "bit explanation"}], "entities": [{"type": "Quantity", "text": "2.4"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by that"}, "sentence": " This is a bit explanation behind the 2.4%, but we are not concerned by that.", "object": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "action": {"verb": {"text": "concern", "tense": "past", "negated": true}, "text": "concerned", "normalized": "concern"}}, {"subject": {"text": "we", "entities": [{"type": "JobTitle", "text": "analyst"}]}, "sentence": " In fact, we are seeing good rebounds in a country like China, for example.", "object": {"text": "good rebounds", "keywords": [{"text": "good rebounds"}]}, "action": {"verb": {"text": "see", "tense": "present"}, "text": "are seeing", "normalized": "be see"}}, {"subject": {"text": "They", "entities": [{"type": "Organization", "text": "Growth Drivers"}]}, "sentence": " They are growing close to 10%, and also very specifically GI because GI is a massive part of our Growth Drivers.", "object": {"text": "close"}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "are growing", "normalized": "be grow"}}, {"subject": {"text": "GI", "entities": [{"type": "HealthCondition", "text": "GI"}]}, "sentence": " They are growing close to 10%, and also very specifically GI because GI is a massive part of our Growth Drivers.", "object": {"text": "a massive part of our Growth Drivers", "keywords": [{"text": "Growth Drivers"}], "entities": [{"type": "HealthCondition", "text": "GI"}, {"type": "Organization", "text": "Growth Drivers"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "they", "entities": [{"type": "Organization", "text": "Growth Drivers"}]}, "sentence": " And they represent today about 63% of overall Takeda revenue.", "object": {"text": "about 63% of overall Takeda revenue", "keywords": [{"text": "overall Takeda revenue"}], "entities": [{"type": "Quantity", "text": "63"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represent", "normalized": "represent"}}, {"subject": {"text": "I"}, "sentence": " I will not go into all the product detail here, but I will outline ENTYVIO, for example, which is a very substantial product for Takeda, still growing 33% in H1.", "action": {"verb": {"text": "go", "tense": "future", "negated": true}, "text": "go", "normalized": "go"}}, {"subject": {"text": "I"}, "sentence": " I will not go into all the product detail here, but I will outline ENTYVIO, for example, which is a very substantial product for Takeda, still growing 33% in H1.", "object": {"text": "ENTYVIO, for example, which is a very substantial product for Takeda, still growing 33% in H1", "keywords": [{"text": "substantial product"}, {"text": "Takeda"}, {"text": "example"}, {"text": "ENTYVIO"}], "entities": [{"type": "Company", "text": "ENTYVIO"}, {"type": "Company", "text": "Takeda"}, {"type": "Quantity", "text": "33"}]}, "action": {"verb": {"text": "outline", "tense": "future"}, "text": "will outline", "normalized": "will outline"}}, {"subject": {"text": "a very substantial product for Takeda,", "keywords": [{"text": "substantial product"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " I will not go into all the product detail here, but I will outline ENTYVIO, for example, which is a very substantial product for Takeda, still growing 33% in H1.", "object": {"text": "33% in H1", "entities": [{"type": "Quantity", "text": "33"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "it"}, "sentence": " So it is -- it has a significant, of course, impact on the overall growth outlook of the company.", "object": {"text": "a significant, of course, impact on the overall growth outlook of the company", "keywords": [{"text": "overall growth outlook"}, {"text": "course"}, {"text": "impact"}, {"text": "company"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}], "concepts": [{"text": "Revenue", "relevance": 0.978351, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Fiscal year", "relevance": 0.739428, "dbpedia_resource": "http://dbpedia.org/resource/Fiscal_year"}, {"text": "Generally Accepted Accounting Principles", "relevance": 0.716881, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Earnings before interest and taxes", "relevance": 0.716421, "dbpedia_resource": "http://dbpedia.org/resource/Earnings_before_interest_and_taxes"}, {"text": "Expense", "relevance": 0.681407, "dbpedia_resource": "http://dbpedia.org/resource/Expense"}, {"text": "Operating expense", "relevance": 0.578633, "dbpedia_resource": "http://dbpedia.org/resource/Operating_expense"}, {"text": "Gross profit margin", "relevance": 0.575232, "dbpedia_resource": "http://dbpedia.org/resource/Gross_profit_margin"}, {"text": "Profit", "relevance": 0.560981, "dbpedia_resource": "http://dbpedia.org/resource/Profit"}, {"text": "Basis point", "relevance": 0.516261, "dbpedia_resource": "http://dbpedia.org/resource/Basis_point"}, {"text": "Profit margin", "relevance": 0.506777, "dbpedia_resource": "http://dbpedia.org/resource/Profit_margin"}, {"text": "Margin", "relevance": 0.491466, "dbpedia_resource": "http://dbpedia.org/resource/Margin_(finance)"}, {"text": "Futures contract", "relevance": 0.479688, "dbpedia_resource": "http://dbpedia.org/resource/Futures_contract"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.471487, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "James Blish", "relevance": 0.471169, "dbpedia_resource": "http://dbpedia.org/resource/James_Blish"}, {"text": "Gross profit", "relevance": 0.454268, "dbpedia_resource": "http://dbpedia.org/resource/Gross_profit"}, {"text": "Earnings growth", "relevance": 0.446316, "dbpedia_resource": "http://dbpedia.org/resource/Earnings_growth"}, {"text": "To Know That You're Alive", "relevance": 0.445176, "dbpedia_resource": "http://dbpedia.org/resource/To_Know_That_You're_Alive"}, {"text": "That that is is that that is not is not is that it it is", "relevance": 0.444993, "dbpedia_resource": "http://dbpedia.org/resource/That_that_is_is_that_that_is_not_is_not_is_that_it_it_is"}, {"text": "Cash flow", "relevance": 0.440701, "dbpedia_resource": "http://dbpedia.org/resource/Cash_flow"}, {"text": "Capital expenditure", "relevance": 0.428384, "dbpedia_resource": "http://dbpedia.org/resource/Capital_expenditure"}], "categories": [{"score": 0.530267, "label": "/finance/financial news"}, {"score": 0.486646, "label": "/business and industrial/company/earnings"}, {"score": 0.483059, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "hasAttribute", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.901873, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [0, 30], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "TKPHF", "location": [39, 44], "entities": [{"type": "Ticker", "text": "TKPHF"}]}]}, {"type": "employedBy", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.710855, "arguments": [{"text": "Officer", "location": [225, 232], "entities": [{"type": "Person", "text": "Officer"}]}, {"text": "Scientific", "location": [214, 224], "entities": [{"type": "Organization", "text": "Scientific"}]}]}, {"type": "agentOf", "sentence": "We don't want to reinvent a new engine with the Shire acquisition.", "score": 0.45553, "arguments": [{"text": "Shire", "location": [26559, 26564], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [26565, 26576], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOfMany", "sentence": "So we see actually integration of Shire as not very disruptive to R&D. We will maintain our research center which are dedicated to therapy area.", "score": 0.464292, "arguments": [{"text": "Shire", "location": [26836, 26841], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "We", "location": [26873, 26875], "entities": [{"type": "Person", "text": "We"}]}]}, {"type": "ownerOf", "sentence": "But what we will do in the future is that we will continue to develop our pipeline.", "score": 0.773698, "arguments": [{"text": "our", "location": [27017, 27020], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "pipeline", "location": [27021, 27029], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "ownerOf", "sentence": "I like -- personally, I like very much the fact, for example, that 45% of our pipeline is partnered.", "score": 0.740023, "arguments": [{"text": "our", "location": [27280, 27283], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "pipeline", "location": [27284, 27292], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "locatedAt", "sentence": "It means that there are many molecules here that we will never be able to develop internally because we were able -- it's because we are able to partner often in the early stage, so we co-create the value, but it's because we are able to partner that we are able to progress this pipeline.", "score": 0.31874, "arguments": [{"text": "molecules", "location": [27355, 27364], "entities": [{"type": "Person", "text": "molecules"}]}, {"text": "here", "location": [27365, 27369], "entities": [{"type": "GeopoliticalEntity", "text": "here"}]}]}, {"type": "partOf", "sentence": "It means that there are many molecules here that we will never be able to develop internally because we were able -- it's because we are able to partner often in the early stage, so we co-create the value, but it's because we are able to partner that we are able to progress this pipeline.", "score": 0.677928, "arguments": [{"text": "partner", "location": [27564, 27571], "entities": [{"type": "Organization", "text": "partner"}]}, {"text": "we", "location": [27577, 27579], "entities": [{"type": "Organization", "text": "we"}]}]}, {"type": "agentOf", "sentence": "In the first trimester, as I said earlier, we have 7 molecule entering into Phase I. So it's still early days, but there are good signs.", "score": 0.983799, "arguments": [{"text": "I", "location": [27678, 27679], "entities": [{"type": "Person", "text": "I"}]}, {"text": "said", "location": [27680, 27684], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "locatedAt", "sentence": "So we'll add rare disease as a therapy area.", "score": 0.553427, "arguments": [{"text": "we", "location": [28102, 28104], "entities": [{"type": "Person", "text": "we"}]}, {"text": "area", "location": [28138, 28142], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "partOf", "sentence": "We'll have our own research center on rare disease, but we will also partner.", "score": 0.256, "arguments": [{"text": "partner", "location": [28213, 28220], "entities": [{"type": "Organization", "text": "partner"}]}, {"text": "we", "location": [28200, 28202], "entities": [{"type": "Organization", "text": "we"}]}]}, {"type": "locatedAt", "sentence": "And actually, rare disease is, we believe, a very promising area.", "score": 0.435558, "arguments": [{"text": "we", "location": [28253, 28255], "entities": [{"type": "Person", "text": "we"}]}, {"text": "area", "location": [28282, 28286], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "employedBy", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.716739, "arguments": [{"text": "Analysts", "location": [290, 298], "entities": [{"type": "Person", "text": "Analysts"}]}, {"text": "Japan Pharma Business Unit", "location": [263, 289], "entities": [{"type": "Organization", "text": "Japan Pharma Business Unit"}]}]}, {"type": "ownerOf", "sentence": "But we are looking forward to also developing the assets that are coming from the pipeline of Shire.", "score": 0.370145, "arguments": [{"text": "Shire", "location": [29503, 29508], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "pipeline", "location": [29491, 29499], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "hasAttribute", "sentence": "And of course, you have the rare disease assets which are there.", "score": 0.663014, "arguments": [{"text": "you", "location": [29587, 29590], "entities": [{"type": "Person", "text": "you"}]}, {"text": "disease", "location": [29605, 29612], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "managerOf", "sentence": "But I think the key message, in our mind, is that this is not -- it will not create a major disruption in R&D. The -- and one of the issue of many M&A in the pharmaceutical industry is that it takes -- it's too difficult to combine the 2 R&D organization, that you lose years of productivity of R&D. We don't think this is the case with Shire.", "score": 0.855302, "arguments": [{"text": "R&D", "location": [29875, 29878], "entities": [{"type": "Person", "text": "R&D"}]}, {"text": "organization", "location": [29879, 29891], "entities": [{"type": "Organization", "text": "organization"}]}]}, {"type": "affectedBy", "sentence": "But I think the key message, in our mind, is that this is not -- it will not create a major disruption in R&D. The -- and one of the issue of many M&A in the pharmaceutical industry is that it takes -- it's too difficult to combine the 2 R&D organization, that you lose years of productivity of R&D. We don't think this is the case with Shire.", "score": 0.454289, "arguments": [{"text": "Shire", "location": [29974, 29979], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "case", "location": [29964, 29968], "entities": [{"type": "EventLegal", "text": "case"}]}]}, {"type": "hasAttribute", "sentence": "We just need to focus on rare disease on top of GI, Oncology and Neuroscience and also make sure that we optimize this plasma-derived therapy business, which is substantial and will be substantial in the future.", "score": 0.829014, "arguments": [{"text": "Oncology", "location": [30190, 30198], "entities": [{"type": "Person", "text": "Oncology"}]}, {"text": "disease", "location": [30168, 30175], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "hasAttribute", "sentence": "We just need to focus on rare disease on top of GI, Oncology and Neuroscience and also make sure that we optimize this plasma-derived therapy business, which is substantial and will be substantial in the future.", "score": 0.635373, "arguments": [{"text": "Neuroscience", "location": [30203, 30215], "entities": [{"type": "Person", "text": "Neuroscience"}]}, {"text": "disease", "location": [30168, 30175], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "agentOf", "sentence": "Look, we talked about the strategic fit, and this is something that we are also looking forward to.", "score": 0.992481, "arguments": [{"text": "we", "location": [30356, 30358], "entities": [{"type": "Person", "text": "we"}]}, {"text": "talked", "location": [30359, 30365], "entities": [{"type": "EventCommunication", "text": "talked"}]}]}, {"type": "partOfMany", "sentence": "With Shire, we'll, of course, broaden our focus.", "score": 0.455078, "arguments": [{"text": "Shire", "location": [30737, 30742], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "we", "location": [30744, 30746], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "hasAttribute", "sentence": "But 75% of our global sales will come from 5 business drivers: oncology; GI; neuroscience; rare disease; and plasma-derived therapies.", "score": 0.571392, "arguments": [{"text": "drivers", "location": [30835, 30842], "entities": [{"type": "Person", "text": "drivers"}]}, {"text": "disease", "location": [30877, 30884], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "partOf", "sentence": "So in fact, it will be a company much more focused than Takeda is today, with some really key global brands in the field of GI, oncology, neuroscience, rare disease and plasma-derived therapies.", "score": 0.432674, "arguments": [{"text": "company", "location": [30941, 30948], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Takeda", "location": [30972, 30978], "entities": [{"type": "Organization", "text": "Takeda"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.837266, "arguments": [{"text": "Steve Barker - CLSA\nKazuaki Hashiguchi - Daiwa Securities\nAtsushi Seki", "location": [299, 369], "entities": [{"type": "Person", "text": "Steve Barker - CLSA\nKazuaki Hashiguchi - Daiwa Securities\nAtsushi Seki"}]}, {"text": "Analysts", "location": [290, 298], "entities": [{"type": "Person", "text": "Analysts"}]}]}, {"type": "locatedAt", "sentence": "Of course, Takeda is the leading company in Japan, will remain the leading company in Japan.", "score": 0.429782, "arguments": [{"text": "company", "location": [31425, 31432], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Japan", "location": [31436, 31441], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "basedIn", "sentence": "Of course, Takeda is the leading company in Japan, will remain the leading company in Japan.", "score": 0.42901, "arguments": [{"text": "company", "location": [31467, 31474], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "Japan", "location": [31478, 31483], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "locatedAt", "sentence": "We'll be in the top 10 pharmaceutical company in the U.S. In Europe and Emerging Market, in many countries, we'll double our size as well.", "score": 0.629423, "arguments": [{"text": "pharmaceutical company", "location": [31753, 31775], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}, {"text": "U.S.", "location": [31783, 31787], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "locatedAt", "sentence": "We'll be in the top 10 pharmaceutical company in the U.S. In Europe and Emerging Market, in many countries, we'll double our size as well.", "score": 0.498088, "arguments": [{"text": "pharmaceutical company", "location": [31753, 31775], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}, {"text": "countries", "location": [31827, 31836], "entities": [{"type": "GeopoliticalEntity", "text": "countries"}]}]}, {"type": "employedBy", "sentence": "We think that for an R&D-driven company, pro-innovation company, being strong in the U.S. is important because the U.S. market is and, we believe, will continue to be the most pro-innovation market.", "score": 0.386878, "arguments": [{"text": "R&D-", "location": [31890, 31894], "entities": [{"type": "Person", "text": "R&D-"}]}, {"text": "company", "location": [31901, 31908], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "hasAttribute", "sentence": "And so of course, when you invest $400 billion per year in R&D, when you discover these new molecules, you want a fast access so that your payback is faster as well.", "score": 0.701836, "arguments": [{"text": "you", "location": [32243, 32246], "entities": [{"type": "Person", "text": "you"}]}, {"text": "\u00a5400 billion", "location": [32254, 32266], "entities": [{"type": "Money", "text": "\u00a5400 billion"}]}]}, {"type": "agentOf", "sentence": "And we are confirming this at least number today.", "score": 0.936799, "arguments": [{"text": "we", "location": [32942, 32944], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "confirming", "location": [32949, 32959], "entities": [{"type": "EventCommunication", "text": "confirming"}]}]}, {"type": "timeOf", "sentence": "And we are confirming this at least number today.", "score": 0.897961, "arguments": [{"text": "today", "location": [32981, 32986], "entities": [{"type": "Date", "text": "today"}]}, {"text": "confirming", "location": [32949, 32959], "entities": [{"type": "EventCommunication", "text": "confirming"}]}]}, {"type": "affectedBy", "sentence": "Whether you look at the underlying EPS or core EPS or reported EPS, it's highly accretive.", "score": 0.698485, "arguments": [{"text": "EPS", "location": [33229, 33232], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "reported", "location": [33220, 33228], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "agentOf", "sentence": "The return on invested capital is higher than what we saw very rapidly for this type of acquisition.", "score": 0.666614, "arguments": [{"text": "we", "location": [33460, 33462], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "acquisition", "location": [33497, 33508], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.582896, "arguments": [{"text": "Watanabe", "location": [383, 391], "entities": [{"type": "Person", "text": "Watanabe"}]}, {"text": "Analysts", "location": [290, 298], "entities": [{"type": "Person", "text": "Analysts"}]}]}, {"type": "agentOf", "sentence": "We have been asked very often about the amortization of intangibles and goodwill and how -- what is the risk of impairment.", "score": 0.881459, "arguments": [{"text": "We", "location": [33600, 33602], "entities": [{"type": "Person", "text": "We"}]}, {"text": "asked", "location": [33613, 33618], "entities": [{"type": "EventCommunication", "text": "asked"}]}]}, {"type": "hasAttribute", "sentence": "So here, what we want is to clarify the size of the combined company goodwill, we give a range between $4,000 billion and $4,500 billion for the goodwill and intangible asset between $6,300 billion and $6,700 billion because we have many numbers floating around.", "score": 0.502758, "arguments": [{"text": "company", "location": [33785, 33792], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "\u00a54,000 billion", "location": [33827, 33841], "entities": [{"type": "Money", "text": "\u00a54,000 billion"}]}]}, {"type": "hasAttribute", "sentence": "So here, what we want is to clarify the size of the combined company goodwill, we give a range between $4,000 billion and $4,500 billion for the goodwill and intangible asset between $6,300 billion and $6,700 billion because we have many numbers floating around.", "score": 0.580255, "arguments": [{"text": "we", "location": [33803, 33805], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "\u00a54,000 billion", "location": [33827, 33841], "entities": [{"type": "Money", "text": "\u00a54,000 billion"}]}]}, {"type": "hasAttribute", "sentence": "So here, what we want is to clarify the size of the combined company goodwill, we give a range between $4,000 billion and $4,500 billion for the goodwill and intangible asset between $6,300 billion and $6,700 billion because we have many numbers floating around.", "score": 0.487179, "arguments": [{"text": "we", "location": [33803, 33805], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "\u00a56,300 billion", "location": [33907, 33921], "entities": [{"type": "Money", "text": "\u00a56,300 billion"}]}]}, {"type": "hasAttribute", "sentence": "So here, what we want is to clarify the size of the combined company goodwill, we give a range between $4,000 billion and $4,500 billion for the goodwill and intangible asset between $6,300 billion and $6,700 billion because we have many numbers floating around.", "score": 0.549621, "arguments": [{"text": "we", "location": [33803, 33805], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "\u00a56,700 billion", "location": [33926, 33940], "entities": [{"type": "Money", "text": "\u00a56,700 billion"}]}]}, {"type": "agentOf", "sentence": "And we think we have been quite prudent in our forecasts, in our assumptions when defining the acquisition price, and therefore -- and that's reflected in the intangibles.", "score": 0.558419, "arguments": [{"text": "our", "location": [34691, 34694], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "acquisition", "location": [34725, 34736], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "So here, we are clarifying the debt level at start with a net debt of $5,452 billion and a deleveraging profile.", "score": 0.944358, "arguments": [{"text": "we", "location": [35200, 35202], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "clarifying", "location": [35207, 35217], "entities": [{"type": "EventCommunication", "text": "clarifying"}]}]}, {"type": "hasAttribute", "sentence": "And you can see here that if you take an assumptions of total value of disposals of $10 billion, you -- we will be able to be at 1.7 net debt-to-EBITDA ratio by March 2023.", "score": 0.844892, "arguments": [{"text": "we", "location": [35566, 35568], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "$10 billion", "location": [35546, 35557], "entities": [{"type": "Money", "text": "$10 billion"}]}]}, {"type": "agentOf", "sentence": "You have seen the recent announcement about the hybrids and so we are continuing to work on the financing.", "score": 0.780154, "arguments": [{"text": "You", "location": [35800, 35803], "entities": [{"type": "Person", "text": "You"}]}, {"text": "announcement", "location": [35825, 35837], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "memberOf", "sentence": "I would like to share with you now the governance and how the board did proceed because we had some questions from investors about the board involvement of the company.", "score": 0.345713, "arguments": [{"text": "investors", "location": [36114, 36123], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "board", "location": [36134, 36139], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.61259, "arguments": [{"text": "Fumiyoshi Sakai", "location": [419, 434], "entities": [{"type": "Person", "text": "Fumiyoshi Sakai"}]}, {"text": "Analysts", "location": [290, 298], "entities": [{"type": "Person", "text": "Analysts"}]}]}, {"type": "partOf", "sentence": "I would like to share with you now the governance and how the board did proceed because we had some questions from investors about the board involvement of the company.", "score": 0.829874, "arguments": [{"text": "board", "location": [36134, 36139], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "company", "location": [36159, 36166], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "partOf", "sentence": "So first, let me remind you about our board composition.", "score": 0.817407, "arguments": [{"text": "board", "location": [36206, 36211], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "our", "location": [36202, 36205], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "managerOf", "sentence": "It's a board with an Audit and Supervisory Committee.", "score": 0.315569, "arguments": [{"text": "Audit", "location": [36246, 36251], "entities": [{"type": "Person", "text": "Audit"}]}, {"text": "board", "location": [36232, 36237], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "managerOf", "sentence": "It's a board chaired by Sakane-san, so he's chairing the board meeting.", "score": 0.461647, "arguments": [{"text": "Sakane-san", "location": [36303, 36313], "entities": [{"type": "Person", "text": "Sakane-san"}]}, {"text": "board", "location": [36286, 36291], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "participantIn", "sentence": "It's a board chaired by Sakane-san, so he's chairing the board meeting.", "score": 0.516074, "arguments": [{"text": "he", "location": [36318, 36320], "entities": [{"type": "Person", "text": "he"}]}, {"text": "meeting", "location": [36342, 36349], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "It's a board chaired by Sakane-san, so he's chairing the board meeting.", "score": 0.624547, "arguments": [{"text": "board", "location": [36336, 36341], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "meeting", "location": [36342, 36349], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "partOf", "sentence": "It's a board, which is dominated by independent directors.", "score": 0.621853, "arguments": [{"text": "board", "location": [36358, 36363], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "which", "location": [36365, 36370], "entities": [{"type": "Organization", "text": "which"}]}]}, {"type": "managerOf", "sentence": "So we think it's a strong board with Audit and Supervisory Committee, Compensation Committee, Nomination Committee chaired by independent director and the board itself is chaired by an independent director.", "score": 0.355664, "arguments": [{"text": "Audit", "location": [36447, 36452], "entities": [{"type": "Person", "text": "Audit"}]}, {"text": "board", "location": [36436, 36441], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "partOf", "sentence": "So we think it's a strong board with Audit and Supervisory Committee, Compensation Committee, Nomination Committee chaired by independent director and the board itself is chaired by an independent director.", "score": 0.542955, "arguments": [{"text": "board", "location": [36436, 36441], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "Supervisory Committee", "location": [36457, 36478], "entities": [{"type": "Organization", "text": "Supervisory Committee"}]}]}, {"type": "managerOf", "sentence": "So we think it's a strong board with Audit and Supervisory Committee, Compensation Committee, Nomination Committee chaired by independent director and the board itself is chaired by an independent director.", "score": 0.313892, "arguments": [{"text": "Audit", "location": [36447, 36452], "entities": [{"type": "Person", "text": "Audit"}]}, {"text": "Supervisory Committee", "location": [36457, 36478], "entities": [{"type": "Organization", "text": "Supervisory Committee"}]}]}, {"type": "employedBy", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.536179, "arguments": [{"text": "Watanabe", "location": [383, 391], "entities": [{"type": "Person", "text": "Watanabe"}]}, {"text": "UBS\nRitsuo", "location": [372, 382], "entities": [{"type": "Organization", "text": "UBS\nRitsuo"}]}]}, {"type": "agentOf", "sentence": "So we think it's a strong board with Audit and Supervisory Committee, Compensation Committee, Nomination Committee chaired by independent director and the board itself is chaired by an independent director.", "score": 0.973308, "arguments": [{"text": "Nomination Committee", "location": [36504, 36524], "entities": [{"type": "Organization", "text": "Nomination Committee"}]}, {"text": "chaired", "location": [36525, 36532], "entities": [{"type": "EventCommunication", "text": "chaired"}]}]}, {"type": "affectedBy", "sentence": "So we think it's a strong board with Audit and Supervisory Committee, Compensation Committee, Nomination Committee chaired by independent director and the board itself is chaired by an independent director.", "score": 0.689505, "arguments": [{"text": "independent director", "location": [36536, 36556], "entities": [{"type": "Person", "text": "independent director"}]}, {"text": "chaired", "location": [36525, 36532], "entities": [{"type": "EventCommunication", "text": "chaired"}]}]}, {"type": "agentOf", "sentence": "So I just want to say that the board has been extensively involved in this acquisition.", "score": 0.475697, "arguments": [{"text": "board", "location": [36648, 36653], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "acquisition", "location": [36692, 36703], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "participantIn", "sentence": "We had many meetings.", "score": 0.851532, "arguments": [{"text": "We", "location": [36807, 36809], "entities": [{"type": "Person", "text": "We"}]}, {"text": "meetings", "location": [36819, 36827], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "timeOf", "sentence": "One was in March 22, a few days before the leak of the potential interest of Takeda occurred a few days before we started approaching Shire board.", "score": 0.449666, "arguments": [{"text": "a few days", "location": [36903, 36913], "entities": [{"type": "Duration", "text": "a few days"}]}, {"text": "leak", "location": [36925, 36929], "entities": [{"type": "EventCommunication", "text": "leak"}]}]}, {"type": "agentOf", "sentence": "One was in March 22, a few days before the leak of the potential interest of Takeda occurred a few days before we started approaching Shire board.", "score": 0.934391, "arguments": [{"text": "Takeda", "location": [36959, 36965], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "leak", "location": [36925, 36929], "entities": [{"type": "EventCommunication", "text": "leak"}]}]}, {"type": "partOfMany", "sentence": "One was in March 22, a few days before the leak of the potential interest of Takeda occurred a few days before we started approaching Shire board.", "score": 0.832269, "arguments": [{"text": "Takeda", "location": [36959, 36965], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "we", "location": [36993, 36995], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "managerOf", "sentence": "One was in March 22, a few days before the leak of the potential interest of Takeda occurred a few days before we started approaching Shire board.", "score": 0.872995, "arguments": [{"text": "Shire", "location": [37016, 37021], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "board", "location": [37022, 37027], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "partOf", "sentence": "And then, of course, there was a negotiation period and we made at the board a final decision on May 7 with the final agreement and it was communicated on May 8.", "score": 0.420237, "arguments": [{"text": "we", "location": [37085, 37087], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "board", "location": [37100, 37105], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "agentOf", "sentence": "And of course, at every board meeting now we have a topic about Shire, the acquisition, how it's going, but also how we are preparing the integration.", "score": 0.678667, "arguments": [{"text": "board", "location": [37215, 37220], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "meeting", "location": [37221, 37228], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "I know that you have a very busy day with many company presenting their results.", "score": 0.97457, "arguments": [{"text": "company", "location": [605, 612], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "presenting", "location": [613, 623], "entities": [{"type": "EventCommunication", "text": "presenting"}]}]}, {"type": "participantIn", "sentence": "And of course, at every board meeting now we have a topic about Shire, the acquisition, how it's going, but also how we are preparing the integration.", "score": 0.653081, "arguments": [{"text": "we", "location": [37233, 37235], "entities": [{"type": "Person", "text": "we"}]}, {"text": "meeting", "location": [37221, 37228], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "partOf", "sentence": "So I think that has been a really, I believe, very strong governance and board involvement, not only is the board, by the way, but also the Takeda executive team, obviously, which have been very much involved.", "score": 0.544772, "arguments": [{"text": "board", "location": [37450, 37455], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "board", "location": [37415, 37420], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "managerOf", "sentence": "So I think that has been a really, I believe, very strong governance and board involvement, not only is the board, by the way, but also the Takeda executive team, obviously, which have been very much involved.", "score": 0.752427, "arguments": [{"text": "executive", "location": [37489, 37498], "entities": [{"type": "Person", "text": "executive"}]}, {"text": "team", "location": [37499, 37503], "entities": [{"type": "Organization", "text": "team"}]}]}, {"type": "participantIn", "sentence": "One of the key discussions at the board was the risk: what type of risks do we take, how do we mitigate these risks.", "score": 0.670835, "arguments": [{"text": "board", "location": [37667, 37672], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "discussions", "location": [37648, 37659], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "agentOf", "sentence": "There was a business risk and also the impairment of the intangibles, as I mentioned.", "score": 0.876542, "arguments": [{"text": "I", "location": [38130, 38131], "entities": [{"type": "Person", "text": "I"}]}, {"text": "mentioned", "location": [38132, 38141], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "partOf", "sentence": "Of course, can we integrate such a company with its specificities with such a strong presence in the U.S., and we discussed that very extensively.", "score": 0.303572, "arguments": [{"text": "company", "location": [38611, 38618], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "we", "location": [38591, 38593], "entities": [{"type": "Organization", "text": "we"}]}]}, {"type": "partOf", "sentence": "Of course, can we integrate such a company with its specificities with such a strong presence in the U.S., and we discussed that very extensively.", "score": 0.435865, "arguments": [{"text": "company", "location": [38611, 38618], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "its", "location": [38624, 38627], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "participantIn", "sentence": "Of course, can we integrate such a company with its specificities with such a strong presence in the U.S., and we discussed that very extensively.", "score": 0.463628, "arguments": [{"text": "we", "location": [38687, 38689], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "discussed", "location": [38690, 38699], "entities": [{"type": "EventMeeting", "text": "discussed"}]}]}, {"type": "managerOf", "sentence": "The executive team has been working together now for 4 years, it's a very global executive team.", "score": 0.873881, "arguments": [{"text": "executive", "location": [38854, 38863], "entities": [{"type": "Person", "text": "executive"}]}, {"text": "team", "location": [38864, 38868], "entities": [{"type": "Organization", "text": "team"}]}]}, {"type": "partOfMany", "sentence": "The R&D description, as we have seen, is really limited, so we think that the R&D integration will be very -- I will never say easy, but it is very much possible without disruption.", "score": 0.601659, "arguments": [{"text": "R&D", "location": [38951, 38954], "entities": [{"type": "Person", "text": "R&D"}]}, {"text": "we", "location": [39007, 39009], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "affectedBy", "sentence": "I know that you have a very busy day with many company presenting their results.", "score": 0.554766, "arguments": [{"text": "their", "location": [624, 629], "entities": [{"type": "Person", "text": "their"}]}, {"text": "presenting", "location": [613, 623], "entities": [{"type": "EventCommunication", "text": "presenting"}]}]}, {"type": "agentOf", "sentence": "So we were also, on the integration risks, we're comfortable that we're able to do that without losing the values of Takeda also that I explained earlier.", "score": 0.970497, "arguments": [{"text": "I", "location": [39263, 39264], "entities": [{"type": "Person", "text": "I"}]}, {"text": "explained", "location": [39265, 39274], "entities": [{"type": "EventCommunication", "text": "explained"}]}]}, {"type": "locatedAt", "sentence": "So we have clarified internally how we'll be organized by business unit, by regions.", "score": 0.634039, "arguments": [{"text": "we", "location": [39643, 39645], "entities": [{"type": "Person", "text": "we"}]}, {"text": "regions", "location": [39683, 39690], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "So we have clarified internally how we'll be organized by business unit, by regions.", "score": 0.43867, "arguments": [{"text": "business unit", "location": [39665, 39678], "entities": [{"type": "Organization", "text": "business unit"}]}, {"text": "regions", "location": [39683, 39690], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "agentOf", "sentence": "This is something we have communicated to all our employees at Takeda and at Shire and so we are starting to plan the integration like that.", "score": 0.914365, "arguments": [{"text": "we", "location": [39926, 39928], "entities": [{"type": "Person", "text": "we"}]}, {"text": "communicated", "location": [39934, 39946], "entities": [{"type": "EventCommunication", "text": "communicated"}]}]}, {"type": "affectedBy", "sentence": "This is something we have communicated to all our employees at Takeda and at Shire and so we are starting to plan the integration like that.", "score": 0.851046, "arguments": [{"text": "employees", "location": [39958, 39967], "entities": [{"type": "Person", "text": "employees"}]}, {"text": "communicated", "location": [39934, 39946], "entities": [{"type": "EventCommunication", "text": "communicated"}]}]}, {"type": "employedBy", "sentence": "This is something we have communicated to all our employees at Takeda and at Shire and so we are starting to plan the integration like that.", "score": 0.962824, "arguments": [{"text": "employees", "location": [39958, 39967], "entities": [{"type": "Person", "text": "employees"}]}, {"text": "our", "location": [39954, 39957], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "managerOf", "sentence": "We have already nominated the future Takeda executive team.", "score": 0.784533, "arguments": [{"text": "executive", "location": [40093, 40102], "entities": [{"type": "Person", "text": "executive"}]}, {"text": "team", "location": [40103, 40107], "entities": [{"type": "Organization", "text": "team"}]}]}, {"type": "managerOf", "sentence": "So postclosing, so on day 1, postclosing, that would be the Takeda executive team with, of course, some Shire leaders joining us.", "score": 0.805134, "arguments": [{"text": "executive", "location": [40176, 40185], "entities": [{"type": "Person", "text": "executive"}]}, {"text": "team", "location": [40186, 40190], "entities": [{"type": "Organization", "text": "team"}]}]}, {"type": "employedBy", "sentence": "So postclosing, so on day 1, postclosing, that would be the Takeda executive team with, of course, some Shire leaders joining us.", "score": 0.306754, "arguments": [{"text": "leaders", "location": [40219, 40226], "entities": [{"type": "Person", "text": "leaders"}]}, {"text": "team", "location": [40186, 40190], "entities": [{"type": "Organization", "text": "team"}]}]}, {"type": "managerOf", "sentence": "So postclosing, so on day 1, postclosing, that would be the Takeda executive team with, of course, some Shire leaders joining us.", "score": 0.401364, "arguments": [{"text": "Shire", "location": [40213, 40218], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "leaders", "location": [40219, 40226], "entities": [{"type": "Person", "text": "leaders"}]}]}, {"type": "locatedAt", "sentence": "We have made a few divestiture of noncore assets in the first trimester, Multilab in Brazil and Techpool in China.", "score": 0.955693, "arguments": [{"text": "Techpool", "location": [2253, 2261], "entities": [{"type": "GeopoliticalEntity", "text": "Techpool"}]}, {"text": "China", "location": [2265, 2270], "entities": [{"type": "GeopoliticalEntity", "text": "China"}]}]}, {"type": "partOfMany", "sentence": "So postclosing, so on day 1, postclosing, that would be the Takeda executive team with, of course, some Shire leaders joining us.", "score": 0.504192, "arguments": [{"text": "leaders", "location": [40219, 40226], "entities": [{"type": "Person", "text": "leaders"}]}, {"text": "us", "location": [40235, 40237], "entities": [{"type": "Person", "text": "us"}]}]}, {"type": "partOf", "sentence": "And it's reflecting our operating model and the organization of the company.", "score": 0.717737, "arguments": [{"text": "organization", "location": [40287, 40299], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "company", "location": [40307, 40314], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "managerOf", "sentence": "And you can see that it's a very diverse, but also very experienced executive team.", "score": 0.862298, "arguments": [{"text": "executive", "location": [40384, 40393], "entities": [{"type": "Person", "text": "executive"}]}, {"text": "team", "location": [40394, 40398], "entities": [{"type": "Organization", "text": "team"}]}]}, {"type": "colleague", "sentence": "We want this integration to be a good experience for both Shire employees and Takeda employees.", "score": 0.214085, "arguments": [{"text": "Shire", "location": [40667, 40672], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "employees", "location": [40673, 40682], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "colleague", "sentence": "We want this integration to be a good experience for both Shire employees and Takeda employees.", "score": 0.25413, "arguments": [{"text": "Takeda", "location": [40687, 40693], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "employees", "location": [40694, 40703], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "partOf", "sentence": "And we want to have a clarity of our strategic intent and our organization as soon as possible and that's why we are preparing the integration.", "score": 0.623123, "arguments": [{"text": "organization", "location": [40767, 40779], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "our", "location": [40763, 40766], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "agentOf", "sentence": "Many of the information I shared here you have heard it before, not all, so we have added some information like the goodwill and intangibles because we have seen many questions here.", "score": 0.945995, "arguments": [{"text": "we", "location": [40995, 40997], "entities": [{"type": "Person", "text": "we"}]}, {"text": "added", "location": [41003, 41008], "entities": [{"type": "EventCommunication", "text": "added"}]}]}, {"type": "agentOf", "sentence": "Many of the information I shared here you have heard it before, not all, so we have added some information like the goodwill and intangibles because we have seen many questions here.", "score": 0.291833, "arguments": [{"text": "here", "location": [41096, 41100], "entities": [{"type": "GeopoliticalEntity", "text": "here"}]}, {"text": "questions", "location": [41086, 41095], "entities": [{"type": "EventCommunication", "text": "questions"}]}]}, {"type": "locatedAt", "sentence": "But we are -- we really believe that this acquisition is really a unique opportunity, quite -- very unique opportunity to accelerate our transformation journey and to really allow us to become this value-based, R&D-driven global biopharmaceutical leader headquarter in Japan.", "score": 0.431171, "arguments": [{"text": "R&D-", "location": [41313, 41317], "entities": [{"type": "Person", "text": "R&D-"}]}, {"text": "Japan", "location": [41371, 41376], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "locatedAt", "sentence": "But we are -- we really believe that this acquisition is really a unique opportunity, quite -- very unique opportunity to accelerate our transformation journey and to really allow us to become this value-based, R&D-driven global biopharmaceutical leader headquarter in Japan.", "score": 0.691916, "arguments": [{"text": "leader headquarter", "location": [41349, 41367], "entities": [{"type": "Person", "text": "leader headquarter"}]}, {"text": "Japan", "location": [41371, 41376], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "ownerOf", "sentence": "But we are very satisfied about the ALUNBRIG data readout, ADCETRIS ECHELON-2 readout as well as our pipeline progression.", "score": 0.374003, "arguments": [{"text": "our", "location": [2480, 2483], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "pipeline", "location": [2484, 2492], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "participantIn", "sentence": "Question-and-Answer Session Operator Thank you very much.", "score": 0.856098, "arguments": [{"text": "Operator", "location": [41427, 41435], "entities": [{"type": "Person", "text": "Operator"}]}, {"text": "Session", "location": [41419, 41426], "entities": [{"type": "EventMeeting", "text": "Session"}]}]}, {"type": "employedBy", "sentence": "[Operator Instructions] Unidentified Company Representative Now we start Q&A session.", "score": 0.490606, "arguments": [{"text": "Representative", "location": [41546, 41560], "entities": [{"type": "Person", "text": "Representative"}]}, {"text": "Company", "location": [41538, 41545], "entities": [{"type": "Organization", "text": "Company"}]}]}, {"type": "agentOf", "sentence": "[Operator Instructions] Unidentified Company Representative Now we start Q&A session.", "score": 0.650127, "arguments": [{"text": "Q&A", "location": [41574, 41577], "entities": [{"type": "Organization", "text": "Q&A"}]}, {"text": "session", "location": [41578, 41585], "entities": [{"type": "EventMeeting", "text": "session"}]}]}, {"type": "locatedAt", "sentence": "But a $35.5 billion increase in revenue, that seems a little low for 6-month sector sales and it's got about $100 million sales per month, I believe, in the U.S. So just if you could give a little bit more clarity around that.", "score": 0.458856, "arguments": [{"text": "I", "location": [42218, 42219], "entities": [{"type": "Person", "text": "I"}]}, {"text": "U.S.", "location": [42236, 42240], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "agentOf", "sentence": "And we are talking about the Fresenius competitors.", "score": 0.909964, "arguments": [{"text": "we", "location": [42800, 42802], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "talking", "location": [42807, 42814], "entities": [{"type": "EventCommunication", "text": "talking"}]}]}, {"type": "participantIn", "sentence": "The ADR -- and then you have the closing date, of course, which is linked to organizing the shareholder meeting on both sides, the [shareholder side] on the Shire side.", "score": 0.669041, "arguments": [{"text": "shareholder", "location": [44773, 44784], "entities": [{"type": "Person", "text": "shareholder"}]}, {"text": "meeting", "location": [44785, 44792], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "But at this stage, we can only say, well, we confirm, in our mind, that the closure will still happen assuming, of course, we get approval by both AGM, by both shareholder meetings in the first semester.", "score": 0.729643, "arguments": [{"text": "we", "location": [44958, 44960], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "say", "location": [44970, 44973], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "But at this stage, we can only say, well, we confirm, in our mind, that the closure will still happen assuming, of course, we get approval by both AGM, by both shareholder meetings in the first semester.", "score": 0.912664, "arguments": [{"text": "we", "location": [44981, 44983], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "confirm", "location": [44984, 44991], "entities": [{"type": "EventCommunication", "text": "confirm"}]}]}, {"type": "participantIn", "sentence": "But at this stage, we can only say, well, we confirm, in our mind, that the closure will still happen assuming, of course, we get approval by both AGM, by both shareholder meetings in the first semester.", "score": 0.369629, "arguments": [{"text": "AGM", "location": [45086, 45089], "entities": [{"type": "Organization", "text": "AGM"}]}, {"text": "meetings", "location": [45111, 45119], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "participantIn", "sentence": "But at this stage, we can only say, well, we confirm, in our mind, that the closure will still happen assuming, of course, we get approval by both AGM, by both shareholder meetings in the first semester.", "score": 0.715834, "arguments": [{"text": "shareholder", "location": [45099, 45110], "entities": [{"type": "Person", "text": "shareholder"}]}, {"text": "meetings", "location": [45111, 45119], "entities": [{"type": "EventMeeting", "text": "meetings"}]}]}, {"type": "employedBy", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.487613, "arguments": [{"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}, {"text": "Takeda Pharmaceutical Co. Ltd.", "location": [0, 30], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd."}]}]}, {"type": "partOf", "sentence": "On the profitability, our Global OPEX Initiative is on full motion, and it's really delivering very strong OpEx management.", "score": 0.87954, "arguments": [{"text": "Global OPEX Initiative", "location": [2602, 2624], "entities": [{"type": "Organization", "text": "Global OPEX Initiative"}]}, {"text": "our", "location": [2598, 2601], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "participantIn", "sentence": "Of course, as you have seen, we are in dialogue with the European Commission.", "score": 0.540358, "arguments": [{"text": "we", "location": [45172, 45174], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "dialogue", "location": [45182, 45190], "entities": [{"type": "EventMeeting", "text": "dialogue"}]}]}, {"type": "participantIn", "sentence": "Of course, as you have seen, we are in dialogue with the European Commission.", "score": 0.89842, "arguments": [{"text": "European Commission", "location": [45200, 45219], "entities": [{"type": "Organization", "text": "European Commission"}]}, {"text": "dialogue", "location": [45182, 45190], "entities": [{"type": "EventMeeting", "text": "dialogue"}]}]}, {"type": "employedBy", "sentence": "Christophe Weber Well, it's an important development for ENTYVIO because, of course, subcutaneous formulation is much more -- it's easier for the patients for the administration.", "score": 0.547367, "arguments": [{"text": "patients", "location": [46155, 46163], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "administration", "location": [46172, 46186], "entities": [{"type": "GeopoliticalEntity", "text": "administration"}]}]}, {"type": "locatedAt", "sentence": "So it's quite -- it's an important development for the product and to offer different alternatives of administration for the patients here.", "score": 0.327105, "arguments": [{"text": "patients", "location": [46424, 46432], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "here", "location": [46433, 46437], "entities": [{"type": "GeopoliticalEntity", "text": "here"}]}]}, {"type": "agentOf", "sentence": "Yes, we communicated to deliver on the synergies of at least $1.4 billion on -- within 30 post close, that we'll need to spend approximately $2.4 billion.", "score": 0.928601, "arguments": [{"text": "we", "location": [46662, 46664], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "communicated", "location": [46665, 46677], "entities": [{"type": "EventCommunication", "text": "communicated"}]}]}, {"type": "participantIn", "sentence": "Of course, we are currently ongoing with the dialogue and evaluating the cost opportunities of the synergies.", "score": 0.485369, "arguments": [{"text": "we", "location": [46861, 46863], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "dialogue", "location": [46895, 46903], "entities": [{"type": "EventMeeting", "text": "dialogue"}]}]}, {"type": "employedBy", "sentence": "Atsushi Seki My name is Seki from UBS.", "score": 0.518559, "arguments": [{"text": "Seki", "location": [47145, 47149], "entities": [{"type": "Person", "text": "Seki"}]}, {"text": "UBS", "location": [47155, 47158], "entities": [{"type": "Organization", "text": "UBS"}]}]}, {"type": "residesIn", "sentence": "And the second, after successful closure of this deal, so you will be no longer restricted by your UK takeover code.", "score": 0.276472, "arguments": [{"text": "your", "location": [47857, 47861], "entities": [{"type": "Person", "text": "your"}]}, {"text": "UK", "location": [47862, 47864], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "affectedBy", "sentence": "And the second, after successful closure of this deal, so you will be no longer restricted by your UK takeover code.", "score": 0.459888, "arguments": [{"text": "your", "location": [47857, 47861], "entities": [{"type": "Person", "text": "your"}]}, {"text": "takeover", "location": [47865, 47873], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "affectedBy", "sentence": "Atsushi Seki And finally, on the ENTYVIO, so now you have maintenance trial data inventory in-house.", "score": 0.384276, "arguments": [{"text": "you", "location": [48884, 48887], "entities": [{"type": "Person", "text": "you"}]}, {"text": "trial", "location": [48905, 48910], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "locatedAt", "sentence": "In fact, we are seeing good rebounds in a country like China, for example.", "score": 0.27842, "arguments": [{"text": "country", "location": [3318, 3325], "entities": [{"type": "GeopoliticalEntity", "text": "country"}]}, {"text": "China", "location": [3331, 3336], "entities": [{"type": "GeopoliticalEntity", "text": "China"}]}]}, {"type": "locatedAt", "sentence": "Atsushi Seki And finally, on the ENTYVIO, so now you have maintenance trial data inventory in-house.", "score": 0.416517, "arguments": [{"text": "you", "location": [48884, 48887], "entities": [{"type": "Person", "text": "you"}]}, {"text": "house", "location": [48929, 48934], "entities": [{"type": "Facility", "text": "house"}]}]}, {"type": "partOfMany", "sentence": "Christophe Weber I think we need still to look at the final readout of the front-line data to answer that question.", "score": 0.734024, "arguments": [{"text": "Christophe Weber", "location": [49031, 49047], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "we", "location": [49056, 49058], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "agentOf", "sentence": "I think this is important to have in order to answer that questions.", "score": 0.490222, "arguments": [{"text": "I", "location": [49257, 49258], "entities": [{"type": "Person", "text": "I"}]}, {"text": "questions", "location": [49315, 49324], "entities": [{"type": "EventCommunication", "text": "questions"}]}]}, {"type": "employedBy", "sentence": "Unidentified Company Representative If you have a question, please raise your hand again.", "score": 0.676408, "arguments": [{"text": "Representative", "location": [49347, 49361], "entities": [{"type": "Person", "text": "Representative"}]}, {"text": "Company", "location": [49339, 49346], "entities": [{"type": "Organization", "text": "Company"}]}]}, {"type": "employedBy", "sentence": "Ritsuo Watanabe Watanabe from Merrill Lynch Securities.", "score": 0.762543, "arguments": [{"text": "Watanabe\nWatanabe", "location": [49423, 49440], "entities": [{"type": "Person", "text": "Watanabe\nWatanabe"}]}, {"text": "Ritsuo", "location": [49416, 49422], "entities": [{"type": "Organization", "text": "Ritsuo"}]}]}, {"type": "employedBy", "sentence": "Ritsuo Watanabe Watanabe from Merrill Lynch Securities.", "score": 0.902567, "arguments": [{"text": "Watanabe\nWatanabe", "location": [49423, 49440], "entities": [{"type": "Person", "text": "Watanabe\nWatanabe"}]}, {"text": "Merrill Lynch Securities", "location": [49446, 49470], "entities": [{"type": "Organization", "text": "Merrill Lynch Securities"}]}]}, {"type": "partOfMany", "sentence": "Christophe Weber I think we are more considering global rights.", "score": 0.751684, "arguments": [{"text": "Christophe Weber", "location": [49806, 49822], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "we", "location": [49831, 49833], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "employedBy", "sentence": "Ritsuo Watanabe Second question about Japanese business.", "score": 0.674528, "arguments": [{"text": "Watanabe", "location": [49877, 49885], "entities": [{"type": "Person", "text": "Watanabe"}]}, {"text": "Ritsuo", "location": [49870, 49876], "entities": [{"type": "Organization", "text": "Ritsuo"}]}]}, {"type": "agentOf", "sentence": "Ritsuo Watanabe Second question about Japanese business.", "score": 0.790255, "arguments": [{"text": "Watanabe", "location": [49877, 49885], "entities": [{"type": "Person", "text": "Watanabe"}]}, {"text": "question", "location": [49893, 49901], "entities": [{"type": "EventCommunication", "text": "question"}]}]}, {"type": "basedIn", "sentence": "Regarding the Japan business, I have a question.", "score": 0.900154, "arguments": [{"text": "business", "location": [49947, 49955], "entities": [{"type": "Organization", "text": "business"}]}, {"text": "Japan", "location": [49941, 49946], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "employedBy", "sentence": "They are growing close to 10%, and also very specifically GI because GI is a massive part of our Growth Drivers.", "score": 0.841727, "arguments": [{"text": "Drivers", "location": [3504, 3511], "entities": [{"type": "Person", "text": "Drivers"}]}, {"text": "our", "location": [3493, 3496], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "employedBy", "sentence": "Regarding the Japan business, I have a question.", "score": 0.388134, "arguments": [{"text": "I", "location": [49957, 49958], "entities": [{"type": "Person", "text": "I"}]}, {"text": "business", "location": [49947, 49955], "entities": [{"type": "Organization", "text": "business"}]}]}, {"type": "managerOf", "sentence": "Your company have divest", "score": 0.406034, "arguments": [{"text": "Your", "location": [49976, 49980], "entities": [{"type": "Person", "text": "Your"}]}, {"text": "company", "location": [49981, 49988], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "agentOf", "sentence": "We communicated about this data.", "score": 0.985904, "arguments": [{"text": "We", "location": [4085, 4087], "entities": [{"type": "Person", "text": "We"}]}, {"text": "communicated", "location": [4088, 4100], "entities": [{"type": "EventCommunication", "text": "communicated"}]}]}, {"type": "affectedBy", "sentence": "Perhaps I will just outline here Pevonedistat because we have now confirmation that the Phase II trial is positive.", "score": 0.481807, "arguments": [{"text": "I", "location": [4933, 4934], "entities": [{"type": "Person", "text": "I"}]}, {"text": "trial", "location": [5022, 5027], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "agentOf", "sentence": "Perhaps I will just outline here Pevonedistat because we have now confirmation that the Phase II trial is positive.", "score": 0.906566, "arguments": [{"text": "Phase II", "location": [5013, 5021], "entities": [{"type": "Organization", "text": "Phase II"}]}, {"text": "trial", "location": [5022, 5027], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "affectedBy", "sentence": "If the readout is positive, could be a trial which would grant us approval.", "score": 0.628614, "arguments": [{"text": "us", "location": [5104, 5106], "entities": [{"type": "Person", "text": "us"}]}, {"text": "trial", "location": [5080, 5085], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "employedBy", "sentence": "Although our Growth Drivers remained strong, there was a negative 1 percentage point on foreign exchange and a minus 3.2 percentage points from divestitures.", "score": 0.777508, "arguments": [{"text": "Drivers", "location": [5961, 5968], "entities": [{"type": "Person", "text": "Drivers"}]}, {"text": "our", "location": [5950, 5953], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "locatedAt", "sentence": "The main foreign exchange items were the appreciation of the yen versus the U.S. dollar and the depreciation of currencies in Brazil and Russia.", "score": 0.773602, "arguments": [{"text": "Brazil", "location": [6225, 6231], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil"}]}, {"text": "Russia", "location": [6236, 6242], "entities": [{"type": "GeopoliticalEntity", "text": "Russia"}]}]}, {"type": "agentOf", "sentence": "Reported EPS declined minus 26.9%, with lower financial income and higher financial expenses offset by a lower tax rate.", "score": 0.443922, "arguments": [{"text": "EPS", "location": [6833, 6836], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "Reported", "location": [6824, 6832], "entities": [{"type": "EventCommunication", "text": "Reported"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.213011, "arguments": [{"text": "AM ET", "location": [110, 115], "entities": [{"type": "Person", "text": "AM ET"}]}, {"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "agentOf", "sentence": "Reported EPS declined minus 26.9%, with lower financial income and higher financial expenses offset by a lower tax rate.", "score": 0.986502, "arguments": [{"text": "EPS", "location": [6833, 6836], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "declined", "location": [6837, 6845], "entities": [{"type": "EventCommunication", "text": "declined"}]}]}, {"type": "employedBy", "sentence": "Underlying revenue was up 4.2%, led by our Growth Drivers growing at 9.8%.", "score": 0.651987, "arguments": [{"text": "Growth", "location": [7081, 7087], "entities": [{"type": "Person", "text": "Growth"}]}, {"text": "our", "location": [7077, 7080], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "employedBy", "sentence": "Underlying revenue was up 4.2%, led by our Growth Drivers growing at 9.8%.", "score": 0.738151, "arguments": [{"text": "Drivers", "location": [7088, 7095], "entities": [{"type": "Person", "text": "Drivers"}]}, {"text": "our", "location": [7077, 7080], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "agentOf", "sentence": "As I mentioned on the previous slide, this includes a 1 percentage point negative foreign exchange impact and a negative 3.2 percentage points impact from divestitures.", "score": 0.976088, "arguments": [{"text": "I", "location": [7629, 7630], "entities": [{"type": "Person", "text": "I"}]}, {"text": "mentioned", "location": [7631, 7640], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "timeOf", "sentence": "Other operating income declined by $146 billion, almost entirely due to the sale of the Wako shares in 2017.", "score": 0.936986, "arguments": [{"text": "2017", "location": [8971, 8975], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "declined", "location": [8891, 8899], "entities": [{"type": "EventBusiness", "text": "declined"}]}]}, {"type": "ownerOf", "sentence": "This is mainly due to prelaunch inventory which was recognized as expenses in fiscal year 2017 and then reversed as a gain in fiscal year 2018 as a result of FDA approval of a manufacturing plant in quarter one.", "score": 0.390524, "arguments": [{"text": "FDA", "location": [9375, 9378], "entities": [{"type": "Organization", "text": "FDA"}]}, {"text": "manufacturing plant", "location": [9393, 9412], "entities": [{"type": "Facility", "text": "manufacturing plant"}]}]}, {"type": "agentOf", "sentence": "On this slide, we also called out the Shire-related costs in the first half.", "score": 0.958867, "arguments": [{"text": "we", "location": [9444, 9446], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "called out", "location": [9452, 9462], "entities": [{"type": "EventCommunication", "text": "called out"}]}]}, {"type": "hasAttribute", "sentence": "Although we also received $38.2 billion cash for securities sold in 2018 fiscal year, we can no longer recognize the gain on the P&L under the new IFRS 9 accounting standards.", "score": 0.786045, "arguments": [{"text": "we", "location": [10086, 10088], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "\u00a538.2 billion", "location": [10026, 10039], "entities": [{"type": "Money", "text": "\u00a538.2 billion"}]}]}, {"type": "agentOf", "sentence": "As explained, the impact of Shire-related costs on operating profit was $11.1 billion, and financial expenses was $8.8 billion, for a total profit before tax impact of $19.8 billion.", "score": 0.677252, "arguments": [{"text": "Shire", "location": [10528, 10533], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "explained", "location": [10503, 10512], "entities": [{"type": "EventCommunication", "text": "explained"}]}]}, {"type": "hasAttribute", "sentence": "As explained, the impact of Shire-related costs on operating profit was $11.1 billion, and financial expenses was $8.8 billion, for a total profit before tax impact of $19.8 billion.", "score": 0.785474, "arguments": [{"text": "Shire", "location": [10528, 10533], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "\u00a511.1 billion", "location": [10572, 10585], "entities": [{"type": "Money", "text": "\u00a511.1 billion"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.954036, "arguments": [{"text": "Christophe Weber", "location": [127, 143], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "employedBy", "sentence": "Underlying revenue growth was a solid 4.2%, driven by our Growth Drivers such as NINLARO, ENTYVIO and the ARIAD-acquired products, Iclusig and ALUNBRIG.", "score": 0.491372, "arguments": [{"text": "Growth", "location": [11149, 11155], "entities": [{"type": "Person", "text": "Growth"}]}, {"text": "our", "location": [11145, 11148], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "employedBy", "sentence": "Underlying revenue growth was a solid 4.2%, driven by our Growth Drivers such as NINLARO, ENTYVIO and the ARIAD-acquired products, Iclusig and ALUNBRIG.", "score": 0.682411, "arguments": [{"text": "Drivers", "location": [11156, 11163], "entities": [{"type": "Person", "text": "Drivers"}]}, {"text": "our", "location": [11145, 11148], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "agentOf", "sentence": "Since I became CFO in April of this year, I've emphasized my commitment to delivering on margin improvement.", "score": 0.964601, "arguments": [{"text": "I", "location": [11761, 11762], "entities": [{"type": "Person", "text": "I"}]}, {"text": "emphasized", "location": [11766, 11776], "entities": [{"type": "EventCommunication", "text": "emphasized"}]}]}, {"type": "hasAttribute", "sentence": "Furthermore, we paid $ 8.8 billion tax related to this transaction in this fiscal year 2018 for a total net negative impact of $37.3 billion.", "score": 0.62108, "arguments": [{"text": "we", "location": [13023, 13025], "entities": [{"type": "Person", "text": "we"}]}, {"text": "\u00a5 8.8 billion", "location": [13031, 13044], "entities": [{"type": "Money", "text": "\u00a5 8.8 billion"}]}]}, {"type": "hasAttribute", "sentence": "In addition, we received $27.2 billion cash from the sale of noncore businesses, Techpool and Multilab.", "score": 0.843891, "arguments": [{"text": "businesses", "location": [13456, 13466], "entities": [{"type": "Organization", "text": "businesses"}]}, {"text": "\u00a527.2 billion", "location": [13412, 13425], "entities": [{"type": "Money", "text": "\u00a527.2 billion"}]}]}, {"type": "agentOf", "sentence": "Our upgraded reported forecast for the full fiscal year 2018, which we are upgrading based on VELCADE upside, Growth Driver momentum and OpEx discipline.", "score": 0.500127, "arguments": [{"text": "Our", "location": [14798, 14801], "entities": [{"type": "Organization", "text": "Our"}]}, {"text": "reported", "location": [14811, 14819], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "partOf", "sentence": "Our EPS forecast has also changed from a negative outlook to positive, and we now expect year-on-year growth of 9.8%.", "score": 0.740139, "arguments": [{"text": "EPS", "location": [15861, 15864], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "Our", "location": [15857, 15860], "entities": [{"type": "Organization", "text": "Our"}]}]}, {"type": "agentOf", "sentence": "With regards to Shire-related costs, as explained earlier, we booked first half expenses of $16.5 billion after tax.", "score": 0.449942, "arguments": [{"text": "Shire", "location": [16058, 16063], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "explained", "location": [16082, 16091], "entities": [{"type": "EventCommunication", "text": "explained"}]}]}, {"type": "hasAttribute", "sentence": "For the full year, we estimate a portion of the Shire-related expenses to be incurred by Takeda to be between $40 billion and $60 billion.", "score": 0.599906, "arguments": [{"text": "Takeda", "location": [16248, 16254], "entities": [{"type": "Organization", "text": "Takeda"}]}, {"text": "\u00a540 billion", "location": [16269, 16280], "entities": [{"type": "Money", "text": "\u00a540 billion"}]}]}, {"type": "hasAttribute", "sentence": "For the full year, we estimate a portion of the Shire-related expenses to be incurred by Takeda to be between $40 billion and $60 billion.", "score": 0.650532, "arguments": [{"text": "Takeda", "location": [16248, 16254], "entities": [{"type": "Organization", "text": "Takeda"}]}, {"text": "\u00a560 billion", "location": [16285, 16296], "entities": [{"type": "Money", "text": "\u00a560 billion"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.761696, "arguments": [{"text": "President", "location": [146, 155], "entities": [{"type": "Person", "text": "President"}]}, {"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "agentOf", "sentence": "Our full year forecast that does include the full impact of Shire will be announced once a reasonable assumption can be made.", "score": 0.724133, "arguments": [{"text": "Shire", "location": [16572, 16577], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "announced", "location": [16586, 16595], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "As I explained back in May, our outlook for other income is impacted by the large gain we booked in fiscal year 2017 related to the sale of Wako shares, which will not be fully offset by the higher outlook for sale of real estate in the fiscal year 2018.", "score": 0.978576, "arguments": [{"text": "I", "location": [17049, 17050], "entities": [{"type": "Person", "text": "I"}]}, {"text": "explained", "location": [17051, 17060], "entities": [{"type": "EventCommunication", "text": "explained"}]}]}, {"type": "timeOf", "sentence": "As I explained back in May, our outlook for other income is impacted by the large gain we booked in fiscal year 2017 related to the sale of Wako shares, which will not be fully offset by the higher outlook for sale of real estate in the fiscal year 2018.", "score": 0.852848, "arguments": [{"text": "May", "location": [17069, 17072], "entities": [{"type": "Date", "text": "May"}]}, {"text": "explained", "location": [17051, 17060], "entities": [{"type": "EventCommunication", "text": "explained"}]}]}, {"type": "timeOf", "sentence": "Here, we show a comparison of the revised forecast as of October 31 versus the previous forecast announced on May 14 and have noted on the right-hand side the main reasons for the upgrade.", "score": 0.896445, "arguments": [{"text": "May 14", "location": [17780, 17786], "entities": [{"type": "Date", "text": "May 14"}]}, {"text": "announced", "location": [17767, 17776], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "This includes an additional of $35.5 billion of VELCADE revenue as well as continued momentum from our Growth Drivers.", "score": 0.897887, "arguments": [{"text": "our", "location": [18083, 18086], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "\u00a535.5 billion", "location": [18015, 18028], "entities": [{"type": "Money", "text": "\u00a535.5 billion"}]}]}, {"type": "employedBy", "sentence": "This includes an additional of $35.5 billion of VELCADE revenue as well as continued momentum from our Growth Drivers.", "score": 0.602643, "arguments": [{"text": "Growth", "location": [18087, 18093], "entities": [{"type": "Person", "text": "Growth"}]}, {"text": "our", "location": [18083, 18086], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "employedBy", "sentence": "This includes an additional of $35.5 billion of VELCADE revenue as well as continued momentum from our Growth Drivers.", "score": 0.750466, "arguments": [{"text": "Drivers", "location": [18094, 18101], "entities": [{"type": "Person", "text": "Drivers"}]}, {"text": "our", "location": [18083, 18086], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "managerOf", "sentence": "This includes an additional of $35.5 billion of VELCADE revenue as well as continued momentum from our Growth Drivers.", "score": 0.296977, "arguments": [{"text": "Growth", "location": [18087, 18093], "entities": [{"type": "Person", "text": "Growth"}]}, {"text": "Drivers", "location": [18094, 18101], "entities": [{"type": "Person", "text": "Drivers"}]}]}, {"type": "hasAttribute", "sentence": "Core earnings improvement of $20.5 billion or 6.6% reflects a VELCADE upside, Growth Driver momentum and OpEx discipline.", "score": 0.819221, "arguments": [{"text": "Core", "location": [18354, 18358], "entities": [{"type": "Organization", "text": "Core"}]}, {"text": "\u00a520.5 billion", "location": [18383, 18396], "entities": [{"type": "Money", "text": "\u00a520.5 billion"}]}]}, {"type": "hasAttribute", "sentence": "It also includes the gain on the sale of Techpool of $18.4 billion, which we booked in quarter 2.", "score": 0.626706, "arguments": [{"text": "Techpool", "location": [18833, 18841], "entities": [{"type": "Person", "text": "Techpool"}]}, {"text": "\u00a518.4 billion", "location": [18845, 18858], "entities": [{"type": "Money", "text": "\u00a518.4 billion"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.796122, "arguments": [{"text": "CEO", "location": [158, 161], "entities": [{"type": "Person", "text": "CEO"}]}, {"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "partOfMany", "sentence": "It also includes the gain on the sale of Techpool of $18.4 billion, which we booked in quarter 2.", "score": 0.565791, "arguments": [{"text": "Techpool", "location": [18833, 18841], "entities": [{"type": "Person", "text": "Techpool"}]}, {"text": "we", "location": [18866, 18868], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "hasAttribute", "sentence": "And we also assume lower restructuring costs by $12.5 billion.", "score": 0.568296, "arguments": [{"text": "we", "location": [18894, 18896], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "\u00a512.5 billion", "location": [18938, 18951], "entities": [{"type": "Money", "text": "\u00a512.5 billion"}]}]}, {"type": "partOf", "sentence": "Our EPS outlook now assumes a more favorable tax rate, improving from approximately 24% to approximately 22% due to a favorable earnings mix and partial release of an uncertain tax provision.", "score": 0.763418, "arguments": [{"text": "EPS", "location": [18957, 18960], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "Our", "location": [18953, 18956], "entities": [{"type": "Organization", "text": "Our"}]}]}, {"type": "employedBy", "sentence": "However, we are upgrading our guidance for underlying core earnings from high single digit to high teen and our guidance for underlying EPS from low teens to mid-20s.", "score": 0.394131, "arguments": [{"text": "teens", "location": [19505, 19510], "entities": [{"type": "Person", "text": "teens"}]}, {"text": "EPS", "location": [19492, 19495], "entities": [{"type": "Organization", "text": "EPS"}]}]}, {"type": "hasAttribute", "sentence": "However, we are upgrading our guidance for underlying core earnings from high single digit to high teen and our guidance for underlying EPS from low teens to mid-20s.", "score": 0.79258, "arguments": [{"text": "teens", "location": [19505, 19510], "entities": [{"type": "Person", "text": "teens"}]}, {"text": "mid-20s", "location": [19514, 19521], "entities": [{"type": "Age", "text": "mid-20s"}]}]}, {"type": "agentOf", "sentence": "And again, as with our reported forecast, the underlying guidance does not include any Shire-related costs in order to achieve a like-for-like comparison.", "score": 0.671136, "arguments": [{"text": "our", "location": [20227, 20230], "entities": [{"type": "Person", "text": "our"}]}, {"text": "reported", "location": [20231, 20239], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "agentOf", "sentence": "Our reported results reflect the large impact from divestitures, most notably Wako and Teva JV products in 2017; and also the booking of onetime costs related to the Shire transaction in 2018.", "score": 0.876684, "arguments": [{"text": "Our", "location": [20760, 20763], "entities": [{"type": "Organization", "text": "Our"}]}, {"text": "reported", "location": [20764, 20772], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "agentOf", "sentence": "Our reported results reflect the large impact from divestitures, most notably Wako and Teva JV products in 2017; and also the booking of onetime costs related to the Shire transaction in 2018.", "score": 0.434746, "arguments": [{"text": "Wako", "location": [20838, 20842], "entities": [{"type": "Person", "text": "Wako"}]}, {"text": "reported", "location": [20764, 20772], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "timeOf", "sentence": "Our reported results reflect the large impact from divestitures, most notably Wako and Teva JV products in 2017; and also the booking of onetime costs related to the Shire transaction in 2018.", "score": 0.522426, "arguments": [{"text": "2017", "location": [20867, 20871], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "reported", "location": [20764, 20772], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "agentOf", "sentence": "When we look out on the full year, we are confident to raise both our reported forecast and underlying guidance due to the VELCADE upside, our growth momentum and OpEx discipline.", "score": 0.509572, "arguments": [{"text": "our", "location": [21120, 21123], "entities": [{"type": "Person", "text": "our"}]}, {"text": "reported", "location": [21124, 21132], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.830858, "arguments": [{"text": "Costa Saroukos - CFO\nAndrew Plump", "location": [162, 195], "entities": [{"type": "Person", "text": "Costa Saroukos - CFO\nAndrew Plump"}]}, {"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "agentOf", "sentence": "As noted throughout, this revised guidance does not include the Shire-related costs.", "score": 0.791903, "arguments": [{"text": "Shire", "location": [21298, 21303], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "noted", "location": [21237, 21242], "entities": [{"type": "EventCommunication", "text": "noted"}]}]}, {"type": "agentOf", "sentence": "So on Slide 20, I want to demonstrate how our strong financial discipline and solid execution is laying the foundation for the Shire acquisition and integration.", "score": 0.486967, "arguments": [{"text": "our", "location": [21519, 21522], "entities": [{"type": "Person", "text": "our"}]}, {"text": "execution", "location": [21561, 21570], "entities": [{"type": "EventLegal", "text": "execution"}]}]}, {"type": "agentOf", "sentence": "So on Slide 20, I want to demonstrate how our strong financial discipline and solid execution is laying the foundation for the Shire acquisition and integration.", "score": 0.432184, "arguments": [{"text": "Shire", "location": [21604, 21609], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [21610, 21621], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Already this year, we have generated over $70 billion from disposal of noncore assets, such as real estate, securities and noncore businesses.", "score": 0.434698, "arguments": [{"text": "we", "location": [22329, 22331], "entities": [{"type": "Person", "text": "we"}]}, {"text": "\u00a570 billion", "location": [22352, 22363], "entities": [{"type": "Money", "text": "\u00a570 billion"}]}]}, {"type": "hasAttribute", "sentence": "Already this year, we have generated over $70 billion from disposal of noncore assets, such as real estate, securities and noncore businesses.", "score": 0.534804, "arguments": [{"text": "businesses", "location": [22441, 22451], "entities": [{"type": "Organization", "text": "businesses"}]}, {"text": "\u00a570 billion", "location": [22352, 22363], "entities": [{"type": "Money", "text": "\u00a570 billion"}]}]}, {"type": "agentOf", "sentence": "As you know, we have set a record date, which means that we have until January 18 to organize the shareholder meeting.", "score": 0.568197, "arguments": [{"text": "we", "location": [23473, 23475], "entities": [{"type": "Person", "text": "we"}]}, {"text": "organize", "location": [23501, 23509], "entities": [{"type": "Crime", "text": "organize"}]}]}, {"type": "timeOf", "sentence": "As you know, we have set a record date, which means that we have until January 18 to organize the shareholder meeting.", "score": 0.482085, "arguments": [{"text": "January 18", "location": [23487, 23497], "entities": [{"type": "Date", "text": "January 18"}]}, {"text": "meeting", "location": [23526, 23533], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "As you know, we have set a record date, which means that we have until January 18 to organize the shareholder meeting.", "score": 0.636855, "arguments": [{"text": "shareholder", "location": [23514, 23525], "entities": [{"type": "Person", "text": "shareholder"}]}, {"text": "meeting", "location": [23526, 23533], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "timeOf", "sentence": "So we have between now and January 18 to organize a shareholder meeting.", "score": 0.681119, "arguments": [{"text": "January 18", "location": [23562, 23572], "entities": [{"type": "Date", "text": "January 18"}]}, {"text": "meeting", "location": [23599, 23606], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "So we have between now and January 18 to organize a shareholder meeting.", "score": 0.393191, "arguments": [{"text": "shareholder", "location": [23587, 23598], "entities": [{"type": "Person", "text": "shareholder"}]}, {"text": "organize", "location": [23576, 23584], "entities": [{"type": "Crime", "text": "organize"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.639462, "arguments": [{"text": "Officer", "location": [225, 232], "entities": [{"type": "Person", "text": "Officer"}]}, {"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "participantIn", "sentence": "So we have between now and January 18 to organize a shareholder meeting.", "score": 0.658542, "arguments": [{"text": "shareholder", "location": [23587, 23598], "entities": [{"type": "Person", "text": "shareholder"}]}, {"text": "meeting", "location": [23599, 23606], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "But we see that it's a great opportunity today to update you about the Shire acquisition.", "score": 0.398175, "arguments": [{"text": "Shire", "location": [23730, 23735], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [23736, 23747], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "employedBy", "sentence": "So we have this opportunity to create this leader headquarter in Japan.", "score": 0.404331, "arguments": [{"text": "leader headquarter", "location": [23792, 23810], "entities": [{"type": "Person", "text": "leader headquarter"}]}, {"text": "we", "location": [23752, 23754], "entities": [{"type": "Organization", "text": "we"}]}]}, {"type": "locatedAt", "sentence": "So we have this opportunity to create this leader headquarter in Japan.", "score": 0.598692, "arguments": [{"text": "leader headquarter", "location": [23792, 23810], "entities": [{"type": "Person", "text": "leader headquarter"}]}, {"text": "Japan", "location": [23814, 23819], "entities": [{"type": "GeopoliticalEntity", "text": "Japan"}]}]}, {"type": "affectedBy", "sentence": "That's really our goal, our intent, and that's why we are contemplating this acquisition.", "score": 0.465194, "arguments": [{"text": "we", "location": [24100, 24102], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "acquisition", "location": [24126, 24137], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "locatedAt", "sentence": "Our vision is to deliver to all patients in the world innovative medicine.", "score": 0.650498, "arguments": [{"text": "patients", "location": [24216, 24224], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "world", "location": [24232, 24237], "entities": [{"type": "GeopoliticalEntity", "text": "world"}]}]}, {"type": "agentOf", "sentence": "And this is, of course, what we are looking for with this acquisition: skill, know-how, but also scale, scale of investment in R&D. But we feel that our vision is the correct vision to be successful in the future.", "score": 0.527001, "arguments": [{"text": "we", "location": [24344, 24346], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "acquisition", "location": [24373, 24384], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "And we don't want these values to be damaged or changed with the Shire acquisition.", "score": 0.499373, "arguments": [{"text": "we", "location": [24702, 24704], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "acquisition", "location": [24769, 24780], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "And we don't want these values to be damaged or changed with the Shire acquisition.", "score": 0.455326, "arguments": [{"text": "Shire", "location": [24763, 24768], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [24769, 24780], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "managerOf", "sentence": "In fact, we would like all Shire employees to understand these values, but more than to understand, to lead these values.", "score": 0.304194, "arguments": [{"text": "Shire", "location": [24809, 24814], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "employees", "location": [24815, 24824], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "partOfMany", "sentence": "Takeda Pharmaceutical Co. Ltd. ( OTCPK:TKPHF ) Q2 2019 Results Earnings Conference Call November 1, 2018 4:30 AM ET Executives Christophe Weber - President & CEO Costa Saroukos - CFO Andrew Plump - Chief Medical & Scientific Officer Masato Iwasaki - President of Japan Pharma Business Unit Analysts Steve Barker - CLSA Kazuaki Hashiguchi - Daiwa Securities Atsushi Seki - UBS Ritsuo Watanabe - Merrill Lynch Securities Fumiyoshi Sakai - Credit Suisse Joe Cairnes - Deutsche Bank Christophe Weber Good afternoon, and thank you very much for joining us today.", "score": 0.623239, "arguments": [{"text": "Masato Iwasaki", "location": [233, 247], "entities": [{"type": "Person", "text": "Masato Iwasaki"}]}, {"text": "Executives", "location": [116, 126], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "partOf", "sentence": "So when we make difficult decisions at Takeda, we use these values as a compass.", "score": 0.378352, "arguments": [{"text": "we", "location": [25109, 25111], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "Takeda", "location": [25140, 25146], "entities": [{"type": "Organization", "text": "Takeda"}]}]}, {"type": "agentOf", "sentence": "We ask ourselves, is it the right thing for the patient?", "score": 0.983618, "arguments": [{"text": "We", "location": [25182, 25184], "entities": [{"type": "Person", "text": "We"}]}, {"text": "ask", "location": [25185, 25188], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "agentOf", "sentence": "We ask ourselves, does it reinforce first with society?", "score": 0.891966, "arguments": [{"text": "We", "location": [25239, 25241], "entities": [{"type": "Person", "text": "We"}]}, {"text": "ask", "location": [25242, 25245], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "affectedBy", "sentence": "We ask ourselves, does it reinforce first with society?", "score": 0.820141, "arguments": [{"text": "ourselves", "location": [25246, 25255], "entities": [{"type": "Person", "text": "ourselves"}]}, {"text": "ask", "location": [25242, 25245], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "agentOf", "sentence": "We ask ourselves, does it reinforce the reputation of the company?", "score": 0.891966, "arguments": [{"text": "We", "location": [25295, 25297], "entities": [{"type": "Person", "text": "We"}]}, {"text": "ask", "location": [25298, 25301], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "affectedBy", "sentence": "We ask ourselves, does it reinforce the reputation of the company?", "score": 0.837957, "arguments": [{"text": "ourselves", "location": [25302, 25311], "entities": [{"type": "Person", "text": "ourselves"}]}, {"text": "ask", "location": [25298, 25301], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "agentOf", "sentence": "And then we ask ourselves, is it developing our business?", "score": 0.948985, "arguments": [{"text": "we", "location": [25371, 25373], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "ask", "location": [25374, 25377], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "affectedBy", "sentence": "And then we ask ourselves, is it developing our business?", "score": 0.878687, "arguments": [{"text": "ourselves", "location": [25378, 25387], "entities": [{"type": "Person", "text": "ourselves"}]}, {"text": "ask", "location": [25374, 25377], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "partOfMany", "sentence": "And this is really helping us and all employees in Takeda to do the right thing.", "score": 0.277635, "arguments": [{"text": "us", "location": [25598, 25600], "entities": [{"type": "Person", "text": "us"}]}, {"text": "employees", "location": [25609, 25618], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "employedBy", "sentence": "We have redesigned our R&D engine, which is based on therapy area focus, which is based on external partnerships.", "score": 0.69402, "arguments": [{"text": "R&D", "location": [26338, 26341], "entities": [{"type": "Person", "text": "R&D"}]}, {"text": "our", "location": [26334, 26337], "entities": [{"type": "Organization", "text": "our"}]}]}], "keywords": [{"text": "Shire", "sentiment": {"score": 0.163295, "label": "positive"}, "relevance": 0.968756}, {"text": "core earnings", "sentiment": {"score": 0.221111, "label": "positive"}, "relevance": 0.94121}, {"text": "Global OPEX Initiative", "sentiment": {"score": 0.528764, "label": "positive"}, "relevance": 0.933088}, {"text": "Christophe Weber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.924833}, {"text": "basis points", "sentiment": {"score": 0.71685, "label": "positive"}, "relevance": 0.882448}, {"text": "OpEx discipline", "sentiment": {"score": 0.442941, "label": "positive"}, "relevance": 0.871019}, {"text": "core earnings margin", "sentiment": {"score": 0.682829, "label": "positive"}, "relevance": 0.866674}, {"text": "Takeda", "sentiment": {"score": 0.194447, "label": "positive"}, "relevance": 0.864225}, {"text": "Teva JV", "sentiment": {"score": -0.454113, "label": "negative"}, "relevance": 0.863028}, {"text": "foreign exchange", "sentiment": {"score": -0.484094, "label": "negative"}, "relevance": 0.855213}, {"text": "business momentum", "sentiment": {"score": 0.422824, "label": "positive"}, "relevance": 0.84839}, {"text": "growth", "sentiment": {"score": 0.541109, "label": "positive"}, "relevance": 0.837498}, {"text": "strict OpEx discipline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.831966}, {"text": "Growth Driver momentum", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.829193}, {"text": "margin improvement", "sentiment": {"score": 0.668575, "label": "positive"}, "relevance": 0.82756}, {"text": "company", "sentiment": {"score": 0.578709, "label": "positive"}, "relevance": 0.81835}, {"text": "Growth Drivers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.81452}, {"text": "Shire-related costs", "sentiment": {"score": -0.420892, "label": "negative"}, "relevance": 0.803638}, {"text": "acquisition", "sentiment": {"score": 0.187517, "label": "positive"}, "relevance": 0.797903}, {"text": "core earnings growth", "sentiment": {"score": 0.669365, "label": "positive"}, "relevance": 0.797619}, {"text": "real estate", "sentiment": {"score": 0.00755769, "label": "positive"}, "relevance": 0.792992}, {"text": "strong business momentum", "sentiment": {"score": 0.36254, "label": "positive"}, "relevance": 0.79222}, {"text": "course", "sentiment": {"score": 0.227366, "label": "positive"}, "relevance": 0.790597}, {"text": "Takeda executive team", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.786608}, {"text": "rare disease", "sentiment": {"score": -0.45102, "label": "negative"}, "relevance": 0.773934}, {"text": "operating profit", "sentiment": {"score": 0.270696, "label": "positive"}, "relevance": 0.77281}, {"text": "free cash flow", "sentiment": {"score": -0.599267, "label": "negative"}, "relevance": 0.770729}, {"text": "Shire acquisition", "sentiment": {"score": 0.712506, "label": "positive"}, "relevance": 0.769603}, {"text": "noncore assets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.764304}, {"text": "R&D", "sentiment": {"score": 0.143306, "label": "positive"}, "relevance": 0.763019}, {"text": "integration", "sentiment": {"score": 0.215634, "label": "positive"}, "relevance": 0.760408}, {"text": "earnings margin improvement", "sentiment": {"score": 0.682829, "label": "positive"}, "relevance": 0.757386}, {"text": "underlying core earnings", "sentiment": {"score": 0.762728, "label": "positive"}, "relevance": 0.757186}, {"text": "margin growth", "sentiment": {"score": 0.489502, "label": "positive"}, "relevance": 0.753263}, {"text": "revenue", "sentiment": {"score": 0.0110153, "label": "positive"}, "relevance": 0.753075}, {"text": "negative impact", "sentiment": {"score": -0.333762, "label": "negative"}, "relevance": 0.747993}, {"text": "core EPS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.74714}, {"text": "research center", "sentiment": {"score": -0.471776, "label": "negative"}, "relevance": 0.740019}, {"text": "plasma-derived therapies", "sentiment": {"score": -0.250393, "label": "negative"}, "relevance": 0.736801}, {"text": "OpEx management", "sentiment": {"score": 0.554732, "label": "positive"}, "relevance": 0.736453}, {"text": "good OpEx management", "sentiment": {"score": 0.478552, "label": "positive"}, "relevance": 0.733061}, {"text": "Steve Barker", "sentiment": {"score": 0.551852, "label": "positive"}, "relevance": 0.730233}, {"text": "major onetime items", "sentiment": {"score": -0.554513, "label": "negative"}, "relevance": 0.728566}, {"text": "Wako shares", "sentiment": {"score": -0.417143, "label": "negative"}, "relevance": 0.727903}, {"text": "strong OpEx management", "sentiment": {"score": 0.55308, "label": "positive"}, "relevance": 0.727773}, {"text": "products", "sentiment": {"score": 0.142233, "label": "positive"}, "relevance": 0.727555}, {"text": "overall Takeda revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.726306}, {"text": "good margin growth", "sentiment": {"score": 0.55308, "label": "positive"}, "relevance": 0.725868}, {"text": "Atsushi Seki", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.725119}, {"text": "global OpEx cost", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.724069}]}, "extracted_metadata": {"sha1": "e3f49b175e15f2c3768cc93d36c41debc2d3bac2", "filename": "1541380558579.zip-8e6e3034bf670583421d38ca37539a3a.xml", "file_type": "json"}, "title": "Takeda Pharmaceutical Co. Ltd. (TKPHF) CEO Christophe Weber on Q2 2019 Transcript", "forum_title": "Healthcare Sector and Stocks Analysis from Seeking Alpha"}, {"id": "uUOuCJDZtZ2ktRtQRarrDC-D7rqikj62FUicVLPv6MlBxJ3mh8YGuWrou8l4Wq2k", "result_metadata": {"score": 33.306202}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.240014, "label": "positive"}, "text": "Abbott Laboratories Inc", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.24872, "label": "negative"}, "text": "Bayer HealthCare AG", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.488078, "label": "negative"}, "text": "Enzon Pharmaceuticals", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medtronic Plc", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9477, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Biotechnology companies", "relevance": 0.846525, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Boston Scientific", "relevance": 0.775581, "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}, {"text": "Abbott Laboratories", "relevance": 0.6942, "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}], "categories": [{"score": 0.535698, "label": "/health and fitness/drugs"}, {"score": 0.528542, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.43602, "label": "/health and fitness/men's health"}], "relations": [{"type": "partOf", "sentence": "Necrotising Enterocolitis Market Worldwide Healthy Growth Rate with Topmost Players Abbott Laboratories Inc, Bayer HealthCare AG, Enzon Pharmaceuticals, Medtronic Plc and More - Outlook Till 2023", "score": 0.480719, "arguments": [{"text": "Necrotising Enterocolitis Market Worldwide Healthy Growth Rate", "location": [0, 62], "entities": [{"type": "Organization", "text": "Necrotising Enterocolitis Market Worldwide Healthy Growth Rate"}]}, {"text": "Topmost Players Abbott Laboratories Inc", "location": [68, 107], "entities": [{"type": "Organization", "text": "Topmost Players Abbott Laboratories Inc", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Enterocolitis Market Worldwide", "sentiment": {"score": 0.240014, "label": "positive"}, "relevance": 0.972631}, {"text": "Bayer HealthCare AG", "sentiment": {"score": -0.24872, "label": "negative"}, "relevance": 0.960152}, {"text": "Healthy Growth Rate", "sentiment": {"score": 0.240014, "label": "positive"}, "relevance": 0.918267}, {"text": "Medtronic Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.790693}, {"text": "Topmost Players", "sentiment": {"score": 0.240014, "label": "positive"}, "relevance": 0.76948}, {"text": "Abbott Laboratories", "sentiment": {"score": 0.240014, "label": "positive"}, "relevance": 0.730702}, {"text": "Enzon Pharmaceuticals", "sentiment": {"score": -0.488078, "label": "negative"}, "relevance": 0.634527}, {"text": "Outlook", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395513}]}, "crawl_date": "2018-11-05T08:07:44Z", "url": "https://www.openpr.com/news/1351190/Necrotising-Enterocolitis-Market-Worldwide-Healthy-Growth-Rate-with-Topmost-Players-Abbott-Laboratories-Inc-Bayer-HealthCare-AG-Enzon-Pharmaceuticals-Medtronic-Plc-and-More-Outlook-Till-2023.html", "host": "openpr.com", "text": "(U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland), Takeda Pharmaceutical Company, Ltd.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T08:00:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.619376, "label": "negative"}, "text": "Necrotising Enterocolitis Market", "relevance": 0.803957, "type": "Company"}, {"count": 12, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEC", "relevance": 0.603549, "type": "Company", "disambiguation": {"subtype": [], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Necrotising Enterocolitis", "relevance": 0.531225, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Necrotising Enterocolitis", "relevance": 0.516054, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": -0.41494, "label": "negative"}, "text": "Necrotizing Enterocolitis", "relevance": 0.385652, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Necrotizing enterocolitis", "dbpedia_resource": "http://dbpedia.org/resource/Necrotizing_enterocolitis"}}, {"count": 12, "sentiment": {"score": -0.308604, "label": "negative"}, "text": "United States", "relevance": 0.223754, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Market Research & Consulting", "relevance": 0.221055, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.176484, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.164736, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ascites", "relevance": 0.163783, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Ascites", "dbpedia_resource": "http://dbpedia.org/resource/Ascites"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.15606, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.155253, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer HealthCare AG", "relevance": 0.154185, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.154118, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Magnetic Resonance Imaging", "relevance": 0.152525, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.354429, "label": "negative"}, "text": "Middle East", "relevance": 0.151561, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.151374, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0.408212, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.149383, "type": "GeographicFeature"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Inc.", "relevance": 0.149027, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly and Co.", "relevance": 0.147936, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.147878, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "volvulus", "relevance": 0.146139, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Volvulus", "dbpedia_resource": "http://dbpedia.org/resource/Volvulus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prometic Life Sciences Inc.", "relevance": 0.145152, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Becton", "relevance": 0.144712, "type": "Company", "disambiguation": {"subtype": [], "name": "Becton Dickinson", "dbpedia_resource": "http://dbpedia.org/resource/Becton_Dickinson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Company , Ltd.", "relevance": 0.144605, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.361448, "label": "negative"}, "text": "pseudomembranous colitis", "relevance": 0.143558, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "InfectiousDisease"], "name": "Pseudomembranous colitis", "dbpedia_resource": "http://dbpedia.org/resource/Pseudomembranous_colitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.143148, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": -0.201232, "label": "negative"}, "text": "Sequana Medical AG", "relevance": 0.14223, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.142095, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.14195, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hadapsar", "relevance": 0.141528, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Hadapsar, Pune", "dbpedia_resource": "http://dbpedia.org/resource/Hadapsar,_Pune"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.139924, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Germany", "dbpedia_resource": "http://dbpedia.org/resource/Germany"}}, {"count": 1, "sentiment": {"score": -0.396823, "label": "negative"}, "text": "MiddleBrook Pharmaceuticals", "relevance": 0.13951, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.354429, "label": "negative"}, "text": "Africa", "relevance": 0.139427, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.138815, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medtronic Plc", "relevance": 0.138615, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.425606, "label": "negative"}, "text": "Enzon Pharmaceuticals, Inc.", "relevance": 0.138454, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd", "relevance": 0.137874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.137853, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kyorin Pharmaceutical Co.", "relevance": 0.135351, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.133234, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.298233, "label": "positive"}, "text": "GI Supply", "relevance": 0.131238, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRFR", "relevance": 0.129283, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories Inc.", "relevance": 0.119811, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.119073, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}], "sentiment": {"document": {"score": 0.0864817, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Market Research Future Necrotising Enterocolitis Market Market Research Future", "keywords": [{"text": "Future Necrotising Enterocolitis"}, {"text": "Market Research Future"}]}, "sentence": "Press release from: Market Research Future Necrotising Enterocolitis Market Market Research Future has Published Prime Research Report on the Global Necrotising Enterocolitis (NEC) Market.", "object": {"text": "Published Prime Research Report on the Global Necrotising Enterocolitis (NEC) Market", "keywords": [{"text": "Prime Research Report"}], "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}, {"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Market Research Future Necrotising Enterocolitis Market Market Research Future", "keywords": [{"text": "Future Necrotising Enterocolitis"}, {"text": "Market Research Future"}]}, "sentence": "Press release from: Market Research Future Necrotising Enterocolitis Market Market Research Future has Published Prime Research Report on the Global Necrotising Enterocolitis (NEC) Market.", "object": {"text": "Prime Research Report", "keywords": [{"text": "Prime Research Report"}]}, "action": {"verb": {"text": "Published", "tense": "past"}, "text": "has Published", "normalized": "have Published"}}, {"subject": {"text": "The Global Necrotising Enterocolitis (NEC) Market", "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}, {"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "sentence": " Segmented on the Basis of Stage, Diagnosis, Treatment, and End-User.Market Scenario for Necrotising Enterocolitis Market:The Global Necrotising Enterocolitis (NEC) Market is expected to gain prominence over the forecast period (2018\u20132023).", "object": {"text": "prominence", "keywords": [{"text": "prominence"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "is expected to gain", "normalized": "be expect to gain"}}, {"subject": {"text": "the Necrotising Enterocolitis (NEC) market", "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}, {"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "sentence": " It is estimated that the Necrotising Enterocolitis (NEC) market is expected to register a CAGR 5.5% during the forecast period of 2018 to 2023.Necrotizing enterocolitis is the most common cause of gastrointestinal-related morbidity and mortality.", "object": {"text": "a CAGR 5.5%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "5.5"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "period of 2018 to 2023.Necrotizing enterocolitis", "keywords": [{"text": "enterocolitis"}, {"text": "period"}]}, "sentence": " It is estimated that the Necrotising Enterocolitis (NEC) market is expected to register a CAGR 5.5% during the forecast period of 2018 to 2023.Necrotizing enterocolitis is the most common cause of gastrointestinal-related morbidity and mortality.", "object": {"text": "the most common cause of gastrointestinal-related morbidity and mortality", "keywords": [{"text": "gastrointestinal-related morbidity"}, {"text": "common cause"}, {"text": "mortality"}], "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The most premature infants", "keywords": [{"text": "premature infants"}]}, "sentence": " The most premature infants are the most vulnerable.", "object": {"text": "the most vulnerable"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "a study", "keywords": [{"text": "study"}]}, "sentence": " According to a study published in the Advances in Neonatal Care (2013), it was estimated that approximately 12% of infants born with the body weight of less than 1500 g are likely to develop Necrotizing Enterocolitis.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "the body weight of less than 1500 g", "keywords": [{"text": "body weight"}], "entities": [{"type": "Quantity", "text": "1500 g"}]}, "sentence": " According to a study published in the Advances in Neonatal Care (2013), it was estimated that approximately 12% of infants born with the body weight of less than 1500 g are likely to develop Necrotizing Enterocolitis.", "object": {"text": "Necrotizing Enterocolitis", "keywords": [{"text": "Enterocolitis"}], "entities": [{"type": "HealthCondition", "text": "Necrotizing Enterocolitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Necrotizing enterocolitis", "dbpedia_resource": "http://dbpedia.org/resource/Necrotizing_enterocolitis"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "The ascites condition", "keywords": [{"text": "ascites"}, {"text": "condition"}], "entities": [{"type": "HealthCondition", "text": "ascites", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Ascites", "dbpedia_resource": "http://dbpedia.org/resource/Ascites"}}]}, "sentence": " The ascites condition is also found to be associated with Stage IIa and IIIa.", "object": {"text": "associated with Stage IIa and IIIa", "keywords": [{"text": "Stage IIa"}, {"text": "IIIa"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The severity of the condition", "keywords": [{"text": "severity"}, {"text": "condition"}]}, "sentence": " The severity of the condition pushes the demand for better diagnosis and treatment approaches.Request Sample Report at www.marketresearchfuture.com/sample_request/5999 Various other factors such as improved reimbursement policies in developed countries, improving regulatory framework, growing research funding, unmet medical needs, and increasing government assistance are continuously contributing to the growth of the global Necrotising Enterocolitis (NEC) market.", "object": {"text": "the demand", "keywords": [{"text": "demand"}]}, "action": {"verb": {"text": "push", "tense": "present"}, "text": "pushes", "normalized": "push"}}, {"subject": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "sentence": " The increasing contribution of marketers is also fueling the growth of the market.", "object": {"text": "The increasing contribution of marketers", "keywords": [{"text": "marketers"}, {"text": "contribution"}]}, "action": {"verb": {"text": "fuel", "tense": "present"}, "text": "fueling", "normalized": "fuel"}}, {"subject": {"text": "Prometic Life Sciences Inc.", "keywords": [{"text": "Prometic Life Sciences"}], "entities": [{"type": "Company", "text": "Prometic Life Sciences Inc."}]}, "sentence": " For instance, on February 15, 2018, Prometic Life Sciences Inc. received the FDA orphan drug designation status to its Inter-Alpha-Inhibitor-Proteins (\"IaIp\") for the treatment of necrotizing enterocolitis.Despite these drivers, there are some issues associated with the Necrotising Enterocolitis (NEC) market.", "object": {"text": "the FDA orphan drug designation status", "keywords": [{"text": "orphan drug designation"}, {"text": "FDA"}], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "these drivers", "keywords": [{"text": "drivers"}]}, "sentence": " For instance, on February 15, 2018, Prometic Life Sciences Inc. received the FDA orphan drug designation status to its Inter-Alpha-Inhibitor-Proteins (\"IaIp\") for the treatment of necrotizing enterocolitis.Despite these drivers, there are some issues associated with the Necrotising Enterocolitis (NEC) market.", "object": {"text": "enterocolitis.Despite", "keywords": [{"text": "enterocolitis.Despite"}]}, "action": {"verb": {"text": "necrotizing", "tense": "future"}, "text": "necrotizing", "normalized": "necrotizing"}}, {"subject": {"text": "some issues associated with the Necrotising Enterocolitis (NEC) market", "keywords": [{"text": "issues"}, {"text": "market"}], "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}, {"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "sentence": " For instance, on February 15, 2018, Prometic Life Sciences Inc. received the FDA orphan drug designation status to its Inter-Alpha-Inhibitor-Proteins (\"IaIp\") for the treatment of necrotizing enterocolitis.Despite these drivers, there are some issues associated with the Necrotising Enterocolitis (NEC) market.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some issues", "keywords": [{"text": "issues"}]}, "sentence": " For instance, on February 15, 2018, Prometic Life Sciences Inc. received the FDA orphan drug designation status to its Inter-Alpha-Inhibitor-Proteins (\"IaIp\") for the treatment of necrotizing enterocolitis.Despite these drivers, there are some issues associated with the Necrotising Enterocolitis (NEC) market.", "object": {"text": "with the Necrotising Enterocolitis (NEC) market", "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}, {"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The Stage II", "keywords": [{"text": "Stage"}]}, "sentence": " The Stage II is further segmented into Stage IIa and Stage IIb.", "object": {"text": "further segmented into Stage IIa and Stage IIb", "keywords": [{"text": "Stage IIb"}, {"text": "Stage IIa"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Stage III", "keywords": [{"text": "Stage"}]}, "sentence": " The Stage III is further segmented into Stage IIIa and Stage IIIb.Based on diagnosis, the market is classified as imaging, laboratory studies, and differential diagnosis.", "object": {"text": "further segmented into Stage IIIa", "keywords": [{"text": "Stage IIIa"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "sentence": " The Stage III is further segmented into Stage IIIa and Stage IIIb.Based on diagnosis, the market is classified as imaging, laboratory studies, and differential diagnosis.", "object": {"text": "classified as imaging", "keywords": [{"text": "imaging"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Necrotising Enterocolitis Market"}]}, "sentence": " The Stage III is further segmented into Stage IIIa and Stage IIIb.Based on diagnosis, the market is classified as imaging, laboratory studies, and differential diagnosis.", "object": {"text": "as imaging", "keywords": [{"text": "imaging"}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "The imaging segment", "keywords": [{"text": "imaging segment"}]}, "sentence": " The imaging segment is further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others.", "object": {"text": "further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others", "keywords": [{"text": "Magnetic Resonance Imaging"}, {"text": "abdominal x-ray"}, {"text": "laparoscopy"}, {"text": "angiography"}], "entities": [{"type": "Company", "text": "Magnetic Resonance Imaging"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The imaging segment", "keywords": [{"text": "imaging segment"}]}, "sentence": " The imaging segment is further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others.", "object": {"text": "as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others", "keywords": [{"text": "Magnetic Resonance Imaging"}, {"text": "abdominal x-ray"}, {"text": "laparoscopy"}, {"text": "angiography"}], "entities": [{"type": "Company", "text": "Magnetic Resonance Imaging"}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "classified", "normalized": "classify"}}, {"subject": {"text": "The laboratory studies segment", "keywords": [{"text": "laboratory studies segment"}]}, "sentence": " The laboratory studies segment is further classified as haemochromocytometric exam, blood culture, serum electrolytes, arterial blood gas analysis, blood pressure monitor, and others.", "object": {"text": "further classified as haemochromocytometric exam, blood culture, serum electrolytes, arterial blood gas analysis, blood pressure monitor, and others", "keywords": [{"text": "serum electrolytes"}, {"text": "arterial blood gas"}, {"text": "blood pressure monitor"}, {"text": "haemochromocytometric exam"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The laboratory studies segment", "keywords": [{"text": "laboratory studies segment"}]}, "sentence": " The laboratory studies segment is further classified as haemochromocytometric exam, blood culture, serum electrolytes, arterial blood gas analysis, blood pressure monitor, and others.", "object": {"text": "as haemochromocytometric exam, blood culture, serum electrolytes, arterial blood gas analysis, blood pressure monitor, and others", "keywords": [{"text": "serum electrolytes"}, {"text": "arterial blood gas"}, {"text": "blood pressure monitor"}, {"text": "haemochromocytometric exam"}], "entities": []}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "classified", "normalized": "classify"}}, {"subject": {"text": "Necrotising Enterocolitis (NEC)", "keywords": [{"text": "(NEC)"}], "entities": [{"type": "Person", "text": "Necrotising Enterocolitis"}, {"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}]}, "sentence": " For instance, in 2013, Necrotising Enterocolitis (NEC) was the cause of 355 deaths per 100,000 live births in the United States.", "object": {"text": "the cause of 355 deaths per 100,000 live births in the United States", "keywords": [{"text": "live births"}, {"text": "United States"}, {"text": "deaths"}, {"text": "cause"}], "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}, {"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The death toll", "keywords": [{"text": "death toll"}]}, "sentence": " The death toll was virtually three times higher in the black population than for the white population.Browse Complete 100 Pages Premium Research Report Enabled with 82 Respective Tables and Figures at www.marketresearchfuture.com/reports/necrotising-enteroco...", "object": {"text": "virtually three times higher in the black population than for the white population.Browse Complete 100 Pages Premium Research Report Enabled with 82 Respective Tables and Figures at www.marketresearchfuture.com/reports/necrotising-enteroco", "keywords": [{"text": "Research Report Enabled"}, {"text": "white population.Browse Complete"}, {"text": "Respective Tables"}, {"text": "black population"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The European region", "keywords": [{"text": "European region"}]}, "sentence": " The European region is the second largest market for global Necrotising Enterocolitis (NEC) due to the surging demand for antifungal drugs.", "object": {"text": "the second largest market for global Necrotising Enterocolitis (NEC) due to the surging demand for antifungal drugs", "keywords": [{"text": "antifungal drugs"}, {"text": "largest market"}, {"text": "demand"}], "entities": [{"type": "Company", "text": "NEC", "disambiguation": {"subtype": ["Organization"], "name": "National Empowerment Center", "dbpedia_resource": "http://dbpedia.org/resource/National_Empowerment_Center"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Arterial blood gas", "relevance": 0.963209, "dbpedia_resource": "http://dbpedia.org/resource/Arterial_blood_gas"}, {"text": "Necrotizing enterocolitis", "relevance": 0.861945, "dbpedia_resource": "http://dbpedia.org/resource/Necrotizing_enterocolitis"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.847844, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Bristol-Myers Squibb", "relevance": 0.815075, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Electrolyte", "relevance": 0.701838, "dbpedia_resource": "http://dbpedia.org/resource/Electrolyte"}, {"text": "Pharmaceutical industry", "relevance": 0.668688, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pediatrics", "relevance": 0.610115, "dbpedia_resource": "http://dbpedia.org/resource/Pediatrics"}, {"text": "Magnetic resonance imaging", "relevance": 0.597704, "dbpedia_resource": "http://dbpedia.org/resource/Magnetic_resonance_imaging"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.560461, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pacific Ocean", "relevance": 0.540135, "dbpedia_resource": "http://dbpedia.org/resource/Pacific_Ocean"}, {"text": "Middle East", "relevance": 0.511139, "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}, {"text": "United States", "relevance": 0.494321, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Clopidogrel", "relevance": 0.483415, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Blood pressure", "relevance": 0.47381, "dbpedia_resource": "http://dbpedia.org/resource/Blood_pressure"}, {"text": "The Stage", "relevance": 0.47348, "dbpedia_resource": "http://dbpedia.org/resource/The_Stage"}, {"text": "Antifungal drug", "relevance": 0.470131, "dbpedia_resource": "http://dbpedia.org/resource/Antifungal_drug"}, {"text": "Orphan drug", "relevance": 0.466559, "dbpedia_resource": "http://dbpedia.org/resource/Orphan_drug"}, {"text": "Differential diagnosis", "relevance": 0.465713, "dbpedia_resource": "http://dbpedia.org/resource/Differential_diagnosis"}, {"text": "Neonatal nursing", "relevance": 0.459314, "dbpedia_resource": "http://dbpedia.org/resource/Neonatal_nursing"}, {"text": "Asia-Pacific", "relevance": 0.458235, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Cancer staging", "relevance": 0.447944, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Neonatal intensive care unit", "relevance": 0.446546, "dbpedia_resource": "http://dbpedia.org/resource/Neonatal_intensive_care_unit"}, {"text": "Medical diagnosis", "relevance": 0.437693, "dbpedia_resource": "http://dbpedia.org/resource/Medical_diagnosis"}], "categories": [{"score": 0.648353, "label": "/health and fitness"}, {"score": 0.580836, "label": "/health and fitness/disease"}, {"score": 0.281302, "label": "/health and fitness/therapy"}], "relations": [{"type": "agentOf", "sentence": "Press release from: Market Research Future Necrotising Enterocolitis Market Market Research Future has Published Prime Research Report on the Global Necrotising Enterocolitis (NEC) Market.", "score": 0.872762, "arguments": [{"text": "Market Research Future Necrotising Enterocolitis Market Market Research Future", "location": [20, 98], "entities": [{"type": "Organization", "text": "Market Research Future Necrotising Enterocolitis Market Market Research Future", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [128, 134], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOf", "sentence": "Key Players for Necrotising Enterocolitis Market:Some of the key players in the global necrotising enterocolitis (NEC) market are Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company , Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), GlaxoSmithKline Plc (UK), Kyorin Pharmaceutical Co., Ltd. (U.S.), Medtronic Plc (U.S.), Merck & Co. Inc. (U.S.), MiddleBrook Pharmaceuticals (Japan), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland),", "score": 0.425942, "arguments": [{"text": "Key Players", "location": [2072, 2083], "entities": [{"type": "Organization", "text": "Key Players", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Necrotising Enterocolitis Market", "location": [2088, 2120], "entities": [{"type": "Organization", "text": "The global Necrotising Enterocolitis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Key Players for Necrotising Enterocolitis Market:Some of the key players in the global necrotising enterocolitis (NEC) market are Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company , Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), GlaxoSmithKline Plc (UK), Kyorin Pharmaceutical Co., Ltd. (U.S.), Medtronic Plc (U.S.), Merck & Co. Inc. (U.S.), MiddleBrook Pharmaceuticals (Japan), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland),", "score": 0.339211, "arguments": [{"text": "Bristol-Myers Squibb Company", "location": [2339, 2367], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "U.S.)", "location": [2369, 2374], "entities": [{"type": "Organization", "text": "Abbott Laboratories Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Key Players for Necrotising Enterocolitis Market:Some of the key players in the global necrotising enterocolitis (NEC) market are Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company , Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), GlaxoSmithKline Plc (UK), Kyorin Pharmaceutical Co., Ltd. (U.S.), Medtronic Plc (U.S.), Merck & Co. Inc. (U.S.), MiddleBrook Pharmaceuticals (Japan), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland),", "score": 0.41098, "arguments": [{"text": "Merck & Co. Inc.", "location": [2623, 2639], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "U.S.)", "location": [2616, 2621], "entities": [{"type": "Organization", "text": "Medtronic Plc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "The Stage III is further segmented into Stage IIIa and Stage IIIb.Based on diagnosis, the market is classified as imaging, laboratory studies, and differential diagnosis.", "score": 0.477457, "arguments": [{"text": "Stage IIIb.Based", "location": [3215, 3231], "entities": [{"type": "Person", "text": "Stage IIIb.Based"}]}, {"text": "laboratory", "location": [3283, 3293], "entities": [{"type": "Facility", "text": "laboratory"}]}]}, {"type": "locatedAt", "sentence": "Regional Analysis for Necrotising Enterocolitis Market:The global Necrotising Enterocolitis (NEC) market consists of regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.The Americas dominated the global Necrotising Enterocolitis (NEC) market owing to the use of numerous therapies for the treatment of Necrotising Enterocolitis (NEC) along with the demand for early diagnosis.", "score": 0.673042, "arguments": [{"text": "Asia", "location": [4380, 4384], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [4385, 4392], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Moreover, factors favoring the growth of Necrotising Enterocolitis (NEC) in the Asia Pacific region are the implementation of various healthcare reforms such as Patient Protection and Affordable Care Act (PPACA), increasing investments in the Asia Pacific region offering huge market potential, and rapidly increasing aging population.", "score": 0.462844, "arguments": [{"text": "Asia", "location": [5244, 5248], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [5249, 5256], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Moreover, factors favoring the growth of Necrotising Enterocolitis (NEC) in the Asia Pacific region are the implementation of various healthcare reforms such as Patient Protection and Affordable Care Act (PPACA), increasing investments in the Asia Pacific region offering huge market potential, and rapidly increasing aging population.", "score": 0.484054, "arguments": [{"text": "Asia", "location": [5407, 5411], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [5412, 5419], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Browse Complete 100 Pages Premium Research Report Enabled with 82 Respective Tables and Figures at www.marketresearchfuture.com/reports/necrotising-enteroco... The European region is the second largest market for global Necrotising Enterocolitis (NEC) due to the surging demand for antifungal drugs.", "score": 0.664964, "arguments": [{"text": "region", "location": [5037, 5043], "entities": [{"type": "GeopoliticalEntity", "text": "Patient Protection and Affordable Care Act"}]}, {"text": "European", "location": [5028, 5036], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Moreover, factors favoring the growth of Necrotising Enterocolitis (NEC) in the Asia Pacific region are the implementation of various healthcare reforms such as Patient Protection and Affordable Care Act (PPACA), increasing investments in the Asia Pacific region offering huge market potential, and rapidly increasing aging population.", "score": 0.68464, "arguments": [{"text": "Pacific", "location": [5249, 5256], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "region", "location": [5257, 5263], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Moreover, factors favoring the growth of Necrotising Enterocolitis (NEC) in the Asia Pacific region are the implementation of various healthcare reforms such as Patient Protection and Affordable Care Act (PPACA), increasing investments in the Asia Pacific region offering huge market potential, and rapidly increasing aging population.", "score": 0.66893, "arguments": [{"text": "Pacific", "location": [5412, 5419], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "region", "location": [5420, 5426], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "productOf", "sentence": "About US:Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.Contact Us:Office No. 528, Amanora ChambersMagarpatta Road, Hadapsar,", "score": 0.881517, "arguments": [{"text": "Office No. 528", "location": [5993, 6007], "entities": [{"type": "Product", "text": "Office No. 528"}]}, {"text": "Market Research & Consulting Services.Contact Us", "location": [5944, 5992], "entities": [{"type": "Organization", "text": "Market Research & Consulting Services.Contact Us", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "About US:Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.Contact Us:Office No. 528, Amanora ChambersMagarpatta Road, Hadapsar,", "score": 0.759858, "arguments": [{"text": "Amanora ChambersMagarpatta Road", "location": [6009, 6040], "entities": [{"type": "Organization", "text": "Amanora ChambersMagarpatta Road"}]}, {"text": "Hadapsar", "location": [6042, 6050], "entities": [{"type": "GeopoliticalEntity", "text": "Hadapsar"}]}]}, {"type": "agentOf", "sentence": "Press release from: Market Research Future Necrotising Enterocolitis Market Market Research Future has Published Prime Research Report on the Global Necrotising Enterocolitis (NEC) Market.", "score": 0.520791, "arguments": [{"text": "Global Necrotising Enterocolitis", "location": [142, 174], "entities": [{"type": "Organization", "text": "The global Necrotising Enterocolitis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [128, 134], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "ownerOf", "sentence": "Press release from: Market Research Future Necrotising Enterocolitis Market Market Research Future has Published Prime Research Report on the Global Necrotising Enterocolitis (NEC) Market.", "score": 0.692954, "arguments": [{"text": "Global Necrotising Enterocolitis", "location": [142, 174], "entities": [{"type": "Organization", "text": "The global Necrotising Enterocolitis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market", "location": [181, 187], "entities": [{"type": "Facility", "text": "Market"}]}]}, {"type": "ownerOf", "sentence": "Press release from: Market Research Future Necrotising Enterocolitis Market Market Research Future has Published Prime Research Report on the Global Necrotising Enterocolitis (NEC) Market.", "score": 0.663335, "arguments": [{"text": "NEC", "location": [176, 179], "entities": [{"type": "Organization", "text": "The global Necrotising Enterocolitis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market", "location": [181, 187], "entities": [{"type": "Facility", "text": "Market"}]}]}, {"type": "ownerOf", "sentence": "Segmented on the Basis of Stage, Diagnosis, Treatment, and End-User.Market Scenario for Necrotising Enterocolitis Market:The Global Necrotising Enterocolitis (NEC) Market is expected to gain prominence over the forecast period (2018-2023).", "score": 0.805575, "arguments": [{"text": "The Global Necrotising Enterocolitis", "location": [310, 346], "entities": [{"type": "Organization", "text": "The global Necrotising Enterocolitis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market", "location": [353, 359], "entities": [{"type": "Facility", "text": "Market"}]}]}, {"type": "ownerOf", "sentence": "Segmented on the Basis of Stage, Diagnosis, Treatment, and End-User.Market Scenario for Necrotising Enterocolitis Market:The Global Necrotising Enterocolitis (NEC) Market is expected to gain prominence over the forecast period (2018-2023).", "score": 0.673965, "arguments": [{"text": "NEC", "location": [348, 351], "entities": [{"type": "Organization", "text": "The global Necrotising Enterocolitis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market", "location": [353, 359], "entities": [{"type": "Facility", "text": "Market"}]}]}, {"type": "basedIn", "sentence": "Segmented on the Basis of Stage, Diagnosis, Treatment, and End-User.Market Scenario for Necrotising Enterocolitis Market:The Global Necrotising Enterocolitis (NEC) Market is expected to gain prominence over the forecast period (2018-2023).", "score": 0.88136, "arguments": [{"text": "Basis", "location": [206, 211], "entities": [{"type": "Organization", "text": "Basis"}]}, {"text": "Stage", "location": [215, 220], "entities": [{"type": "GeopoliticalEntity", "text": "Stage"}]}]}, {"type": "locatedAt", "sentence": "Segmented on the Basis of Stage, Diagnosis, Treatment, and End-User.Market Scenario for Necrotising Enterocolitis Market:The Global Necrotising Enterocolitis (NEC) Market is expected to gain prominence over the forecast period (2018-2023).", "score": 0.969819, "arguments": [{"text": "Stage", "location": [215, 220], "entities": [{"type": "GeopoliticalEntity", "text": "Stage"}]}, {"text": "Diagnosis", "location": [222, 231], "entities": [{"type": "GeopoliticalEntity", "text": "Diagnosis"}]}]}, {"type": "locatedAt", "sentence": "Segmented on the Basis of Stage, Diagnosis, Treatment, and End-User.Market Scenario for Necrotising Enterocolitis Market:The Global Necrotising Enterocolitis (NEC) Market is expected to gain prominence over the forecast period (2018-2023).", "score": 0.917011, "arguments": [{"text": "Diagnosis", "location": [222, 231], "entities": [{"type": "GeopoliticalEntity", "text": "Diagnosis"}]}, {"text": "Treatment", "location": [233, 242], "entities": [{"type": "GeopoliticalEntity", "text": "Treatment"}]}]}, {"type": "locatedAt", "sentence": "According to a study published in the Advances in Neonatal Care (2013), it was estimated that approximately 12% of infants born with the body weight of less than 1500 g are likely to develop Necrotizing Enterocolitis.", "score": 0.953462, "arguments": [{"text": "Advances", "location": [766, 774], "entities": [{"type": "GeopoliticalEntity", "text": "Advances"}]}, {"text": "Neonatal Care", "location": [778, 791], "entities": [{"type": "GeopoliticalEntity", "text": "Neonatal Care"}]}]}, {"type": "agentOf", "sentence": "Request Sample Report at www.marketresearchfuture.com/sample_request/5999 Various other factors such as improved reimbursement policies in developed countries, improving regulatory framework, growing research funding, unmet medical needs, and increasing government assistance are continuously contributing to the growth of the global Necrotising Enterocolitis (NEC) market.", "score": 0.489734, "arguments": [{"text": "www.marketresearchfuture.com/sample_request/", "location": [1143, 1187], "entities": [{"type": "Person", "text": "www.marketresearchfuture.com/sample_request/"}]}, {"text": "Report", "location": [1133, 1139], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "employedBy", "sentence": "For instance, on February 15, 2018, Prometic Life Sciences Inc. received the FDA orphan drug designation status to its Inter-Alpha-Inhibitor-Proteins (\"IaIp\") for the treatment of necrotizing enterocolitis.", "score": 0.891682, "arguments": [{"text": "orphan", "location": [1656, 1662], "entities": [{"type": "Person", "text": "orphan"}]}, {"text": "FDA", "location": [1652, 1655], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}]}], "keywords": [{"text": "global necrotising enterocolitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.755796}, {"text": "Necrotising Enterocolitis Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.634727}, {"text": "Future Necrotising Enterocolitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50599}, {"text": "Market Research Future", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350513}, {"text": "Necrotizing Enterocolitis", "sentiment": {"score": -0.41494, "label": "negative"}, "relevance": 0.343598}, {"text": "Market Market Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.323556}, {"text": "Asia Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27477}, {"text": "Research Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270706}, {"text": "Prime Research Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.267446}, {"text": "huge market potential", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265025}, {"text": "Stage IIa", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262368}, {"text": "treatment approaches.Request Sample", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256097}, {"text": "Cooked Research Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.255205}, {"text": "neonatal pseudomembranous colitis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254582}, {"text": "forecast period", "sentiment": {"score": -0.422285, "label": "negative"}, "relevance": 0.254241}, {"text": "Half-Cooked Research Reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253372}, {"text": "Raw Research Reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253321}, {"text": "Research Report Enabled", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253191}, {"text": "Life Sciences Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252534}, {"text": "Daiichi Sankyo Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252261}, {"text": "differential diagnosis segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251686}, {"text": "Astellas Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251396}, {"text": "unmet medical needs", "sentiment": {"score": -0.405475, "label": "negative"}, "relevance": 0.249496}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249463}, {"text": "Abbott Laboratories Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248961}, {"text": "Kyorin Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248006}, {"text": "laboratory studies segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247886}, {"text": "largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24721}, {"text": "various healthcare reforms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246942}, {"text": "drug designation status", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246849}, {"text": "improved reimbursement policies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246397}, {"text": "Sequana Medical AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246051}, {"text": "blood gas analysis", "sentiment": {"score": -0.332253, "label": "negative"}, "relevance": 0.245787}, {"text": "F. Hoffmann-La Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245653}, {"text": "spontaneous intestinal perforation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245211}, {"text": "Magnetic Resonance Imaging", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244783}, {"text": "population.The Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244069}, {"text": "Total Parenteral Nutrition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24347}, {"text": "blood pressure monitor", "sentiment": {"score": -0.306681, "label": "negative"}, "relevance": 0.243468}, {"text": "ambulatory surgical center", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242675}, {"text": "Amanora ChambersMagarpatta Road", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242608}, {"text": "Affordable Care Act", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242069}, {"text": "white population.Browse Complete", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.241988}, {"text": "Stage IIIa", "sentiment": {"score": -0.301124, "label": "negative"}, "relevance": 0.240747}, {"text": "Neonatal Care", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238926}, {"text": "Stage IIb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238614}]}, "extracted_metadata": {"sha1": "254a0533accc0e0746dd6d3e65c9961c399a174a", "filename": "1541405264231.zip-2c9964a650ebe38e025fc3a62fa83ba0.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/reports/necrotising-enterocolitis-market-5999", "https://www.marketresearchfuture.com/sample_request/5999"], "title": "Necrotising Enterocolitis Market Worldwide Healthy Growth Rate with Topmost Players Abbott Laboratories Inc, Bayer HealthCare AG, Enzon Pharmaceuticals, Medtronic Plc and More \u2013 Outlook Till 2023", "forum_title": "openPR.com - New Public Relations: Business, Economy, Finances, Banking & Insurance"}, {"id": "ORy7iz82Osl-_Bu7EPd7RZdcBwzL0GtnGo1SqGK0dcUVbdpVYSXTJAJEfSX4ldsL", "result_metadata": {"score": 33.17355}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Crescendo Biologics Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics Ltd"}]}, "sentence": "IP : Crescendo Biologics Ltd - Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody\u00ae | MarketScreener", "object": {"text": "early licensing by Takeda of first oncology-targeted Humabody\u00ae | MarketScreener", "keywords": [{"text": "early licensing"}, {"text": "Takeda"}, {"text": "oncology-targeted Humabody\u00ae"}, {"text": "MarketScreener"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}], "concepts": [], "categories": [{"score": 0.557369, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.478708, "label": "/health and fitness/drugs"}, {"score": 0.463746, "label": "/health and fitness/disease"}], "relations": [{"type": "agentOf", "sentence": "IP : Crescendo Biologics Ltd - Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody\u00ae | MarketScreener", "score": 0.940049, "arguments": [{"text": "Crescendo Biologics Ltd - Crescendo Biologics", "location": [5, 50], "entities": [{"type": "Organization", "text": "Crescendo Biologics Ltd - Crescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [51, 60], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}], "keywords": [{"text": "Crescendo Biologics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.987225}, {"text": "early licensing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.68597}, {"text": "oncology-targeted Humabody\u00ae", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616125}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561071}, {"text": "IP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437428}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433465}]}, "crawl_date": "2018-11-05T14:15:42Z", "url": "https://www.marketscreener.com/IP-GROUP-PLC-38908802/news/IP-Crescendo-Biologics-Ltd-Crescendo-Biologics-announces-early-licensing-by-Takeda-of-first-onco-27548353/", "host": "marketscreener.com", "text": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T00:00:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0.794797, "label": "positive"}, "text": "Crescendo Biologics", "relevance": 0.900464, "type": "Company"}, {"count": 6, "sentiment": {"score": 0.792411, "label": "positive"}, "text": "Takeda", "relevance": 0.67738, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Crescendo Biologics Ltd", "relevance": 0.503171, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.66777, "label": "positive"}, "text": "Crescendo", "relevance": 0.480207, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.427982, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "At Takeda", "relevance": 0.392594, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.363026, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr Peter Pack", "relevance": 0.269963, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.310782, "label": "positive"}, "text": "Takeda Ventures", "relevance": 0.262589, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oncology Drug Discovery Unit & Immunology Unit", "relevance": 0.238625, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.236436, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Instinctif Partners", "relevance": 0.193484, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "cancer", "relevance": 0.192637, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Humabodies", "relevance": 0.191632, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.47819, "label": "positive"}, "text": "Humabody", "relevance": 0.186197, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.625382, "label": "positive"}, "text": "Chris Arendt", "relevance": 0.183663, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.247346, "label": "negative"}, "text": "developer", "relevance": 0.182837, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "IP Group", "relevance": 0.172109, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Deborah Bell", "relevance": 0.160427, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sofinnova Partners", "relevance": 0.159037, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cambridge", "relevance": 0.156728, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "City"], "name": "Cambridge", "dbpedia_resource": "http://dbpedia.org/resource/Cambridge"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr Christelle Kerouedan", "relevance": 0.156694, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Melanie Toyne-Sewell", "relevance": 0.147554, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.145959, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas", "relevance": 0.144227, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Andera Partners", "relevance": 0.135932, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quan Capital", "relevance": 0.134306, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "info@crescendobiologics.com", "relevance": 0.134306, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "crescendo@instinctif.com", "relevance": 0.134306, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$754 million", "relevance": 0.134306, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "100%", "relevance": 0.134306, "type": "Quantity"}], "sentiment": {"document": {"score": 0.667271, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "therapeutics", "keywords": [{"text": "therapeutics"}]}, "sentence": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "object": {"text": "T-cell", "keywords": [{"text": "T-cell"}]}, "action": {"verb": {"text": "enhance", "tense": "present"}, "text": "enhancing", "normalized": "enhance"}}, {"subject": {"text": "Takeda Pharmaceutical Company Limited (Takeda),", "keywords": [{"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "object": {"text": "exercised an option under its existing, multi-target collaboration and license agreement", "keywords": [{"text": "multi-target collaboration"}, {"text": "license agreement"}, {"text": "option"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical Company Limited (Takeda),", "keywords": [{"text": "Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "object": {"text": "an option under its existing, multi-target collaboration and license agreement", "keywords": [{"text": "multi-target collaboration"}, {"text": "license agreement"}, {"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "has exercised", "normalized": "have exercise"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has taken an exclusive licence to Humabodies directed to one of its oncology targets.", "object": {"text": "an exclusive licence to Humabodies directed to one of its oncology targets", "keywords": [{"text": "exclusive licence"}, {"text": "oncology targets"}, {"text": "Humabodies"}], "entities": [{"type": "Location", "text": "Humabodies", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "has taken", "normalized": "have take"}}, {"subject": {"text": "This licence", "keywords": [{"text": "licence"}]}, "sentence": " This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae leads meeting its stringent criteria.", "object": {"text": "the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae", "keywords": [{"text": "highly successful delivery"}, {"text": "pre-clinical evaluation"}, {"text": "Takeda"}, {"text": "Humabody\u00ae"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "mark", "tense": "present"}, "text": "earlier than planned and marks", "normalized": "early than plan and mark"}}, {"subject": {"text": "the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae", "keywords": [{"text": "highly successful delivery"}, {"text": "pre-clinical evaluation"}, {"text": "Takeda"}, {"text": "Humabody\u00ae"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody\u00ae leads meeting its stringent criteria.", "object": {"text": "meeting its stringent criteria", "keywords": [{"text": "stringent criteria"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leads", "normalized": "lead"}}, {"subject": {"text": "'The team at Crescendo", "keywords": [{"text": "Crescendo"}, {"text": "team"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " 'The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "object": {"text": "made great progress on our Humabody programmes", "keywords": [{"text": "great progress"}, {"text": "Humabody programmes"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "'The team at Crescendo", "keywords": [{"text": "Crescendo"}, {"text": "team"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " 'The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "object": {"text": "great progress", "keywords": [{"text": "great progress"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "has made", "normalized": "have make"}}, {"subject": {"text": "'The team at Crescendo", "keywords": [{"text": "Crescendo"}, {"text": "team"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " 'The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "object": {"text": "with the Takeda team", "keywords": [{"text": "Takeda team"}]}, "action": {"verb": {"text": "work", "tense": "present"}, "text": "working", "normalized": "work"}}, {"subject": {"text": "we"}, "sentence": " To date, we have met all the technical milestones on time or earlier than planned, which is proof of our excellent collaboration.", "object": {"text": "met all the technical milestones on time", "keywords": [{"text": "technical milestones"}, {"text": "time"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " To date, we have met all the technical milestones on time or earlier than planned, which is proof of our excellent collaboration.", "object": {"text": "all the technical milestones", "keywords": [{"text": "technical milestones"}]}, "action": {"verb": {"text": "meet", "tense": "past"}, "text": "have met", "normalized": "have meet"}}, {"subject": {"text": "We"}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.'", "object": {"text": "that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes", "keywords": [{"text": "future successes"}, {"text": "Takeda"}, {"text": "option"}, {"text": "schedule"}]}, "action": {"verb": {"text": "delight", "tense": "past"}, "text": "delighted", "normalized": "delight"}}, {"subject": {"text": "the option to license", "keywords": [{"text": "option"}]}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.'", "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been taken", "normalized": "have be take"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}]}, "sentence": " We are delighted that the option to license has been taken by Takeda ahead of schedule and look forward to further future successes.'", "object": {"text": "the option to license", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "has been taken", "normalized": "have be take"}}, {"subject": {"text": "we"}, "sentence": " 'At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "to research diverse modalities to bring transformative treatments to patients with cancer", "keywords": [{"text": "research diverse modalities"}, {"text": "transformative treatments"}, {"text": "patients"}, {"text": "cancer"}]}, "action": {"verb": {"text": "continue", "tense": "present"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "we"}, "sentence": " 'At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "object": {"text": "diverse modalities", "keywords": [{"text": "diverse modalities"}]}, "action": {"verb": {"text": "research", "tense": "future"}, "text": "continue to research", "normalized": "continue to research"}}, {"subject": {"text": "the licence", "keywords": [{"text": "licence"}]}, "sentence": " Our decision to exercise the licence was based on the quality of the Humabody leads and the potential we see to develop improved and differentiated immuno-oncology therapies.'", "object": {"text": "on the quality of the Humabody", "keywords": [{"text": "quality"}, {"text": "Humabody"}], "entities": [{"type": "Location", "text": "Humabody", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "was based", "normalized": "be base"}}, {"subject": {"text": "we"}, "sentence": " Our decision to exercise the licence was based on the quality of the Humabody leads and the potential we see to develop improved and differentiated immuno-oncology therapies.'", "object": {"text": "improved and differentiated immuno-oncology therapies", "keywords": [{"text": "differentiated immuno-oncology therapies"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "see to develop", "normalized": "see to develop"}}, {"subject": {"text": "Takeda's option", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "part of the existing multi-target collaboration", "keywords": [{"text": "multi-target collaboration"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "licence agreement", "keywords": [{"text": "licence agreement"}]}, "sentence": " Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration", "keywords": [{"text": "Humabody\u00ae-based therapeutics"}, {"text": "Takeda"}, {"text": "collaboration"}, {"text": "right"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "from the collaboration", "keywords": [{"text": "collaboration"}]}, "sentence": " Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "object": {"text": "commercialise Humabody\u00ae-based therapeutics", "keywords": [{"text": "commercialise Humabody\u00ae-based therapeutics"}]}, "action": {"verb": {"text": "result", "tense": "present"}, "text": "resulting", "normalized": "result"}}, {"subject": {"text": "Crescendo", "keywords": [{"text": "Crescendo"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " Under the agreement, Crescendo is eligible to receive clinical development, regulatory and sales-based milestone payments of up to $754 million plus royalties on Humabody\u00ae-based product sales by Takeda.", "object": {"text": "eligible to receive clinical development", "keywords": [{"text": "clinical development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Crescendo", "keywords": [{"text": "Crescendo"}], "entities": [{"type": "Company", "text": "Crescendo"}]}, "sentence": " Under the agreement, Crescendo is eligible to receive clinical development, regulatory and sales-based milestone payments of up to $754 million plus royalties on Humabody\u00ae-based product sales by Takeda.", "object": {"text": "clinical development, regulatory and sales-based milestone payments of up to $754 million plus royalties on Humabody\u00ae-based product sales by Takeda", "keywords": [{"text": "sales-based milestone payments"}, {"text": "Humabody\u00ae-based product sales"}, {"text": "clinical development"}, {"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Quantity", "text": "$754 million"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "to receive", "normalized": "to receive"}}, {"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": " Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody\u00ae therapeutics in oncology with a focus on innovative targeted T-cell approaches.", "object": {"text": "a biopharmaceutical company developing potent", "keywords": [{"text": "biopharmaceutical company"}, {"text": "potent"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a biopharmaceutical company", "keywords": [{"text": "biopharmaceutical company"}]}, "sentence": " Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody\u00ae therapeutics in oncology with a focus on innovative targeted T-cell approaches.", "object": {"text": "potent, truly differentiated Humabody\u00ae therapeutics in oncology with a focus on innovative targeted T-cell approaches", "keywords": [{"text": "truly differentiated Humabody\u00ae"}, {"text": "innovative targeted T-cell"}, {"text": "therapeutics"}, {"text": "oncology"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": " Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity.", "object": {"text": "CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment", "keywords": [{"text": "bispecific PSMA-targeted T-cell"}, {"text": "selective activation"}, {"text": "tumour-specific T-cells"}, {"text": "tumour microenvironment"}]}, "action": {"verb": {"text": "develop", "tense": "past"}, "text": "has developed", "normalized": "have develop"}}, {"subject": {"text": "a novel bispecific PSMA-targeted T-cell enhancer", "keywords": [{"text": "bispecific PSMA-targeted T-cell"}, {"text": "enhancer"}]}, "sentence": " Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity.", "object": {"text": "systemic toxicity", "keywords": [{"text": "systemic toxicity"}]}, "action": {"verb": {"text": "avoid", "tense": "present"}, "text": "thereby avoiding", "normalized": "thereby avoid"}}, {"subject": {"text": "This highly modular format", "keywords": [{"text": "highly modular format"}]}, "sentence": " This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.", "object": {"text": "re-configured"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "This highly modular format", "keywords": [{"text": "highly modular format"}]}, "sentence": " This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.", "object": {"text": "a pipeline of multiple therapeutic candidates each treating a different cancer indication", "keywords": [{"text": "multiple therapeutic candidates"}, {"text": "different cancer indication"}, {"text": "pipeline"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "to create", "normalized": "to create"}}, {"subject": {"text": "The Company", "keywords": [{"text": "Company"}]}, "sentence": " The Company's ability to develop multi-functional Humabody\u00ae therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody\u00ae VH).", "object": {"text": "multi-functional Humabody\u00ae therapeutics", "keywords": [{"text": "multi-functional Humabody\u00ae therapeutics"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "The Company's ability to develop multi-functional Humabody\u00ae therapeutics", "keywords": [{"text": "multi-functional Humabody\u00ae therapeutics"}, {"text": "Company"}]}, "sentence": " The Company's ability to develop multi-functional Humabody\u00ae therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody\u00ae VH).", "object": {"text": "based on its unique"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Company's ability to develop multi-functional Humabody\u00ae therapeutics", "keywords": [{"text": "multi-functional Humabody\u00ae therapeutics"}, {"text": "Company"}]}, "sentence": " The Company's ability to develop multi-functional Humabody\u00ae therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody\u00ae VH).", "object": {"text": "on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody\u00ae VH)", "keywords": [{"text": "human VH domain"}, {"text": "transgenic mouse platform"}, {"text": "Humabody\u00ae VH"}, {"text": "building blocks"}], "entities": [{"type": "Quantity", "text": "100"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "is based", "normalized": "be base"}}, {"subject": {"text": "therapeutic targets", "keywords": [{"text": "therapeutic targets"}]}, "sentence": " These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution.", "object": {"text": "novel biology and superior bio-distribution", "keywords": [{"text": "superior bio-distribution"}, {"text": "novel biology"}]}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "delivering", "normalized": "deliver"}}, {"subject": {"text": "windows", "keywords": [{"text": "windows"}], "entities": []}, "sentence": " This results in larger therapeutic windows compared to conventional IgG approaches.", "object": {"text": "to conventional IgG approaches", "keywords": [{"text": "conventional IgG approaches"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": " Crescendo Biologics is pursuing novel Humabody\u00ae-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody\u00ae drug conjugates (HDCs), the next generation of ADCs.", "object": {"text": "pursuing novel Humabody\u00ae-based product opportunities", "keywords": [{"text": "novel Humabody\u00ae-based product"}, {"text": "opportunities"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": " Crescendo Biologics is pursuing novel Humabody\u00ae-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody\u00ae drug conjugates (HDCs), the next generation of ADCs.", "object": {"text": "novel Humabody\u00ae-based product opportunities", "keywords": [{"text": "novel Humabody\u00ae-based product"}, {"text": "opportunities"}]}, "action": {"verb": {"text": "pursue", "tense": "present"}, "text": "is pursuing", "normalized": "be pursue"}}, {"subject": {"text": "multi-functional immuno-oncology modulators and Humabody\u00ae drug conjugates", "keywords": [{"text": "multi-functional immuno-oncology modulators"}, {"text": "Humabody\u00ae drug conjugates"}]}, "sentence": " Crescendo Biologics is pursuing novel Humabody\u00ae-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody\u00ae drug conjugates (HDCs), the next generation of ADCs.", "object": {"text": "in-house development and strategic partnerships", "keywords": [{"text": "in-house development"}, {"text": "strategic partnerships"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Humabody\u00ae-based formats", "keywords": [{"text": "Humabody\u00ae-based formats"}]}, "sentence": " Humabody\u00ae-based formats can also be applied across a range of non-cancer indications.", "object": {"text": "applied"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Humabody\u00ae-based formats", "keywords": [{"text": "Humabody\u00ae-based formats"}]}, "sentence": " Humabody\u00ae-based formats can also be applied across a range of non-cancer indications.", "object": {"text": "across a range of non-cancer indications", "keywords": [{"text": "non-cancer indications"}, {"text": "range"}]}, "action": {"verb": {"text": "apply", "tense": "future"}, "text": "can also be applied", "normalized": "can also be apply"}}, {"subject": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "sentence": " Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.", "action": {"verb": {"text": "locate", "tense": "past"}, "text": "is located", "normalized": "be locate"}}, {"subject": {"text": "by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas", "keywords": [{"text": "blue-chip investors"}, {"text": "Takeda Ventures"}, {"text": "Sofinnova Partners"}, {"text": "Quan Capital"}], "entities": [{"type": "Company", "text": "Sofinnova Partners"}, {"type": "Company", "text": "Andera Partners"}, {"type": "Company", "text": "IP Group"}, {"type": "Company", "text": "Takeda Ventures"}, {"type": "Company", "text": "Quan Capital"}, {"type": "Location", "text": "Astellas", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.", "object": {"text": "Crescendo Biologics", "keywords": [{"text": "Crescendo Biologics"}], "entities": [{"type": "Company", "text": "Crescendo Biologics"}]}, "action": {"verb": {"text": "back", "tense": "past"}, "text": "is backed", "normalized": "be back"}}, {"subject": {"text": "Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas", "keywords": [{"text": "Takeda Ventures"}, {"text": "Sofinnova Partners"}, {"text": "Quan Capital"}, {"text": "IP Group"}], "entities": [{"type": "Company", "text": "Sofinnova Partners"}, {"type": "Company", "text": "Andera Partners"}, {"type": "Company", "text": "IP Group"}, {"type": "Company", "text": "Takeda Ventures"}, {"type": "Company", "text": "Quan Capital"}, {"type": "Location", "text": "Astellas", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.", "object": {"text": "blue-chip investors", "keywords": [{"text": "blue-chip investors"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "IP Group plc", "keywords": [{"text": "IP Group plc"}], "entities": [{"type": "Company", "text": "IP Group"}]}, "sentence": " IP Group plc published this content on 05 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 05 November 2018 13:50:10 UTC", "object": {"text": "10 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "License", "relevance": 0.868971, "dbpedia_resource": "http://dbpedia.org/resource/License"}, {"text": "Royalties", "relevance": 0.822885, "dbpedia_resource": "http://dbpedia.org/resource/Royalties"}, {"text": "Medicine", "relevance": 0.792553, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.611845, "label": "/health and fitness/disease/cancer"}, {"score": 0.579532, "label": "/health and fitness/therapy"}, {"score": 0.315199, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "agentOf", "sentence": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "score": 0.614341, "arguments": [{"text": "Crescendo Biologics Ltd", "location": [0, 23], "entities": [{"type": "Organization", "text": "Crescendo Biologics\nCrescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [112, 121], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}, {"type": "agentOf", "sentence": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "score": 0.668978, "arguments": [{"text": "Crescendo", "location": [25, 34], "entities": [{"type": "Organization", "text": "Crescendo Biologics\nCrescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announces", "location": [112, 121], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}, {"type": "agentOf", "sentence": "' Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "score": 0.835884, "arguments": [{"text": "Takeda", "location": [1490, 1496], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "collaboration", "location": [1593, 1606], "entities": [{"type": "Crime", "text": "collaboration"}]}]}, {"type": "managerOf", "sentence": "- ENDS - For further information, please contact Crescendo Biologics + 44 (0)1223 497140 info@crescendobiologics.com Dr Peter Pack, CEO Instinctif Partners + 44 (0)20 7457 2020 crescendo@instinctif.com Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell About Crescendo Biologics Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody\u00ae therapeutics in oncology with a focus on innovative targeted T-cell approaches.", "score": 0.333782, "arguments": [{"text": "Instinctif", "location": [1947, 1957], "entities": [{"type": "Person", "text": "Instinctif"}]}, {"text": "Partners", "location": [1958, 1966], "entities": [{"type": "Person", "text": "Partners"}]}]}, {"type": "partOfMany", "sentence": "- ENDS - For further information, please contact Crescendo Biologics + 44 (0)1223 497140 info@crescendobiologics.com Dr Peter Pack, CEO Instinctif Partners + 44 (0)20 7457 2020 crescendo@instinctif.com Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell About Crescendo Biologics Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody\u00ae therapeutics in oncology with a focus on innovative targeted T-cell approaches.", "score": 0.523248, "arguments": [{"text": "crescendo@instinctif.com\nDeborah Bell", "location": [1988, 2025], "entities": [{"type": "Person", "text": "crescendo@instinctif.com\nDeborah Bell"}]}, {"text": "Partners", "location": [1958, 1966], "entities": [{"type": "Person", "text": "Partners"}]}]}, {"type": "subsidiaryOf", "sentence": "- ENDS - For further information, please contact Crescendo Biologics + 44 (0)1223 497140 info@crescendobiologics.com Dr Peter Pack, CEO Instinctif Partners + 44 (0)20 7457 2020 crescendo@instinctif.com Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell About Crescendo Biologics Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody\u00ae therapeutics in oncology with a focus on innovative targeted T-cell approaches.", "score": 0.175073, "arguments": [{"text": "Crescendo Biologics\nCrescendo Biologics", "location": [2079, 2118], "entities": [{"type": "Organization", "text": "Crescendo Biologics\nCrescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "biopharmaceutical company", "location": [2124, 2149], "entities": [{"type": "Organization", "text": "CB307"}]}]}, {"type": "hasAttribute", "sentence": "This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.", "score": 0.942458, "arguments": [{"text": "candidates", "location": [2637, 2647], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "cancer", "location": [2674, 2680], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "hasAttribute", "sentence": "This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.", "score": 0.722762, "arguments": [{"text": "candidates", "location": [2637, 2647], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "tumour", "location": [2736, 2742], "entities": [{"type": "HealthCondition", "text": "tumour"}]}]}, {"type": "authorOf", "sentence": "Crescendo Biologics is pursuing novel Humabody\u00ae-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody\u00ae drug conjugates (HDCs), the next generation of ADCs.", "score": 0.543165, "arguments": [{"text": "Humabody\u00ae", "location": [3225, 3234], "entities": [{"type": "Person", "text": "Humabody\u00ae"}]}, {"text": "novel", "location": [3219, 3224], "entities": [{"type": "TitleWork", "text": "novel"}]}]}, {"type": "basedIn", "sentence": "Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.", "score": 0.692761, "arguments": [{"text": "Crescendo Biologics", "location": [3528, 3547], "entities": [{"type": "Organization", "text": "Crescendo Biologics\nCrescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Cambridge", "location": [3562, 3571], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}]}, {"type": "locatedAt", "sentence": "Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.", "score": 0.988524, "arguments": [{"text": "Cambridge", "location": [3562, 3571], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}, {"text": "UK", "location": [3573, 3575], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "employedBy", "sentence": "Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.", "score": 0.454085, "arguments": [{"text": "investors", "location": [3604, 3613], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Sofinnova Partners", "location": [3624, 3642], "entities": [{"type": "Organization", "text": "Sofinnova Partners", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "score": 0.772949, "arguments": [{"text": "today", "location": [106, 111], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announces", "location": [112, 121], "entities": [{"type": "EventCommunication", "text": "announces"}]}]}, {"type": "agentOf", "sentence": "Attachments Original document Permalink Disclaimer IP Group plc published this content on 05 November 2018 and is solely responsible for the information contained herein.", "score": 0.9704, "arguments": [{"text": "IP Group plc", "location": [3843, 3855], "entities": [{"type": "Organization", "text": "IP Group plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [3856, 3865], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "Attachments Original document Permalink Disclaimer IP Group plc published this content on 05 November 2018 and is solely responsible for the information contained herein.", "score": 0.511013, "arguments": [{"text": "November 2018", "location": [3885, 3898], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [3856, 3865], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "agentOf", "sentence": "Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.", "score": 0.532985, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [127, 164], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "exercised", "location": [179, 188], "entities": [{"type": "EventCommunication", "text": "exercised"}]}]}, {"type": "agentOf", "sentence": "Dr Peter Pack, CEO of Crescendo, commented: 'The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "score": 0.674468, "arguments": [{"text": "Peter Pack", "location": [573, 583], "entities": [{"type": "Person", "text": "Peter Pack"}]}, {"text": "commented", "location": [603, 612], "entities": [{"type": "EventCommunication", "text": "commented"}]}]}, {"type": "managerOf", "sentence": "Dr Peter Pack, CEO of Crescendo, commented: 'The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "score": 0.711911, "arguments": [{"text": "CEO", "location": [585, 588], "entities": [{"type": "Person", "text": "Peter Pack"}]}, {"text": "Crescendo", "location": [592, 601], "entities": [{"type": "Organization", "text": "Crescendo Biologics\nCrescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Dr Peter Pack, CEO of Crescendo, commented: 'The team at Crescendo has made great progress on our Humabody programmes, working closely with the Takeda team.", "score": 0.63818, "arguments": [{"text": "team", "location": [619, 623], "entities": [{"type": "Organization", "text": "developer"}]}, {"text": "Crescendo", "location": [627, 636], "entities": [{"type": "Organization", "text": "Crescendo Biologics\nCrescendo Biologics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "' Chris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: 'At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "score": 0.666299, "arguments": [{"text": "Chris Arendt", "location": [991, 1003], "entities": [{"type": "Person", "text": "Chris Arendt"}]}, {"text": "we", "location": [1090, 1092], "entities": [{"type": "Person", "text": "our"}]}]}, {"type": "hasAttribute", "sentence": "' Chris Arendt, Head, Oncology Drug Discovery Unit & Immunology Unit, Takeda, commented: 'At Takeda, we continue to research diverse modalities to bring transformative treatments to patients with cancer.", "score": 0.900254, "arguments": [{"text": "patients", "location": [1171, 1179], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [1185, 1191], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "timeOf", "sentence": "' Takeda's option is part of the existing multi-target collaboration and licence agreement announced in October 2016 where Takeda received the right to develop and commercialise Humabody\u00ae-based therapeutics resulting from the collaboration.", "score": 0.817771, "arguments": [{"text": "October 2016 where", "location": [1471, 1489], "entities": [{"type": "Date", "text": "October 2016 where"}]}, {"text": "announced", "location": [1458, 1467], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}], "keywords": [{"text": "Crescendo Biologics", "sentiment": {"score": 0.794797, "label": "positive"}, "relevance": 0.976688}, {"text": "Takeda", "sentiment": {"score": 0.662, "label": "positive"}, "relevance": 0.770275}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.767404}, {"text": "Dr Peter Pack", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.71918}, {"text": "Takeda team", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.693809}, {"text": "crescendo@instinctif.com", "sentiment": {"score": 0.706537, "label": "positive"}, "relevance": 0.677115}, {"text": "Takeda Ventures", "sentiment": {"score": 0.310782, "label": "positive"}, "relevance": 0.662691}, {"text": "multi-target collaboration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.640167}, {"text": "differentiated Humabody\u00ae therapeutics", "sentiment": {"score": 0.662614, "label": "positive"}, "relevance": 0.629379}, {"text": "multi-functional Humabody\u00ae therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626243}, {"text": "bispecific PSMA-targeted T-cell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625115}, {"text": "innovative targeted T-cell", "sentiment": {"score": 0.662614, "label": "positive"}, "relevance": 0.619811}, {"text": "Oncology Drug Discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.616065}, {"text": "highly successful delivery", "sentiment": {"score": 0.792411, "label": "positive"}, "relevance": 0.614664}, {"text": "differentiated immuno-oncology therapies", "sentiment": {"score": 0.47819, "label": "positive"}, "relevance": 0.613383}, {"text": "Humabody\u00ae-based product sales", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611147}, {"text": "Dr Christelle Kerouedan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609389}, {"text": "human VH domain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.607916}, {"text": "multi-functional immuno-oncology modulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606369}, {"text": "sales-based milestone payments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606335}, {"text": "novel Humabody\u00ae-based product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605127}, {"text": "document Permalink Disclaimer", "sentiment": {"score": -0.677643, "label": "negative"}, "relevance": 0.601756}, {"text": "different cancer indication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601228}, {"text": "multiple therapeutic candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.600935}, {"text": "alternative tumour-specific markers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59927}, {"text": "conventional IgG approaches", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.599261}, {"text": "highly modular format", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598918}, {"text": "larger therapeutic windows", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598542}, {"text": "IP Group plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597256}, {"text": "transgenic mouse platform", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.596646}, {"text": "licence option", "sentiment": {"score": 0.792411, "label": "positive"}, "relevance": 0.589204}, {"text": "licence agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579561}, {"text": "exclusive licence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57955}, {"text": "Humabody\u00ae-based therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577829}, {"text": "license agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5723}, {"text": "oncology targets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570692}, {"text": "drug developer", "sentiment": {"score": -0.247346, "label": "negative"}, "relevance": 0.568619}, {"text": "pre-clinical evaluation", "sentiment": {"score": 0.792411, "label": "positive"}, "relevance": 0.567828}, {"text": "Humabody\u00ae VH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567706}, {"text": "stringent criteria", "sentiment": {"score": 0.792411, "label": "positive"}, "relevance": 0.565159}, {"text": "excellent collaboration", "sentiment": {"score": 0.650341, "label": "positive"}, "relevance": 0.563826}, {"text": "transformative treatments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561701}, {"text": "Chris Arendt", "sentiment": {"score": 0.625382, "label": "positive"}, "relevance": 0.561329}, {"text": "tumour-specific T-cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5605}, {"text": "technical milestones", "sentiment": {"score": 0.559271, "label": "positive"}, "relevance": 0.560479}, {"text": "Humabody\u00ae drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560109}, {"text": "future successes", "sentiment": {"score": 0.882806, "label": "positive"}, "relevance": 0.559847}, {"text": "info@crescendobiologics.com", "sentiment": {"score": 0.657894, "label": "positive"}, "relevance": 0.559194}, {"text": "Sofinnova Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558718}]}, "extracted_metadata": {"sha1": "da3f27ae6de1eee1632dcbcf0f364c671c2a1cea", "filename": "1541427342894.zip-5da89c3f509e6c036afd5d3a3ed85237.xml", "file_type": "json"}, "external_links": ["https://www.ipgroupplc.com/media/portfolio-news/2018/2018-11-05a", "http://www.publicnow.com/view/E6B42A0D421D8546AFCD742508ABC9A8D3599FD7"], "title": "IP : Crescendo Biologics Ltd - Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody\u00ae | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "_dbaqKX-aS4MT8Uh257aVK0H-ImIH6tPUFaTihzE95M2UYChn9Xhk7DVeLBQowao", "result_metadata": {"score": 32.450523}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-05T12:21:40Z", "url": "https://www.businesswire.com/news/home/20181105005422/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T12:14:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.744442, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.711265, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.577114, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.572194, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.551751, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542901, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.527006, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512841, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.469949, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.4531, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,045,264 1.39%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,775,786 1.48%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,185,679 1.53%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,342,650 4.20%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,382,579 4.20%", "relevance": 0.4531, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.4531, "type": "Quantity"}], "sentiment": {"document": {"score": 0.106395, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,342,650 4.20% 33,382,579 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "33,342,650 4.20"}, {"type": "Quantity", "text": "33,382,579 4.20"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,045,264 1.39% 12,185,679 1.53% (2) Cash-settled derivatives: 11,775,786 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,342,650 4.20% 33,382,579 4.20% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "33,342,650 4.20% 33,382,579 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,342,650 4.20"}, {"type": "Quantity", "text": "33,382,579 4.20"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,045,264 1.39% 12,185,679 1.53% (2) Cash-settled derivatives: 11,775,786 1.48% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,342,650 4.20% 33,382,579 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 5 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658783 Time of Receipt (offset from UTC): 20181105T115443+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.978383, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.739459, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.697642, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.622005, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.506519, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.410966, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.406139, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378912, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.348541, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.330104, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.32527, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.302996, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United States dollar", "relevance": 0.299845, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Barclays", "relevance": 0.295797, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.577665, "label": "/real estate/buying and selling homes"}, {"score": 0.467878, "label": "/finance/financial news"}, {"score": 0.453998, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "agentOf", "sentence": "JPY Ordinary NPV Sale 3,200 4,593.4218 JPY Ordinary NPV Sale 5,000 4,618.5000 JPY Ordinary NPV Sale 5,800 4,591.7931 JPY Ordinary NPV Sale 7,300 4,620.4246 JPY Ordinary NPV Sale 7,800 4,617.1794 JPY Ordinary NPV Sale 9,100 4,623.8131 JPY Ordinary NPV Sale 19,500 4,627.0000 JPY Ordinary NPV Sale 35,000 TRANSFER Ordinary NPV Sale 87,500 4,612.3805 JPY Ordinary NPV Sale 112,200 4,600.9073 JPY Ordinary NPV Sale 209,900 4,609.0900 JPY Ordinary NPV Sale 405,900 4,599.9152 JPY Ordinary NPV Sale 406,200 4,600.1356 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 27,900 4,595.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.682599, "arguments": [{"text": "i", "location": [5337, 5338], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5340, 5347], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6311, 6317], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6328, 6335], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 5 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7236, 7242], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7250, 7254], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7682, 7688], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7696, 7709], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7317, 7341], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7309, 7314], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9828, 9852], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9820, 9825], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7476, 7481], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7495, 7522], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9987, 9992], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10006, 10033], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7758, 7764], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7790, 7802], "entities": [{"type": "Organization", "text": "Contacts BARCLAYS PLC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9322, 9323], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9313, 9321], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658783 Time of Receipt (offset from UTC): 20181105T115443+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10133, 10136], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10112, 10119], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.906919}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.738004}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.724023}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415182}, {"text": "TRANSFER Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413129}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409061}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40745}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.396206}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362395}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349354}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318615}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.312798}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.262841}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259197}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257808}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256114}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.255173}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.254957}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254725}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253888}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252981}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251734}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251692}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240604}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239568}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.235825}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235512}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235254}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.235023}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234775}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234664}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234484}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234179}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.234023}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233749}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.233309}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233298}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233102}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232718}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23207}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231961}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231537}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231453}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.231434}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231225}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230794}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229906}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229762}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229208}, {"text": "derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.229201}]}, "extracted_metadata": {"sha1": "bfd07872e14a987ba0a896d9147634859c6049d7", "filename": "1541420500387.zip-1e24f58810862f22bc935f22c0c227d0.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "Press release distribution, EDGAR filing, XBRL, regulatory filings | Business Wire"}, {"id": "Px6QyouCu6n17JF6AkSefydtwzcyVARKgDEoMPe-MwLt9m49WNg1TnQeGPcBvH2w", "result_metadata": {"score": 32.02109}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.504344, "label": "/finance/investing/brokerages"}, {"score": 0.502277, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.49338, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995973}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.917124}, {"text": "UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.834559}]}, "crawl_date": "2018-11-05T08:47:33Z", "url": "https://www.businesswire.com/news/home/20181104005055/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-05T07:39:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.730901, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.642533, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.623963, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.568511, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.546249, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.530026, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.502271, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.498047, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.491347, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.491347, "type": "Quantity"}], "sentiment": {"document": {"score": -0.261081, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "2 November 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 2 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 658749 Time of Receipt (offset from UTC): 20181105T072356+0000 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.986243, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.523759, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Call option", "relevance": 0.52202, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.504086, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.465944, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.423508, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.414755, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.407639, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.390028, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.387114, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Balance sheet", "relevance": 0.383439, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.379982, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.375763, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.362737, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uniform Commercial Code", "relevance": 0.359192, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.355328, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Security", "relevance": 0.352267, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}], "categories": [{"score": 0.698319, "label": "/real estate/buying and selling homes"}, {"score": 0.489938, "label": "/finance/financial news"}, {"score": 0.310228, "label": "/finance/investing/day trading"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 658749 Time of Receipt (offset from UTC): 20181105T072356+0000 Contacts Daiwa Asset Management", "score": 0.434823, "arguments": [{"text": "UTC", "location": [5856, 5859], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [5835, 5842], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 2 November 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [700, 707], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [626, 663], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORD Purchase 20,000 4587 JPY ORD Purchase 200 4631.16 JPY ORD Sale 12,000 4627.9325 JPY ORD Purchase 3,100 4606.98 JPY ORD Sale 6,000 4589.4167 JPY (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit - - - - - (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.787954, "arguments": [{"text": "i", "location": [3338, 3339], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3341, 3348], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) - - - - 4.", "score": 0.591687, "arguments": [{"text": "Price", "location": [3964, 3969], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3974, 3978], "entities": [{"type": "Organization", "text": "Type e.g. American"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4346, 4352], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4363, 4370], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 5 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5181, 5193], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5195, 5224], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 5 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5284, 5290], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5298, 5302], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5365, 5389], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5357, 5362], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5644, 5668], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5636, 5641], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5700, 5705], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5719, 5746], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.994536}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.881715}, {"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.794399}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.716166}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.710635}, {"text": "short positions", "sentiment": {"score": -0.356746, "label": "negative"}, "relevance": 0.645338}, {"text": "JPY ORD Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.630772}, {"text": "JPY ORD Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627496}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601591}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580043}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565368}, {"text": "reference securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555354}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.554833}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549443}, {"text": "Short positions Number", "sentiment": {"score": -0.245708, "label": "negative"}, "relevance": 0.53998}, {"text": "relevant security Purchase/sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537927}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.534036}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531726}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.52964}, {"text": "Asset Management Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528674}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525769}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522508}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52244}, {"text": "derivative transactions", "sentiment": {"score": -0.408268, "label": "negative"}, "relevance": 0.52016}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519803}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51958}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519516}, {"text": "Contacts Daiwa Asset", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516632}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.515166}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.513988}, {"text": "Expiry date Option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512669}, {"text": "Cash-settled derivative transactions", "sentiment": {"score": -0.403941, "label": "negative"}, "relevance": 0.512294}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.51152}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510567}, {"text": "unit Type e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508868}, {"text": "RET Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506551}, {"text": "Asset Management Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505591}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504883}, {"text": "Product description e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503805}, {"text": "long/short position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503565}, {"text": "Management Category Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503359}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4969}, {"text": "person", "sentiment": {"score": 0.217529, "label": "positive"}, "relevance": 0.49597}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.494215}, {"text": "Nil", "sentiment": {"score": -0.611983, "label": "negative"}, "relevance": 0.488634}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485934}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483163}, {"text": "LONDON-\nFORM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474996}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47409}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472769}]}, "extracted_metadata": {"sha1": "739b711ae8160734aba55c09a14f2745ddb34ee5", "filename": "1541407653846.zip-6975e2f2af41c5371b1e6dad52418bde.xml", "file_type": "json"}, "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}, {"id": "piA624fV2irYEd8f0dd40GCUZj977Q9_gT6ZldZmzu_B3lbKQolx5VDXJkdLGY3h", "result_metadata": {"score": 31.582739}, "author": "sandesh", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Blow fill seal", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Blow_fill_seal"}], "categories": [{"score": 0.8673, "label": "/finance/accounting and auditing"}], "relations": [{"type": "hasAttribute", "sentence": "Blow Fill Seal Technology Market Accounting for US$ 7.2 Bn in 2027", "score": 0.890372, "arguments": [{"text": "Fill Seal Technology Market Accounting for US$", "location": [5, 51], "entities": [{"type": "Organization", "text": "Fill Seal Technology Market Accounting for US$", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "7.2 Bn", "location": [52, 58], "entities": [{"type": "Money", "text": "7.2 Bn", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "Blow Fill Seal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.986176}, {"text": "Technology Market Accounting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.863966}, {"text": "Bn", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627097}]}, "crawl_date": "2018-11-05T04:34:58Z", "url": "https://www.findmarketresearch.org/2018/07/blow-fill-seal-technology-market-accounting-for-us-7-2-bn-in-2027/", "host": "findmarketresearch.org", "text": "Ltd., Amanta Healthcare Ltd., Automatic Liquid Packaging Solutions LLC., Asept Pak, Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-07-04T12:05:00+05:00", "enriched_text": {"entities": [{"count": 13, "sentiment": {"score": 0.557159, "label": "positive"}, "text": "BFS Technology", "relevance": 0.921145, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.17618, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Unicep Packaging", "relevance": 0.144683, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Automatic Liquid Packaging Solutions LLC.", "relevance": 0.143718, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.532373, "label": "negative"}, "text": "Unither Pharmaceuticals", "relevance": 0.132217, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.131246, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mexico", "relevance": 0.122773, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.118958, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laboratorios SALVAT", "relevance": 0.118112, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.29334, "label": "negative"}, "text": "Nephron Pharmaceuticals Corporation", "relevance": 0.113418, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals International AG", "relevance": 0.111444, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.110015, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Recipharm AB", "relevance": 0.107519, "type": "Company", "disambiguation": {"subtype": [], "name": "Recipharm", "dbpedia_resource": "http://dbpedia.org/resource/Recipharm"}}, {"count": 1, "sentiment": {"score": -0.421229, "label": "negative"}, "text": "Horizon Pharmaceuticals", "relevance": 0.105899, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.104702, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Catalent, Inc.", "relevance": 0.104557, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asept Pak, Inc", "relevance": 0.103564, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.100631, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmapack Co. Ltd.", "relevance": 0.100088, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Unipharma LLC.", "relevance": 0.0992293, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.693597, "label": "positive"}, "text": "US", "relevance": 0.0961625, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.0951822, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brevetti Angela", "relevance": 0.0941855, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.0924892, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Amanta Healthcare Ltd.", "relevance": 0.0915549, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Weiler Engineering, Inc.", "relevance": 0.0910967, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.693597, "label": "positive"}, "text": "China", "relevance": 0.0905654, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.0903985, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.0898443, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "The Ritedose Corporation", "relevance": 0.0850075, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8.7%", "relevance": 0.0850075, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.8%", "relevance": 0.0850075, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "35%", "relevance": 0.0850075, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "60%", "relevance": 0.0850075, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "97%", "relevance": 0.0850075, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0850075, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.371893, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": "In North America, pharmaceutical companies are extensively employing blow fill seal (BFS) technology to facilitate their need for unit dose packaging.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are extensively employing", "normalized": "be extensively employ"}}, {"subject": {"text": "pharmaceutical companies", "keywords": [{"text": "pharmaceutical companies"}], "entities": []}, "sentence": "In North America, pharmaceutical companies are extensively employing blow fill seal (BFS) technology to facilitate their need for unit dose packaging.", "object": {"text": "blow fill seal", "keywords": [{"text": "blow fill seal"}]}, "action": {"verb": {"text": "employ", "tense": "present"}, "text": "are extensively employing", "normalized": "be extensively employ"}}, {"subject": {"text": "A greater demand for unit dose packaging in pharmaceutical industries", "keywords": [{"text": "unit dose packaging"}, {"text": "greater demand"}, {"text": "pharmaceutical industries"}]}, "sentence": " A greater demand for unit dose packaging in pharmaceutical industries is prevalent in other parts of the world, as well.", "object": {"text": "prevalent"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Latin American countries such as Brazil and Mexico", "keywords": [{"text": "Latin American countries"}, {"text": "Brazil"}, {"text": "Mexico"}], "entities": [{"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "Country", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}]}, "sentence": " Latin American countries such as Brazil and Mexico are witnessing a shift from conventional packaging to advanced pharmaceutical packaging, wherein unit dose packaging solutions are gaining preference.", "object": {"text": "witnessing a shift from conventional packaging to advanced pharmaceutical packaging, wherein unit dose packaging solutions are gaining preference", "keywords": [{"text": "unit dose packaging"}, {"text": "advanced pharmaceutical packaging"}, {"text": "conventional packaging"}, {"text": "preference"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Latin American countries such as Brazil and Mexico", "keywords": [{"text": "Latin American countries"}, {"text": "Brazil"}, {"text": "Mexico"}], "entities": [{"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "Country", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}]}, "sentence": " Latin American countries such as Brazil and Mexico are witnessing a shift from conventional packaging to advanced pharmaceutical packaging, wherein unit dose packaging solutions are gaining preference.", "object": {"text": "a shift from conventional packaging to advanced pharmaceutical packaging, wherein unit dose packaging solutions are gaining preference", "keywords": [{"text": "unit dose packaging"}, {"text": "advanced pharmaceutical packaging"}, {"text": "conventional packaging"}, {"text": "preference"}]}, "action": {"verb": {"text": "witness", "tense": "present"}, "text": "are witnessing", "normalized": "be witness"}}, {"subject": {"text": "unit dose packaging solutions", "keywords": [{"text": "unit dose packaging"}]}, "sentence": " Through BFS technology, unit dose packaging solutions can improve patient adherence to prescribed drug regime.", "object": {"text": "patient adherence to prescribed drug regime", "keywords": [{"text": "patient adherence"}, {"text": "drug regime"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "can improve", "normalized": "can improve"}}, {"subject": {"text": "packaging companies", "keywords": [{"text": "packaging companies"}]}, "sentence": " In addition to this, packaging companies are actively adopting blow fill seal machines due to their low energy consumption, reduced waste generation, and an overall low carbon imprint.", "object": {"text": "blow fill seal machines due to their low energy consumption", "keywords": [{"text": "blow fill seal"}, {"text": "low energy consumption"}, {"text": "machines"}], "entities": []}, "action": {"verb": {"text": "adopt", "tense": "present"}, "text": "adopting", "normalized": "adopt"}}, {"subject": {"text": "packaging companies", "keywords": [{"text": "packaging companies"}]}, "sentence": " In addition to this, packaging companies are actively adopting blow fill seal machines due to their low energy consumption, reduced waste generation, and an overall low carbon imprint.", "object": {"text": "waste generation", "keywords": [{"text": "waste generation"}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "Future Market Insights\u2019 recent study on the global blow fill seal technology market", "keywords": [{"text": "Future Market Insights"}, {"text": "blow fill seal"}, {"text": "recent study"}, {"text": "technology market"}], "entities": []}, "sentence": " Future Market Insights\u2019 recent study on the global blow fill seal technology market observes the rising preference to unit dosage packaging as a key driver.", "object": {"text": "the rising preference to unit dosage packaging as a key driver", "keywords": [{"text": "unit dosage packaging"}, {"text": "preference"}, {"text": "key driver"}]}, "action": {"verb": {"text": "observe", "tense": "present"}, "text": "observes", "normalized": "observe"}}, {"subject": {"text": "the global market for BFS technology", "keywords": [{"text": "BFS technology"}, {"text": "global market"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " According to the report, the global market for BFS technology is anticipated to reach US$ 3.1 Bn value by the end of 2017.", "object": {"text": "anticipated to reach US$ 3.1 Bn value", "keywords": [{"text": "Bn value"}], "entities": [{"type": "Location", "text": "BFS Technology", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market for BFS technology", "keywords": [{"text": "BFS technology"}, {"text": "global market"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " According to the report, the global market for BFS technology is anticipated to reach US$ 3.1 Bn value by the end of 2017.", "object": {"text": "$ 3.1 Bn value", "keywords": [{"text": "Bn value"}], "entities": [{"type": "Quantity", "text": "$ 3.1"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is anticipated to reach", "normalized": "be anticipate to reach"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report projects that prime demand for flexible glass vials will continue to drive the need for BFS technology in the packaging industry.", "object": {"text": "that prime demand for flexible glass vials will continue to drive the need for BFS technology in the packaging industry", "keywords": [{"text": "flexible glass vials"}, {"text": "prime demand"}, {"text": "BFS technology"}, {"text": "packaging industry"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "action": {"verb": {"text": "project", "tense": "present"}, "text": "projects", "normalized": "project"}}, {"subject": {"text": "the global market for BFS technology", "keywords": [{"text": "BFS technology"}, {"text": "global market"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " By the end of 2027, the global market for BFS technology will have soared robustly at 8.7% CAGR, bringing in revenues worth over US$ 7.2 Bn.", "action": {"verb": {"text": "soar", "tense": "future"}, "text": "will have soared", "normalized": "will have soar"}}, {"subject": {"text": "packaging companies", "keywords": [{"text": "packaging companies"}]}, "sentence": " With the use of blow fill seal technology, packaging companies are improving the flexibility of products namely, bottles, ampules, vials, and prefilled syringes & injectables.", "object": {"text": "improving the flexibility of products namely, bottles, ampules, vials, and prefilled syringes & injectables", "keywords": [{"text": "injectables"}, {"text": "syringes"}, {"text": "vials"}, {"text": "flexibility"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "packaging companies", "keywords": [{"text": "packaging companies"}]}, "sentence": " With the use of blow fill seal technology, packaging companies are improving the flexibility of products namely, bottles, ampules, vials, and prefilled syringes & injectables.", "object": {"text": "the flexibility of products namely, bottles, ampules, vials, and prefilled syringes & injectables", "keywords": [{"text": "injectables"}, {"text": "syringes"}, {"text": "vials"}, {"text": "flexibility"}]}, "action": {"verb": {"text": "improve", "tense": "present"}, "text": "are improving", "normalized": "be improve"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report estimates that towards the end of 2027, more than 14 billion units of products developed by BFS technology will be sold across the globe.", "object": {"text": "that towards the end of 2027, more than 14 billion units of products developed by BFS technology will be sold across the globe", "keywords": [{"text": "BFS technology"}, {"text": "globe"}, {"text": "end"}, {"text": "units"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "action": {"verb": {"text": "estimate", "tense": "present"}, "text": "estimates", "normalized": "estimate"}}, {"subject": {"text": "by BFS technology", "keywords": [{"text": "BFS technology"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " The report estimates that towards the end of 2027, more than 14 billion units of products developed by BFS technology will be sold across the globe.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "develop", "tense": "past"}, "text": "developed", "normalized": "develop"}}, {"subject": {"text": "more than 14 billion units of products developed by BFS technology", "keywords": [{"text": "BFS technology"}, {"text": "units"}, {"text": "products"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " The report estimates that towards the end of 2027, more than 14 billion units of products developed by BFS technology will be sold across the globe.", "object": {"text": "sold across the globe", "keywords": [{"text": "globe"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "more than 14 billion units of products developed by BFS technology", "keywords": [{"text": "BFS technology"}, {"text": "units"}, {"text": "products"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " The report estimates that towards the end of 2027, more than 14 billion units of products developed by BFS technology will be sold across the globe.", "action": {"verb": {"text": "sell", "tense": "future"}, "text": "will be sold", "normalized": "will be sell"}}, {"subject": {"text": "nearly three-fourth of global BFS technology market value", "keywords": [{"text": "global BFS technology"}, {"text": "market value"}]}, "sentence": " Throughout the forecast period, nearly three-fourth of global BFS technology market value will be accounted by sales of prefilled syringes and injectables.", "object": {"text": "by sales of prefilled syringes and injectables", "keywords": [{"text": "prefilled syringes"}, {"text": "injectables"}, {"text": "sales"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be accounted", "normalized": "will be account"}}, {"subject": {"text": "by sales of prefilled syringes and injectables", "keywords": [{"text": "prefilled syringes"}, {"text": "injectables"}, {"text": "sales"}]}, "sentence": " Throughout the forecast period, nearly three-fourth of global BFS technology market value will be accounted by sales of prefilled syringes and injectables.", "object": {"text": "nearly three-fourth of global BFS technology market value", "keywords": [{"text": "global BFS technology"}, {"text": "market value"}]}, "action": {"verb": {"text": "account", "tense": "future"}, "text": "will be accounted", "normalized": "will be account"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report also projects a steadfast rise in adoption of polypropylene as raw material.", "object": {"text": "a steadfast rise in adoption of polypropylene as raw material", "keywords": [{"text": "steadfast rise"}, {"text": "raw material"}, {"text": "polypropylene"}, {"text": "adoption"}]}, "action": {"verb": {"text": "project", "tense": "present"}, "text": "projects", "normalized": "project"}}, {"subject": {"text": "BFS products", "keywords": [{"text": "BFS products"}]}, "sentence": " In 2017, over US$ 1.1 Bn worth of BFS products sold in the global market will made from polypropylene.", "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "$ 1.1 Bn worth of BFS products sold in the global market", "keywords": [{"text": "BFS products"}, {"text": "Bn worth"}, {"text": "global market"}], "entities": [{"type": "Quantity", "text": "$ 1.1"}]}, "sentence": " In 2017, over US$ 1.1 Bn worth of BFS products sold in the global market will made from polypropylene.", "object": {"text": "from polypropylene", "keywords": [{"text": "polypropylene"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "will made", "normalized": "will make"}}, {"subject": {"text": "the global market for BFS technology", "keywords": [{"text": "BFS technology"}, {"text": "global market"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " However, in terms of revenue share, the global market for BFS technology is anticipated to witness dominance of polyethylene materials.", "object": {"text": "anticipated to witness dominance of polyethylene materials", "keywords": [{"text": "polyethylene materials"}, {"text": "dominance"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "their adoption", "keywords": [{"text": "adoption"}]}, "sentence": " With more than 60% share on global revenues, polyethylene materials will be a widely-preferred raw material in the global blow fill seal technology market, however, their adoption will incur a marginal decline towards the latter half of the forecast period.", "object": {"text": "a marginal decline", "keywords": [{"text": "marginal decline"}]}, "action": {"verb": {"text": "incur", "tense": "future"}, "text": "will incur", "normalized": "will incur"}}, {"subject": {"text": "A key highlight of the report", "keywords": [{"text": "key highlight"}, {"text": "report"}]}, "sentence": " A key highlight of the report reveals that pharmaceutical packaging is the outright dominant end-use of BFS technology.", "object": {"text": "that pharmaceutical packaging is the outright dominant end-use of BFS technology", "keywords": [{"text": "outright dominant end-use"}, {"text": "BFS technology"}, {"text": "pharmaceutical packaging"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "action": {"verb": {"text": "reveal", "tense": "present"}, "text": "reveals", "normalized": "reveal"}}, {"subject": {"text": "the adoption of blow fill seal machines", "keywords": [{"text": "blow fill seal"}, {"text": "machines"}, {"text": "adoption"}]}, "sentence": " While the adoption of blow fill seal machines is likely to gain momentum in the food & beverage industry, pharmaceutical end-use of BFS technology will procure over 97% share on global market, throughout the forecast period.", "object": {"text": "likely to gain momentum", "keywords": [{"text": "momentum"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the adoption of blow fill seal machines", "keywords": [{"text": "blow fill seal"}, {"text": "machines"}, {"text": "adoption"}]}, "sentence": " While the adoption of blow fill seal machines is likely to gain momentum in the food & beverage industry, pharmaceutical end-use of BFS technology will procure over 97% share on global market, throughout the forecast period.", "object": {"text": "momentum", "keywords": [{"text": "momentum"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "to gain", "normalized": "to gain"}}, {"subject": {"text": "pharmaceutical end-use of BFS technology", "keywords": [{"text": "pharmaceutical end-use"}, {"text": "BFS technology"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "sentence": " While the adoption of blow fill seal machines is likely to gain momentum in the food & beverage industry, pharmaceutical end-use of BFS technology will procure over 97% share on global market, throughout the forecast period.", "action": {"verb": {"text": "procure", "tense": "future"}, "text": "will procure", "normalized": "will procure"}}, {"subject": {"text": "Thriving pharmaceutical sectors across countries such as the UK, Canada, India, China and the US", "keywords": [{"text": "pharmaceutical sectors"}, {"text": "countries"}, {"text": "UK"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "UK", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Thriving pharmaceutical sectors across countries such as the UK, Canada, India, China and the US are likely to boost the market\u2019s growth to a significant degree.", "object": {"text": "the market\u2019s growth", "keywords": [{"text": "market"}, {"text": "growth"}], "entities": []}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "to boost", "normalized": "to boost"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America, in particular, is expected to dominate the market with over 35% share on global BFS technology revenues.", "object": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "is expected to dominate", "normalized": "be expect to dominate"}}, {"subject": {"text": "seal technology market", "keywords": [{"text": "seal technology market"}]}, "sentence": " Through 2027, North America\u2019s blow fill seal technology market will have soared at 9.8% CAGR in terms of value.", "object": {"text": "North America\u2019s blow", "keywords": [{"text": "America\u2019s blow"}, {"text": "North"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "fill", "tense": "present"}, "text": "fill", "normalized": "fill"}}, {"subject": {"text": "North America\u2019s blow fill seal technology market", "keywords": [{"text": "seal technology market"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Through 2027, North America\u2019s blow fill seal technology market will have soared at 9.8% CAGR in terms of value.", "object": {"text": "at 9.8% CAGR in terms of value", "keywords": [{"text": "CAGR"}, {"text": "terms"}, {"text": "value"}], "entities": [{"type": "Quantity", "text": "9.8"}]}, "action": {"verb": {"text": "soar", "tense": "future"}, "text": "will have soared", "normalized": "will have soar"}}, {"subject": {"text": "the Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Western Europe and the Asia-Pacific excluding Japan (APEJ) region will also be at the forefront of expansion of global BFS technology market.", "object": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}]}, "action": {"verb": {"text": "exclude", "tense": "present"}, "text": "excluding", "normalized": "exclude"}}, {"subject": {"text": "Western Europe and the Asia-Pacific excluding Japan (APEJ) region", "keywords": [{"text": "Western Europe"}, {"text": "Japan"}, {"text": "APEJ"}, {"text": "region"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}]}, "sentence": " Western Europe and the Asia-Pacific excluding Japan (APEJ) region will also be at the forefront of expansion of global BFS technology market.", "object": {"text": "at the forefront of expansion of global BFS technology market", "keywords": [{"text": "global BFS technology"}, {"text": "forefront"}, {"text": "expansion"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will also be", "normalized": "will also be"}}, {"subject": {"text": "leading packaging companies", "keywords": [{"text": "packaging companies"}]}, "sentence": " The report also profiles leading packaging companies employing BFS technology across the world.", "object": {"text": "BFS technology", "keywords": [{"text": "BFS technology"}], "entities": [{"type": "Company", "text": "BFS Technology"}]}, "action": {"verb": {"text": "employ", "tense": "present"}, "text": "employing", "normalized": "employ"}}, {"subject": {"text": "Pharmapack Co. Ltd., Amanta Healthcare Ltd., Automatic Liquid Packaging Solutions LLC., Asept Pak, Inc", "keywords": [{"text": "Automatic Liquid Packaging"}, {"text": "Pharmapack Co. Ltd."}, {"text": "Amanta Healthcare Ltd."}, {"text": "Asept Pak"}], "entities": [{"type": "Company", "text": "Pharmapack Co. Ltd."}, {"type": "Company", "text": "Amanta Healthcare Ltd."}, {"type": "Company", "text": "Automatic Liquid Packaging Solutions LLC."}, {"type": "Company", "text": "Asept Pak, Inc"}]}, "sentence": " The key players in the global market for blow fill seal technology include Pharmapack Co. Ltd., Amanta Healthcare Ltd., Automatic Liquid Packaging Solutions LLC., Asept Pak, Inc.", "object": {"text": "The key players in the global market for blow fill seal technology", "keywords": [{"text": "blow fill seal"}, {"text": "key players"}, {"text": "global market"}, {"text": "technology"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.987182, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.808419, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "GlaxoSmithKline", "relevance": 0.804826, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Injection", "relevance": 0.735472, "dbpedia_resource": "http://dbpedia.org/resource/Injection_(medicine)"}, {"text": "Pharmacy", "relevance": 0.725573, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmaceutical drug", "relevance": 0.721337, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "North America", "relevance": 0.63854, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Technology", "relevance": 0.564216, "dbpedia_resource": "http://dbpedia.org/resource/Technology"}, {"text": "United States", "relevance": 0.49062, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}], "categories": [{"score": 0.526784, "label": "/business and industrial/manufacturing"}, {"score": 0.49091, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.482289, "label": "/business and industrial/paper industry"}], "relations": [{"type": "basedIn", "sentence": "Latin American countries such as Brazil and Mexico are witnessing a shift from conventional packaging to advanced pharmaceutical packaging, wherein unit dose packaging solutions are gaining preference.", "score": 0.395114, "arguments": [{"text": "countries", "location": [287, 296], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Latin American", "location": [272, 286], "entities": [{"type": "GeopoliticalEntity", "text": "Latin American", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Western Europe and the Asia-Pacific excluding Japan (APEJ) region will also be at the forefront of expansion of global BFS technology market.", "score": 0.848511, "arguments": [{"text": "Western", "location": [3349, 3356], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [3357, 3363], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Western Europe and the Asia-Pacific excluding Japan (APEJ) region will also be at the forefront of expansion of global BFS technology market.", "score": 0.815061, "arguments": [{"text": "Asia-Pacific", "location": [3372, 3384], "entities": [{"type": "Organization", "text": "Asia-Pacific"}]}, {"text": "APEJ", "location": [3402, 3406], "entities": [{"type": "Ticker", "text": "APEJ"}]}]}, {"type": "locatedAt", "sentence": "Western Europe and the Asia-Pacific excluding Japan (APEJ) region will also be at the forefront of expansion of global BFS technology market.", "score": 0.519458, "arguments": [{"text": "region", "location": [3408, 3414], "entities": [{"type": "GeopoliticalEntity", "text": "Western"}]}, {"text": "Japan", "location": [3395, 3400], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "The report also profiles leading packaging companies employing BFS technology across the world.", "score": 0.250268, "arguments": [{"text": "companies", "location": [3534, 3543], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BFS technology", "location": [3554, 3568], "entities": [{"type": "Organization", "text": "Top-selling Products of BFS Technology"}]}]}, {"type": "locatedAt", "sentence": "The report also profiles leading packaging companies employing BFS technology across the world.", "score": 0.700547, "arguments": [{"text": "companies", "location": [3534, 3543], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "world", "location": [3580, 3585], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The report also profiles leading packaging companies employing BFS technology across the world.", "score": 0.534397, "arguments": [{"text": "BFS technology", "location": [3554, 3568], "entities": [{"type": "Organization", "text": "Top-selling Products of BFS Technology"}]}, {"text": "world", "location": [3580, 3585], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": ", Weiler Engineering, Inc., GlaxoSmithKline plc., Takeda Pharmaceuticals International AG, Nephron Pharmaceuticals Corporation, Horizon Pharmaceuticals, Inc., Brevetti Angela S.R.L., Recipharm AB, SIFI S.p.A, Laboratorios SALVAT, S.A., The Ritedose Corporation, and Unicep Packaging, LLC.", "score": 0.676588, "arguments": [{"text": "Recipharm AB", "location": [4072, 4084], "entities": [{"type": "Person", "text": "Recipharm AB"}]}, {"text": "SIFI S.p.A, Laboratorios SALVAT, S.A.", "location": [4086, 4123], "entities": [{"type": "Organization", "text": "SIFI S.p.A, Laboratorios SALVAT, S.A.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Request to Sample of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4407", "score": 0.761829, "arguments": [{"text": "Sample", "location": [4189, 4195], "entities": [{"type": "Person", "text": "Sample"}]}, {"text": "Request", "location": [4178, 4185], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "agentOf", "sentence": "Request to Sample of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4407", "score": 0.906594, "arguments": [{"text": "Sample", "location": [4189, 4195], "entities": [{"type": "Person", "text": "Sample"}]}, {"text": "Report", "location": [4199, 4205], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOfMany", "sentence": "Latin American countries such as Brazil and Mexico are witnessing a shift from conventional packaging to advanced pharmaceutical packaging, wherein unit dose packaging solutions are gaining preference.", "score": 0.609669, "arguments": [{"text": "Brazil", "location": [305, 311], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [287, 296], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Latin American countries such as Brazil and Mexico are witnessing a shift from conventional packaging to advanced pharmaceutical packaging, wherein unit dose packaging solutions are gaining preference.", "score": 0.806082, "arguments": [{"text": "Mexico", "location": [316, 322], "entities": [{"type": "GeopoliticalEntity", "text": "Mexico", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [287, 296], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "By the end of 2027, the global market for BFS technology will have soared robustly at 8.7% CAGR, bringing in revenues worth over US$ 7.2 Bn.", "score": 0.545137, "arguments": [{"text": "BFS technology", "location": [1233, 1247], "entities": [{"type": "Organization", "text": "Top-selling Products of BFS Technology"}]}, {"text": "7.2 Bn", "location": [1324, 1330], "entities": [{"type": "Money", "text": "7.2 Bn", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOf", "sentence": "Prefilled Syringes & Injectables - Top-selling Products of BFS Technology With the use of blow fill seal technology, packaging companies are improving the flexibility of products namely, bottles, ampules, vials, and prefilled syringes & injectables.", "score": 0.561513, "arguments": [{"text": "Top-selling Products of BFS Technology", "location": [1367, 1405], "entities": [{"type": "Organization", "text": "Top-selling Products of BFS Technology"}]}, {"text": "Syringes & Injectables", "location": [1342, 1364], "entities": [{"type": "Organization", "text": "Syringes & Injectables"}]}]}, {"type": "partOfMany", "sentence": "Prefilled Syringes & Injectables - Top-selling Products of BFS Technology With the use of blow fill seal technology, packaging companies are improving the flexibility of products namely, bottles, ampules, vials, and prefilled syringes & injectables.", "score": 0.292876, "arguments": [{"text": "Top-selling Products of BFS Technology", "location": [1367, 1405], "entities": [{"type": "Organization", "text": "Top-selling Products of BFS Technology"}]}, {"text": "companies", "location": [1459, 1468], "entities": [{"type": "Organization", "text": "pharmaceutical companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Thriving pharmaceutical sectors across countries such as the UK, Canada, India, China and the US are likely to boost the market's growth to a significant degree.", "score": 0.406553, "arguments": [{"text": "pharmaceutical sectors", "location": [2964, 2986], "entities": [{"type": "Organization", "text": "pharmaceutical sectors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "countries", "location": [2994, 3003], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Thriving pharmaceutical sectors across countries such as the UK, Canada, India, China and the US are likely to boost the market's growth to a significant degree.", "score": 0.547508, "arguments": [{"text": "pharmaceutical sectors", "location": [2964, 2986], "entities": [{"type": "Organization", "text": "pharmaceutical sectors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "UK", "location": [3016, 3018], "entities": [{"type": "GeopoliticalEntity", "text": "UK", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Thriving pharmaceutical sectors across countries such as the UK, Canada, India, China and the US are likely to boost the market's growth to a significant degree.", "score": 0.308075, "arguments": [{"text": "countries", "location": [2994, 3003], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Canada", "location": [3020, 3026], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "bfs technology", "sentiment": {"score": 0.00749373, "label": "positive"}, "relevance": 0.984711}, {"text": "blow fill seal", "sentiment": {"score": -0.360758, "label": "negative"}, "relevance": 0.803046}, {"text": "unit dose packaging", "sentiment": {"score": 0.495069, "label": "positive"}, "relevance": 0.738672}, {"text": "global BFS technology", "sentiment": {"score": -0.603024, "label": "negative"}, "relevance": 0.720691}, {"text": "BFS technology market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.677821}, {"text": "seal technology market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646908}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.632675}, {"text": "BFS technology revenues", "sentiment": {"score": -0.603024, "label": "negative"}, "relevance": 0.579376}, {"text": "dose packaging solutions", "sentiment": {"score": 0.486339, "label": "positive"}, "relevance": 0.536342}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514737}, {"text": "BFS products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511137}, {"text": "forecast period", "sentiment": {"score": -0.321543, "label": "negative"}, "relevance": 0.485765}, {"text": "packaging companies", "sentiment": {"score": 0.114147, "label": "positive"}, "relevance": 0.47959}, {"text": "technology market value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463719}, {"text": "global blow", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459695}, {"text": "advanced pharmaceutical packaging", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458328}, {"text": "unit dosage packaging", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.443738}, {"text": "seal machines", "sentiment": {"score": -0.360758, "label": "negative"}, "relevance": 0.443701}, {"text": "Future Market Insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440572}, {"text": "Latin American countries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429679}, {"text": "Packaging Solutions LLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426918}, {"text": "raw material", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420793}, {"text": "low carbon imprint", "sentiment": {"score": -0.50116, "label": "negative"}, "relevance": 0.420703}, {"text": "low energy consumption", "sentiment": {"score": -0.360758, "label": "negative"}, "relevance": 0.419347}, {"text": "flexible glass vials", "sentiment": {"score": 0.610518, "label": "positive"}, "relevance": 0.418984}, {"text": "Nephron Pharmaceuticals Corporation", "sentiment": {"score": -0.29334, "label": "negative"}, "relevance": 0.418599}, {"text": "outright dominant end-use", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416973}, {"text": "prefilled syringes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413986}, {"text": "Pharmaceuticals International AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41231}, {"text": "Kunststoff-Maschinen Vertriebsgesellschaft mbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411925}, {"text": "widely-preferred raw material", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409729}, {"text": "Pharmapack Co. Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408273}, {"text": "Amanta Healthcare Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408202}, {"text": "polyethylene materials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406695}, {"text": "conventional packaging", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.390106}, {"text": "packaging industry", "sentiment": {"score": 0.610518, "label": "positive"}, "relevance": 0.384374}, {"text": "global revenues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383548}, {"text": "pharmaceutical companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380473}, {"text": "Largest Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380093}, {"text": "pharmaceutical industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37767}, {"text": "Bn value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376618}, {"text": "Unicep Packaging", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376503}, {"text": "report", "sentiment": {"score": 0.610518, "label": "positive"}, "relevance": 0.374717}, {"text": "injectables", "sentiment": {"score": 0.436293, "label": "positive"}, "relevance": 0.371044}, {"text": "Bn worth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371021}, {"text": "pharmaceutical end-use", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370541}, {"text": "greater demand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.369158}, {"text": "Top-selling Products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368871}, {"text": "patient adherence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367893}, {"text": "drug regime", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367015}]}, "extracted_metadata": {"sha1": "5b029c3fc9e86ff8ed2a59f020dc17827ee961da", "filename": "1541392498653.zip-4c73079805636e30aac30356c462dcb6.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/sample/rep-gb-4407", "https://www.futuremarketinsights.com/reports/blow-fill-seal-technology-market"], "title": "Blow Fill Seal Technology Market Accounting for US$ 7.2 Bn in 2027", "forum_title": "Research Insights \u2013 Page 52 \u2013 Find Market Research"}]}